

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
28 February 2002 (28.02.2002)

PCT

(10) International Publication Number  
**WO 02/16318 A1**

(51) International Patent Classification<sup>7</sup>: **C07C 335/16**,  
311/00, A61K 31/00, C07D 221/00

(21) International Application Number: PCT/KR01/01407

(22) International Filing Date: 20 August 2001 (20.08.2001)

(25) Filing Language: Korean

(26) Publication Language: English

(30) Priority Data:  
2000/48385 21 August 2000 (21.08.2000) KR  
2000/48388 21 August 2000 (21.08.2000) KR  
2000/85126 29 December 2000 (29.12.2000) KR

(71) Applicant (for all designated States except US): **PACIFIC CORPORATION** [KR/KR]; 181, Hankang-ro 2-ka, Yongsan-ku, Seoul 140-777 (KR).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **SUH, Young, Ger** [KR/KR]; 1223-602, Hanyang Apt., Sanbon-dong, Gunpo-si 435-040, Kyunggi-do (KR). **OH, Uh, Taek** [KR/KR]; 615-102, Eulji Apt., Sanbon-dong, Gunpo-si 435-040, Kyunggi-do (KR). **KIM, Hee, Doo** [KR/KR]; 601-601, Mokdong Apt., Mok 6-dong, Yangchon-ku, Seoul 158-056 (KR). **LEE, Jee, Woo** [KR/KR]; 27-901, Misung Apt., 406, Apgujung-dong, Kangnam-ku, Seoul 135-110 (KR). **PARK, Hyeung, Geun** [KR/KR]; 206-1103, Doosan Apt., 1708-1, Bongchon-bondong, Kwanak-ku, Seoul 151-782 (KR). **PARK, Ok, Hui** [KR/KR]; 179, Gikyung 1-ri, Sangwal-myeon, Nonsan-si 320-933, Chungchongnam-do (KR). **LEE, Yong, Sil** [KR/KR]; 103-ho, 196-54, Bongchon 11-dong, Kwanak-ku, Seoul 151-817 (KR). **PARK, Young, Ho** [KR/KR]; 3-1201, Daerim Apt., Sadang-dong, Dongjak-ku, Seoul 156-775 (KR). **JOO, Yung, Hyup** [KR/KR]; 1062-13, Hwagok 5-dong, Kangsuh-ku, Seoul 157-015 (KR). **CHOI, Jin, Kyu** [KR/KR]; 308-203, Sunkyung 3-cha Apt., Ingaedong, Paldal-ku, Suwon-si 442-762, Kyunggi-do (KR). **LIM, Kyung, Min** [KR/KR]; 835-1703, Byukjeokgol Jukong Apt., Youngtong-dong, Paldal-ku, Suwon-si 442-470, Kyunggi-do

(KR). **KIM, Sun, Young** [KR/KR]; 102-1604, Sannaedeul Hyundae Apt., 331, Jukjeon-ri, Suji-eup, Yongin-si 449-984, Kyunggi-do (KR). **KIM, Jin, Kwan** [KR/KR]; 344-208, Jukong Apt., Banpo 1-dong, Seocho-ku, Seoul 137-930 (KR). **KOH, Hyun, Ju** [KR/KR]; 604, Jayang 2-dong, Kwangjin-ku, Seoul 143-865 (KR). **MOH, Joo, Hyun** [KR/KR]; 314-1, Bora-ri Kiheung-eup, Yongin-si 449-729, Kyunggi-do (KR). **JEONG, Yeon, Su** [KR/KR]; 118-803, Sungwon Apt., Sanghyun-ri, Suji-eup, Yongin-si 449-840, Kyunggi-do (KR). **YI, Jung, Bum** [KR/KR]; 113-205, SuwonHaniltown Apt., 881, Jowon-dong, Jangan-ku, Suwon-si 440-850, Kyunggi-do (KR). **OH, Young, Im** [KR/KR]; 102-304, Byuksantown Apt., 832, Jukjeon-ri, Suji-eup, Yongin-si 449-840, Kyunggi-do (KR).

(74) Agent: **SUH, Jong, Wan**; 7th Floor, New-Seoul Building, 828-8, Yeoksam-dong, Kangnam-ku, Seoul 135-080 (KR).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

- with international search report
- entirely in electronic form (except for this front page) and available upon request from the International Bureau

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: NOVEL THIOUREA DERIVATIVES AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME

(57) Abstract: The present invention relates to novel thiourea derivatives as a modulator for vanilloid receptor (VR) and the pharmaceutical compositions containing the same. As diseases associated with the activity of vanilloid receptor, pain acute pain, chronic pain, neuropathic pain, post-operative pain, migraine, arthralgia, neuropathies, nerve injury, diabetic neuropathy, neurodegeneration, neurotic skin disorder, stroke, urinary bladder hypersensitiveness, irritable bowel syndrome, a respiratory disorder such as asthma or chronic obstructive pulmonary disease, irritation of skin, eye or mucous membrane, fervescence, stomach-duodenal ulcer, inflammatory bowel disease and inflammatory diseases can be enumerated. The present invention provides a pharmaceutical composition for prevention or treatment of these diseases.



WO 02/16318 A1

## **Novel thiourea derivatives and the pharmaceutical compositions containing the same**

### **Technical Field**

5           The present invention relates to novel thiourea derivatives and the pharmaceutical compositions containing the same, and particularly, to novel thiourea compounds as a modulator for vanilloid receptor (VR) and the pharmaceutical compositions thereof. Here, the modulator means the thing that can be bonded to the receptor to act as an antagonist or an agonist.

10

### **Background Art**

As diseases associated with the activity of vanilloid receptor, pain, acute pain, chronic pain, neuropathic pain, post-operative pain, migraine, arthralgia, neuropathies, nerve injury, diabetic neuropathy, neurodegeneration, neurotic skin disorder, stroke, urinary bladder hypersensitiveness, irritable bowel syndrome, a respiratory disorder such as asthma or chronic obstructive pulmonary disease, irritation of skin, eye or mucous membrane, fervescence, stomach-duodenal ulcer, inflammatory bowel disease and inflammatory diseases can be enumerated. The present invention provides pharmaceutical compositions for prevention or treatment of these diseases.

15

Yet, the diseases described above are only for enumeration, not to limit the scope of clinical application of vanilloid receptor modulator.

Capsaicin (8-methyl-N-vanillyl-6-nonenamide) is a main pungent component in  
5 hot peppers. Hot peppers have been used, for a long time, not only as a spice but also  
as traditional medicine in the treatment of gastric disorders and when applied locally,  
for the relief of pain and inflammation (Szallasi and Blumberg, 1999, Pharm, Rev. 51,  
pp159-211). Capsaicin has a wide spectrum of biological actions, and not only  
exhibits effects on the cardiovascular and respiratory systems but also induces pain and  
10 irritancy on local application. Capsaicin, however, after such induction of pain,  
induces desensitization, both to capsaicin itself and also to other noxious stimuli to  
make the pain stopped. Based on this property, capsaicin and its analogues such as  
olvanil, nuvanil, DA-5018, SDZ-249482, resiniferatoxin are either used as analgesic  
agent, therapeutic agent for incontinentia urinae or skin disorder, or under development  
15 (Wriggleworth and Walpole, 1998, Drugs of the Future 23, pp 531-538).

Transmissions of mechanical, thermal and chemical noxious stimuli are mainly  
occurred by primary afferent nerve fibers of fine unmyelinated nerve (C-fiber) and thin  
myelinated nerve (A-fiber), and main reaction site of capsaicin and its analog called  
vanilloid is present at the nerve fiber transmitting the noxious stimuli. Capsaicin acts

at the receptor existing on these neurons to induce potent stimuli by causing potent inflow of mono-and di-valent cations such as calcium and sodium, then exhibits potent analgesic effect by blocking the nervous function (Wood et al., 1988, J. Neurosci, 8, pp3208-3220). Vanilloid receptor (VR-1) has been recently cloned and its existence becomes clear (Caterina et al., 1997, Nature 389, pp816-824). It was clarified that this receptor transmits not only stimuli by capsaicin analogues (vanilloid) but also various noxious stimuli such as proton and thermal stimuli (Tominaga et al., 1998, Neuron 21, pp531-543). Based on this, it is considered that vanilloid receptor functions as a integrative modulator against various noxious stimuli and carries out critical role in transmissions of pain and noxious stimuli. Recently, knock-out mouse in which gene encoding for vanilloid receptor was deleted was prepared (Caterina et al., 2000, Science 288, pp306-313; Davis et al., 2000, Nature 405, pp183-187). Compared to normal mice, the mouse was found out to exhibit much reduced reaction to thermal stimuli and thermal pain, while exhibiting no difference in general behavior, reconfirming the importance of the receptor in transmission of noxious signal. However, except proton, no other endogenous ligand, not exogenous ligand such as capsaicin, actually involved in transmission of noxious stimuli at vanilloid receptor was known. It is considered that leucotriene metabolite represented by 12-hydroperoxyeicosatetraenoic acid (12-HPETE) (Hwang et al., 2000, PNAS 11, pp6155-6160) and arachidonic acid

derivatives such as anandamide (Zygmunt et al., 2000, Trends Pharmacol. Sci. 21, pp43-44) act as the most likely endogenous ligand for the receptor and proton acts as a cofactor with receptor-stimulating activity, rather than as a direct ligand.

5       As such, a capsaicin-sensitive sensory nerve cell and a vanilloid receptor existing in the cell are distributed over the entire body and play basic function in transmission of noxious stimuli and pain, further act as crucial factor in expression of neurogenic inflammation, thereby to have close relation with the cause of neuropathies, nerve injury, stroke, asthma, chronic obstructive pulmonary diseases, urinary bladder  
10 hypersensitiveness, irritable bowel syndrome, inflammatory bowel disease, fervescence, skin disorder and inflammatory disease. Lately, their correlation even with neuropathic disease is suggested (WO 99/00125). Recently, attention has focused to the role of afferent sensory nerve responding to capsaicin in gastrointestinal injury, and it was proposed that the afferent nerve might have a dual character that it exhibits  
15 protective action against gastric damage by improving gastric microcirculation through releasing peripheral neuropeptide such as CGRP (calcitonin gene-related peptide), while inducing gastric injury by stimulating sympathetic nervous system (Ren et al., 2000, Dig. Dis. Sci. 45, pp830-836). It is determined that vanilloid receptor modulator has very high potential to be used for prevention or treatment of the said various diseases by

modulating the activity of the vanilloid receptor conducting such varied functions.


As described above, there has been widely studied for clinical application of vanilloid receptor agonist, and it is understood that there is a possibility that the agonist  
5 derived from the present studies will be developed for clinical application. Though it may be, theoretically, anticipated that antagonist for this receptor would exhibit substantial degree of inhibitory action against pain and neurogenic inflammation, it was found out that the competitive antagonist for this receptor, capsazepine, almost the only one known until now, failed to exhibit significant analgesic and anti-inflammatory  
10 effects (Perkins and Campbell, 1992, Br. J. Pharmacol. 107, pp329-333). Therefore, not much progress was made on this field. However, recently, there has been a report on significant results for analgesic action of capsazepine in animal studies (Kwak et al., 1998, Neurosci. 86, pp619-626; Santos and calixto, 1997, Neurosci. Lett. 235, pp73-76), in particular, the inventors of the present invention clearly demonstrated through animal  
15 studies the analgesic and anti-inflammatory effects of the strong vanilloid receptor antagonists which were identified through experiments in our laboratory, and based on this, strongly suggest the development potential of vanilloid receptor antagonist as an analgesic, anti-inflammatory and anti-ulcerous agent. Yet, though the vanilloid receptor antagonist or agonist derived from the present studies will mainly act based on

the antagonistic or agonistic activity of itself, even a possibility that it could exhibit the pharmacological activity through transformation into agonist or antagonist via metabolism after absorption into body is not to be excluded.

The present invention is to provide novel compounds which are acted as a modulator for vanilloid receptor and exhibit excellent analgesic, anti-inflammatory and anti-ulcer effects, and pharmaceutical compositions containing the same.

#### Disclosure of the invention

In order to attain the above objects, the present invention provides a novel compound of the following formula (I):




(I)

wherein,

X represents S, O or -NCN;

Y represents single bond, NR<sup>3</sup>, O or S;


R<sup>1</sup> represents



pyridinylmethyl, pyrrolylmethyl, oxazolylmethyl, pyrazolylmethyl, imidazolylmethyl, anthracenylmethyl, naphthylmethyl, quinolinylmethyl, alkoxycarbonyl or alkylcarbonyloxy (wherein, m is 0, 1, 2, 3 or 4;  $R^4$  and  $R^5$  are independently hydrogen, lower alkyl having 1 to 5 carbon atoms, hydroxy, methanesulfonylamino, lower alkoxy having 1 to 5 carbon atoms, methoxyalkoxy, methoxyalkoxyalkyl, alkoxycarbonyloxy, benzyloxy, acetoxymethyl, propionyloxymethyl, butoxyalkyl, trimethylacetoxymethyl or halogen; and  $R^6$  and  $R^7$  are independently hydrogen, lower alkyl having 1 to 5 carbon atoms);

$R^2$  represents  $R^8-(CH_2)_n-$


{wherein, n is 0, 1, 2, 3 or 4;  $R^8$  is benzoyl, imidazolyl, indolyl, indazolyl, thiazolyl, pyrazolyl, oxazolyl, isoxazolyl, benzimidazolyl, chromonyl or benzothiazolyl substituted or unsubstituted with lower alkyl having 1 to 5 carbon atoms, nitro, amino, cyano, methanesulfonylamino, formyl or halogen, or



(wherein,  $R^9$  is hydrogen, halogen, lower alkyl having 1 to 5 carbon atoms,




lower alkoxy having 1 to 5 carbon atoms, hydroxy, nitro, cyano,  $\text{-NHSO}_2\text{R}^{12}$ ,  $\text{-S(O)}_p\text{R}^{12}$ ,  $\text{-NR}^{13}\text{R}^{14}$ , carboxyl;  $\text{R}^{10}$  is hydrogen, nitro,  $\text{NHSO}_2\text{R}^{12}$ ,  $\text{S(O)}_p\text{R}^{12}$  or  $\text{NR}^{13}\text{R}^{14}$ ;  $\text{R}^{11}$  is hydrogen or cyano;  $\text{R}^{12}$  is lower alkyl having 1 to 5 carbon atoms, methylphenyl,  $\text{NR}^{13}\text{R}^{14}$ , trifluoromethyl or alkenyl;  $\text{R}^{13}$  and  $\text{R}^{14}$  are independently hydrogen or lower alkyl having 1 to 5 carbon atoms; and p is 0 or 2.); or



or

(wherein, Z is O, S, NH or  $\text{-NCH}_3$ ;  $\text{R}^{15}$  is hydrogen, halogen, lower alkyl having 1 to 5 carbon atoms, nitro, cyano,  $\text{-NHSO}_2\text{R}^{12}$ ,  $\text{-S(O)}_p\text{R}^{12}$ , N,N-dimethylaminomethyl or alkoxycarbonylamino; and p and  $\text{R}^{12}$  have the same meanings as defined in  $\text{R}^9$ );

or




or

(wherein, W is O, S, NH,  $\text{NR}^{16}$ ,  $\text{-N(SO}_2\text{CH}_3\text{)-}$  or  $\text{-CH}_2\text{-}$ ; and  $\text{R}^{16}$  is pyridinyl or pyrimidinyl substituted or unsubstituted with lower alkyl having 1 to 5 carbon atoms, nitro, methanesulfonylamino or halogen; or benzyl or phenethyl substituted or

unsubstituted with lower alkyl having 1 to 5 carbon atoms, alkoxy, hydroxy, nitro, methanesulfonylamino or halogen);

or



or

5 (wherein, R<sup>17</sup>, R<sup>18</sup>, R<sup>19</sup>, R<sup>20</sup> and R<sup>21</sup> are independently hydrogen, halogen, lower alkyl having 1 to 5 carbon atoms, alkoxy, methylenedioxy, methanesulfonylaminomethyl, alkoxycarbonyl, hydroxy, sulfamoyl, aminoalkoxy, alkoxycarbonylamino, -NHCH<sub>2</sub>CO<sub>2</sub>H, alkoxyalkylcarbonylamino, alkoxycarbonylalkylamino, nitro, formyl, acetyl, formylamino, acetoxamino, cyano, 10 -OSO<sub>2</sub>CH<sub>3</sub>, -NHSO<sub>2</sub>R<sup>12</sup>, -N(SO<sub>2</sub>R<sup>12</sup>)CH<sub>3</sub>, -N(SO<sub>2</sub>R<sup>12</sup>)<sub>2</sub>, -S(O)<sub>p</sub>R<sup>12</sup>, -NR<sup>13</sup>R<sup>14</sup>, thiocarbamoyl, -C(=O)NHNH<sub>2</sub>, -C(=O)NHOH, -C(=O)NHOCH<sub>3</sub>, -PO(=O)(OCH<sub>3</sub>)<sub>2</sub>, carboxyl, NHBoc, -NHC(=O)SCH<sub>3</sub> or guanidine; R<sup>22</sup> and R<sup>23</sup> are independently hydrogen, halogen, alkoxy or hydroxy; and p, R<sup>12</sup>, R<sup>13</sup> and R<sup>14</sup> have the same meanings as defined in R<sup>9</sup>);

15 or hydroxyphenylalkyl or (methanesulfonylaminophenyl)alkyl}; and

R<sup>3</sup> represents hydrogen, alkyl or cycloalkyl having 1 to 8 carbon atoms, lower alkylphenyl having 1 to 5 carbon atoms, pyridinylethyl, bisphenylmethyl; or


phenylalkyl substituted with lower alkyl having 1 to 5 carbon atoms, halogen or methanesulfonylamino.

Preferably, in the above formula (I),

X represents S, O or -NCN;

5 Y represents  $\text{NR}^3$  or O;


$\text{R}^1$  represents



(wherein, m is 0, 1 or 2; and  $\text{R}^4$  and  $\text{R}^5$  are independently hydrogen, lower alkyl having 1 to 4 carbon atoms, hydroxy, methanesulfonylamino, lower alkoxy having 1 to 5 carbon atoms, methoxyalkoxy, methoxyalkoxyalkyl, benzyloxy, acetoxymethyl, trimethylacetoxymethyl or halogen);


$\text{R}^2$  represents  $\text{R}^8-(\text{CH}_2)_n-$

{wherein, n is 0, 1, 2 or 3; and  $\text{R}^8$  is benzoyl, imidazolyl, indolyl, indazolyl, thiazolyl, pyrazolyl, oxazolyl, benzimidazolyl or chromonyl substituted or unsubstituted with lower alkyl having 1 to 5 carbon atoms, nitro, amino, cyano, methanesulfonylamino, formyl or halogen, or




(wherein,  $R^9$  is hydrogen, halogen, lower alkyl having 1 to 4 carbon atoms, lower alkoxy having 1 to 4 carbon atoms, nitro, cyano,  $-NHSO_2R^{12}$ ,  $-NR^{13}R^{14}$  or carboxyl;  $R^{10}$  is hydrogen, nitro,  $NHSO_2R^{12}$  or  $-NR^{13}R^{14}$ ;  $R^{11}$  is hydrogen or cyano;  $R^{12}$  is lower alkyl having 1 to 4 carbon atoms, methylphenyl,  $-NR^{13}R^{14}$  or trifluoromethyl;  $R^{13}$  and  $R^{14}$  are independently hydrogen or lower alkyl having 1 to 4 carbon atoms; and p is 0 or 2);

or



or


(wherein, Z is O, S, NH or  $-NCH_3$ ;  $R^{15}$  is hydrogen, lower alkyl having 1 to 4 carbon atoms, nitro, cyano or  $NHSO_2R^{12}$ ; and  $R^{12}$  has the same meanings as defined in  $R^9$ ); or



or

(wherein, W is O, S, NH, NR<sup>16</sup> or -CH<sub>2</sub>-; and R<sup>16</sup> is pyridinyl or pyrimidinyl substituted or unsubstituted with lower alkyl having 1 to 4 carbon atoms, nitro or methanesulfonylamino; or benzyl or phenethyl substituted or unsubstituted with lower alkyl having 1 to 4 carbon atoms, alkoxy, hydroxy or methanesulfonylamino);

or



or

(wherein, R<sup>17</sup>, R<sup>18</sup>, R<sup>19</sup>, R<sup>20</sup> and R<sup>21</sup> are independently hydrogen, halogen, lower alkyl having 1 to 5 carbon atoms, alkoxy, methylenedioxy, methanesulfonylaminomethyl, alkoxycarbonyl, hydroxy, sulfamoyl, alkoxycarbonylamino, -NHCH<sub>2</sub>CO<sub>2</sub>H, alkoxyalkylcarbonylamino, alkoxycarbonylalkylamino, nitro, formyl, acetyl, formylamino, acetoxymino, cyano, -OSO<sub>2</sub>CH<sub>3</sub>, -NHSO<sub>2</sub>R<sup>12</sup>, -N(SO<sub>2</sub>R<sup>12</sup>)CH<sub>3</sub>, -N(SO<sub>2</sub>R<sup>12</sup>)<sub>2</sub>, -S(O)<sub>p</sub>R<sup>12</sup>, NR<sup>13</sup>R<sup>14</sup>, thiocarbamoyl, -C(=O)NHNH<sub>2</sub>, -C(=O)NHOH, -C(=O)NHOCH<sub>3</sub>, carboxyl, NHBoc, -NHC(=O)SCH<sub>3</sub>, guanidine; R<sup>22</sup> and R<sup>23</sup> are independently hydrogen, alkoxy or

hydroxy; and p,  $R^{12}$ ,  $R^{13}$  and  $R^{14}$  have the same meanings as defined in  $R^9$ ;

or hydroxyphenylalkyl or (methanesulfonylaminophenyl)alkyl}; and


$R^3$  represents hydrogen, alkyl having 1 to 4 carbon atoms, lower alkylphenyl having 1 to 3 carbon atoms, pyridinylethyl or bisphenylmethyl; or phenylalkyl substituted with lower alkyl having 1 to 4 carbon atoms, halogen or methanesulfonylamino.

More preferably, in the above formula (I),

X represents S, O or -NCN;

Y represents  $NR^3$  or O;

$R^1$  represents




(wherein, m is 1 or 2; and  $R^4$  and  $R^5$  are independently hydrogen, t-butyl, hydroxy, methanesulfonylamino, lower alkoxy having 1 to 5 carbon atoms, methoxymethoxy, methoxyethoxy, benzyloxy, acetoxymethyl, trimethylacetoxymethyl or halogen);

$R^2$  represents  $R^8-(CH_2)_n-$

{wherein, n is 1, 2 or 3;  $R^8$  is benzoyl, imidazolyl, indolyl, indazolyl, thiazolyl,

pyrazolyl or benzimidazolyl substituted or unsubstituted with methyl, nitro or halogen;


or



(wherein,  $R^9$  is hydrogen, halogen, methyl, nitro or methanesulfonylamino;  $R^{10}$  is

5 hydrogen or nitro; and  $R^{11}$  is hydrogen or cyano);

or




or

(wherein, Z is O, S, NH or -NCH<sub>3</sub>; and  $R^{15}$  is hydrogen, methyl, nitro, cyano

or methanesulfonylamino);

10

or




or

(wherein, W is O, S, NH,  $NR^{16}$  or -CH<sub>2</sub>-; and  $R^{16}$  is pyridinyl, pyrimidinyl; or benzyl

or phenethyl substituted or unsubstituted with methyl, methoxy or hydroxy);

or



or

(wherein,  $R^{17}$ ,  $R^{18}$ ,  $R^{19}$ ,  $R^{20}$  and  $R^{21}$  are independently hydrogen, halogen, lower  
 5 alkyl having 1 to 4 carbon atoms, methoxy, methylenedioxy, methanesulfonylaminomethyl, methoxycarbonyl, hydroxy, sulfamoyl, alkoxy-carbonylamino,  $-NHCH_2CO_2H$ , methoxymethylcarbonylamino, alkoxy-carbonylalkylamino, nitro, acetyl, formylamino, acetoxylamino, cyano,  $-OSO_2CH_3$ ,  $-NH-SO_2R^{12}$ ,  $-N(SO_2R^{12})CH_3$ ,  $-N(SO_2R^{12})_2$ ,  $-S(O)_pR^{12}$ ,  $NR^{13}R^{14}$ ,  
 10 thiocarbamoyl,  $-C(=O)NHNH_2$ ,  $-C(=O)NHOH$ ,  $-C(=O)NH-OCH_3$ , carboxyl,  $NHBoc$ ,  $-NHC(=O)SCH_3$ , guanidine;  $R^{22}$  and  $R^{23}$  are independently hydrogen, methoxy or hydroxy; and  $p$ ,  $R^{12}$ ,  $R^{13}$  and  $R^{14}$  have the same meanings as defined in  $R^9$ );

or hydroxyphenylalkyl or (methanesulfonylaminophenyl)alkyl}; and

$R^3$  represents hydrogen, methyl, isopropyl, isobutyl, cyclohexyl, benzyl,  
 15 phenethyl or bisphenylmethyl; or phenylalkyl substituted with t-butyl, halogen or methanesulfonylamino.

Preferable examples of the compounds of formula (I) according to the present



invention are as follows:

- 1-(4-t-butylbenzyl)-3-[2-(1-methyl-1H-pyrrol-2-yl)ethyl]thiourea;
- 1-(4-t-butylbenzyl)-3-(4-amino-2,5-difluorobenzyl)thiourea;
- 1-(4-t-butylbenzyl)-3-(4-sulfamoylbenzyl)thiourea;
- 5 1-(4-t-butylbenzyl)-3-(3-fluoro-4-methanesulfonylaminobenzyl)thiourea;
- 1-phenethyl-3-(3-fluoro-4-methanesulfonylaminobenzyl)thiourea;
- 1-(4-t-butylbenzyl)-3-(3-chloro-4-methanesulfonylaminobenzyl)thiourea;
- 1-(4-t-butylbenzyl)-3-(3-methoxycarboxyl-4-methanesulfonylaminobenzyl)thio  
urea;
- 10 1-(4-t-butylbenzyl)-3-(3-carboxyl-4-methanesulfonylaminobenzyl)thiourea;
- 1-(4-t-butylbenzyl)-3-((3-N-hydroxyaminocarbonyl-4-methanesulfonylamino)b  
enzyl)thiourea;
- 1-(4-t-butylbenzyl)-3-(3-methoxycarboxylbenzyl)thiourea;
- 1-(4-t-butylbenzyl)-3-(3-carboxylbenzyl)thiourea;
- 15 1-(4-t-butylbenzyl)-3-(2,3,5,6-tetrafluoro-4-methanesulfonylaminobenzyl)thiou  
rea;
- 1-(4-t-butylbenzyl)-3-(2,5-difluoro-4-methanesulfonylaminobenzyl)thiourea;
- 1-(4-t-butylbenzyl)-3-[(3-methanesulfonylamino-6-pyridinyl)methyl]thiourea;
- 1-(4-t-butylbenzyl)-3-(2,6-dichloro-5-methanesulfonylaminobenzyl)thiourea;

1-(4-t-butylbenzyl)-3-(4-methanesulfonylamino)phenethylthiourea;

1-(4-t-butylbenzyl)-3-(4-methanesulfonylamino)benzylthiourea;

1-(4-t-butylbenzyl)-3-[2,6-difluoro-3-(N-methanesulfonylamino)benzyl]thiourea;

a;

5 1-(4-t-butylbenzyl)-3-[3-(N-methanesulfonylamino)benzyl]thiourea;

1-(4-t-butyl-2-methoxybenzyl)-3-(4-methanesulfonylamino)benzylthiourea;

1-(4-t-butyl-2-ethoxybenzyl)-3-(4-methanesulfonylamino)benzylthiourea;

1-(4-t-butyl-2-propoxybenzyl)-3-(4-methanesulfonylamino)benzylthiourea;

1-(4-t-butyl-2-butoxybenzyl)-3-(4-methanesulfonylamino)benzylthiourea;

10 1-(4-t-butyl-2-isopropoxybenzyl)-3-(4-methanesulfonylamino)benzylthiourea;

1-(4-t-butyl-2-isobutoxybenzyl)-3-(4-methanesulfonylamino)benzylthiourea;

1-(4-t-butyl-2-neopentoxymethyl)-3-(4-methanesulfonylamino)benzylthiourea;

1-(4-t-butyl-2-methoxymethoxybenzyl)-3-(4-methanesulfonylamino)benzylthiourea;

urea;

15 1-(4-t-butyl-2-methoxyethoxybenzyl)-3-(4-methanesulfonylamino)benzylthiourea;

ea;

1-(4-t-butyl-2-benzyloxybenzyl)-3-(4-methanesulfonylamino)benzylthiourea;

1-(2-acetoxymethyl-4-t-butylbenzyl)-3-(4-methanesulfonylamino)benzylthiourea;

a;

1-(4-t-butylbenzyl)-3-[2-(4-methylthiazol-5-yl)ethyl]thiourea;

1-(4-t-butylbenzyl)-3-((2-chloro-5-pyridinyl)methyl)thiourea;

1-(4-t-butylbenzyl)-3-(2-pyridin-2-ylethyl)thiourea;

1-(4-t-butylbenzyl)-3-(2,5-difluorobenzyl)thiourea;

5 1-(4-t-butylbenzyl)-3-(3-fluorophenethyl)thiourea;

1-(4-t-butylbenzyl)-3-(4-sulfamoylphenethyl)thiourea;

1-(4-t-butylbenzyl)-3-(4-morpholinylethyl)thiourea;

1-(4-t-butylbenzyl)-3-[2-(1H-imidazol-4-yl)ethyl]thiourea;

1-(4-t-butylbenzyl)-3-[2-thiophen-2-ethyl]thiourea;

10 1-(4-t-butylbenzyl)-3-(4-methanesulfonylamino-1-methyl-1H-pyrrol-2-yl)thiourea;  
rea;

1-benzyl-1-(3-(4-hydroxy-3-methoxyphenyl)propyl)-3-phenethylthiourea;

1-(3-(4-hydroxy-3-methoxyphenyl)propyl)-1-phenethyl-3-phenethylthiourea;

1-bisphenylmethyl-1-(3-(4-hydroxy-3-methoxyphenyl)propyl)-3-phenethylthio

15 urea; or

N"-cyano-N-(4-t-butylbenzyl)-N'-(4-methanesulfonylaminobenzyl)guanidine.

More preferable examples of the compounds of formula (I) according to the present invention are follows:

1-(4-t-butylbenzyl)-3-(3-fluoro-4-methanesulfonylaminobenzyl)thiourea;

1-(4-t-butylbenzyl)-3-(3-chloro-4-methanesulfonylaminobenzyl)thiourea;

1-(4-t-butylbenzyl)-3-(3-methoxycarboxyl-4-methanesulfonylaminobenzyl)thio

urea;


1-(4-t-butylbenzyl)-3-(4-methanesulfonylaminobenzyl)thiourea; or

5 1-(4-t-butyl-2-isobutoxybenzyl)-3-(4-methanesulfonylamino)thiourea.

The compounds according to the present invention can chemically be synthesized by the following reaction schemes. However, these are given only for illusion of the invention and not intended to limit them.

10


# 【SCHEME 1】



As depicted in the above Scheme 1, the nitrile compound 1-1 or 1-3 is reduced with lithium aluminium hydride or hydrogen to afford an amine 1-2 or 1-4, and then

suitable isothiocyanate or isocyanate is reacted therewith to prepare thiourea or urea compound 1-5 ~ 1-13.


【SCHEME 2】



5

As depicted in the above Scheme 2, pipsyl chloride is treated with ammonia solution to afford compound 2-2 and the nitrile compound 2-3 is obtained therefrom using palladium catalyst. The compound 2-3 is subjected to catalytic reduction using palladium and concentrated hydrochloric acid to prepare amine compound 2-4, and compounds 2-5, 2-6 and 2-7 are synthesized therefrom according to the procedure as described in Scheme 1.


【SCHEME 3】



As depicted in the above Scheme 3, 2-fluoro-4-iodo phenylamine compound 3-1 is mesylated, and cyano group is introduced thereinto in the presence of palladium catalyst. And the compound 3-3 is reduced to afford primary amine compound 3-4.


- 5 The obtained intermediate is reacted with isocyanate or isothiocyanate to synthesize compounds 3-5 ~ 3-7. And their derivatives such as compound 3-8 ~ 3-10 (Example 16 ~ 18) and 4-6 ~ 4-13 (Example 24 ~ 31) are synthesized according to the similar procedure as the synthetic method of the compounds 3-5 ~ 3-7.

# 10 【SCHEME 4】



As depicted in the above Scheme 4, the compound 4-1 obtained according to the procedure as described in Example 19 is reacted with oxalyl chloride to give acid chloride, and then the acid chloride is subjected to various reaction to yield compounds 4-2 ~ 4-5.


# 【SCHEME 5】



As depicted in the above Scheme 5, amine compound 5-1 is mesylated and the

obtained compound 5-2 is hydrogenated to afford amine compound 5-3, and then 4-t-butylbenzylisothiocyanate is reacted therewith to synthesize compound 5-4 ~ 5-9.

【SCHEME 6】




5

As depicted in the above Scheme 6, the amine group of 4-nitrobenzylamine hydrochloride compound 6-1 is protected. Nitro group thereof is reduced to give amino group and then methylchlorothiol formate is reacted therewith to prepare compound 6-3, followed by reacting 4-t-butylbenzylisothiocyanate therewith to obtain compound 6-5.

10


【SCHEME 7】





As depicted in the above Scheme 7, guanidine group and cyano group are introduced into 4-iodoaniline 7-1 to prepare compound 7-3, and the compound 7-3 is reduced in the presence of palladium catalyst to give amine compound 7-4. The compound 7-4 is reacted with 4-*t*-butylbenzylisothiocyanate, followed by deprotection to synthesize compound 7-6.


#### 【SCHEME 8】



As depicted in the above Scheme 8, 4-aminobenzylamine is selectively protected with t-butoxycarbonyl group (Boc) to prepare compound 8-1 and methanesulfonyl chloride is reacted with NH<sub>2</sub> group thereof to yield compound 8-2. Boc group is removed therefrom in acidic condition, and then

5 2-(1-methyl-1H-pyrrol-2-yl)ethylisocyanate is reacted therewith to yield compound 8-4.


## 【SCHEME 9】



Compounds 9a ~ 9h are synthesized by reacting 4-t-butylbenzylisothiocyanate

10 with corresponding benzylamine derivatives, respectively.

## 【SCHEME 10】




As depicted in the above Scheme 10, hydroxy group of 2-hydroxy-4-nitrobenzaldehyde is protected with TBDPS, and then oxime 10-1 is prepared therefrom. The compound 10-1 is reduced with hydrogen in the presence of

5 palladium catalyst and protected with Boc group to afford compounds 10-2 and 10-3. The compound 10-2 is reacted with t-butylbenzylisothiocyanate, and then TBDPS is removed therefrom to synthesize compound 10-4. Two protecting groups of compound 10-3 are removed using trifluoroacetic acid and the deprotected compound is protected with Boc group in the presence of triethylamine to synthesize compound 10-5.


10 TBDPS and Boc group are removed from the compound 10-5 and t-butylbenzylisothiocyanate is reacted therewith in the presence of triethylamine to give compound 10-6.

【SCHEME 11】



As depicted in the above Scheme 11, 2,6-difluoro-3-nitrobenzonitrile is reduced and then protected with Boc group to prepare compound 11-1. The amino group of the compound 11-1 is mesylated, and after removing of the Boc group therefrom, the mesylated compound is reacted with 4-*t*-butylbenzylisothiocyanate to give compound 11-2.

#### 【SCHEME 12】



10


As depicted in the above Scheme 12, the carbonyl group of nitrobenzaldehyde is converted into oxime group, and the oxime group and nitro group are reduced with hydrogen in the presence of Pd/C catalyst to prepare amine compound 12-1. The

amine compound 12-1 is selectively protected and mesylated to afford compound 12-2.

Boc group is removed from compound 12-2, and, in the presence of triethylamine, t-butylbenzylisothiocyanate compound is reacted therewith to synthesize compound 12-3a ~ 12-3g.

5

### 【SCHEME 13】




As depicted in the above Scheme 13, 4-t-butyl-2-hydroxybenzonitrile 13-1 as a starting material is O-alkylated and reduced to prepare amine compound 13-3.

10 4-Methanesulfonaminobenzylisothiocyanate is reacted therewith to yield thiourea compound 13-4a ~ 13-4k. And compound 13-1 is reacted with O-triflate, and subsequently with carbon monoxide in the presence of palladium acetate catalyst to yield ester 13-6. The ester 13-6 is reduced, and then reacted with

4-methanesulfonaminobenzylisothiocyanate to prepare alcohol compound 13-8. The prepared compound 13-8 is subjected to condensation reaction with acid to yield the corresponding thiourea compound 13-9a and 13-9b.


5      **【SCHEME 14】**



As depicted in the above Scheme 14, respective compounds 14-1 and 14-4 are  
 10 obtained from 4-(methylthio)benzylalcohol and 4-methylthiazol-5-ethanol, respectively,  
 under Mitsunobu condition, or obtained by introducing mesyl group into  
 4-(methylthio)benzylalcohol and 4-methylthiazol-5-ethanol, respectively, followed by  
 reacting potassium phthalimide therewith. Phthalimide group is removed from  
 compounds 14-1 and 14-4 with hydrazine to give amine compounds 14-2 and 14-5,  
 15 respectively. The obtained amine compounds 14-2 and 14-5 are separately reacted  
 with one equivalent of 4-t-butylbenzylisothiocyanate to the objective thiourea  
 compounds 14-3 and 14-6, respectively. 2-Chloro-5-chloromethylpyridine is reacted

with potassium phthalimide to yield compound 14-7, and then compound 14-9 is synthesized according to the same procedure as the synthetic method of the compounds 14-3 and 14-6.


5      **【SCHEME 15】**



Thiomorpholine is reacted with 2-(bromoethyl)phthalimide in the presence of base to yield compound 15-1. Phthaloyl group of the compound 15-1 is treated with hydrazine to prepare amine compound 15-2 and 4-*t*-butylbenzylisothiocyanate is reacted therewith to afford the objective compound 15-3.

10

**【SCHEME 16】**




$\text{R}^2$  = furanylmethyl, 2-pyridinyl, 2-thiophenemethyl, 2-thiophenethyl,  
 2-pyridinylmethyl, 3-pyridinylmethyl, 4-pyridinylmethyl, 2-pyridinylethyl,  
 2-fluorobenzyl, 3-fluorobenzyl, 4-fluorobenzyl,  
 3,4-difluorobenzyl, 3,5-difluorobenzyl, 2,5-difluorobenzyl, 2,4-difluorobenzyl,  
 2,6-difluorobenzyl, 2,3,4-trifluorobenzyl, 2,3,6-trifluorobenzyl,  
 2-fluorophenethyl, 3-fluorophenethyl, 4-fluorophenethyl, 3,4-difluorophenethyl,  
 4-methoxyphenethyl, 3-methoxyphenethyl, 2-methoxyphenethyl,  
 3,4-dimethoxyphenethyl, 3,4,5-trimethoxybenzyl, 4-aminosulfonylphenethyl,  
 3,4-dihydroxyphenethyl, 3,4-methylenedioxyphenyl,  
 4-morpholino-, 4-morpholinoethyl, 4-morpholinopropyl,  
 1-piperidineethyl, 1*H*-imidazolyl-4-ethyl, 1*H*-indolyl-3-ethyl, benzimidazol-2-yl,  
 5-nitro-pyridin-2-ylaminoethyl, 1*H*-imidazolyl-1-propyl,  
 1-methylpyrrolidin-2-ylethyl  
 (2-hydroxy-1-methyl-2-phenyl)ethyl

$\text{R}^1$  = 4-*t*-butylbenzyl, phenethyl, 4-methoxybenzyl

As depicted in the above Scheme 16, compound **A** and isothiocyanate  
 compound **B** of the above formula are reacted with each other in the presence of  
 suitable solvent (dichloromethane, acetonitrile, ethylacetate, dimethylformamide) using  
 5 suitable condition (triethylamine) to yield thiourea compound **C** (Example 76 ~ 122).


# 【SCHEME 17】





As depicted in the above Scheme 17, pyrrolecarboxaldehyde and 5-nitro-2-thiophenecarboxaldehyde are respectively converted to oximes, and the oximes are reduced to prepare primary amine hydrochloride. The prepared intermediates are reacted with isothiocyanates to give compounds 17-1 ~ 17-4, respectively.

### 【SCHEME 18】




10

As depicted in the above Scheme 18, ethyl-2-methyl nicotinate 18-1 is reduced to prepare alcohol, and then amine is introduced thereinto. The prepared intermediate


is reacted with 4-t-butylbenzylisothiocyanate to yield compound 18-5.

【SCHEME 19】



- 5 As depicted in the above Scheme 19, 5-nitro-1H-indazole is reduced to prepare amine, and then isothiocyanate is reacted therewith to afford compounds 19-1 and 19-2.


【SCHEME 20】



- 10 As depicted in the above Scheme 20, 2-fluoro-4-hydroxybenzonitrile is reduced with sodium borohydride in the presence of nickel catalyst, and protected with Boc group to prepare protected amine compounds 20-1a and 20-1b. Phenol group of compound 20-1a is mesylated, and Boc group is removed therefrom, followed by reacting with t-butylbenzylisothiocyanate to give compound 20-2a. And compound

20-2b is obtained from compound 20-1b, according to the similar procedure as the synthetic method of compound 20-2a.


【SCHEME 21】



5

As depicted in the above Scheme 21, 2-aminopicoline is reacted with pivaloyl chloride to yield compound 21-1. The compound 21-1 is brominated with NBS to prepare compound 21-2 and potassium phthalimide is reacted therewith to obtain compound 21-3 protected with phthaloyl group. Pivaloyl group is removed from compound 21-3 in the presence of concentrated sulfuric acid, and methanesulfonylchloride is reacted therewith to prepare compound 21-5. The prepared compound 21-5 is treated with hydrazine and reacted with 4-t-butylbenzylisothiocyanate to yield compound 21-7.

## 【SCHEME 22】




Nitro group is selectively introduced into pyrrolecarboxaldehyde under nitric acid/acetic anhydride condition and the compound 22-1 was reduced with borane to

5 prepare alcohol 22-2. The prepared compound 22-2 is reacted with 4-*t*-butylbenzylisothiocyanate in the presence of sodium hydride to yield compound 22-3. And pyrrolecarboxaldehyde is reacted with hydroxylamine hydrochloride in the presence of 1-methyl-2-pyrrolidinone (NMP) as a solvent to produce nitrile compound 22-4 and nitro group is introduced thereinto under the similar condition as above. The


10 nitro group is reduced and mesylated to give compound 22-7. The nitrile group of the compound 22-7 is reduced in the presence of palladium/carbon and 4-*t*-butylbenzylisothiocyanate is reacted therewith to synthesize compound 22-9.

## 【SCHEME 23】



As depicted in the above Scheme 23, 4-nitrobenzylamine hydrochloride is converted to methanesulfonyl derivatives 23-1. Nitro group of the compound 23-1 is reduced with tin (II) chloride and 4-*t*-butylbenzylisothiocyanate is reacted therewith to give compound 23-2.

## 【SCHEME 24】




$R^K R^L NH$  = 4-Benzyl-piperazine  
 4-Pyridin-2-yl-piperazine  
 4-Pyrimidin-2-yl-piperazine  
 1,2,3,4-tetrahydroisoquinoline  
 4-Pyrazolecarboxylic acid

$R^1$  = 4-*t*-butylbenzyl, phenethyl


As depicted in the above Scheme 24, amine compound **D** is reacted with isothiocyanate compound **B** in suitable solvent to yield thiourea compound **E** (Example 136 ~ 141).

5      **【SCHEME 25】**




As depicted in the above Scheme 25, benzaldehyde, phenylacetaldehyde and cinnamaldehyde derivatives are subjected to reductive amination with alkylamine to prepare the corresponding secondary amines, respectively, and phenethylisothiocyanates are reacted therewith to obtain compounds 25-1 ~ 25-26 (Example 142 ~ 167, respectively).

**【SCHEME 26】**




As depicted in the above Scheme 26, 2-fluoro-4-iodo methanesulfonylbenzylamine 3-2 is subjected to cross coupling using palladium to prepare compound 26-1 and the compound 26-1 is hydrogenated in the presence of  
 5 palladium/carbon to give compound 26-2. The compound 26-2 is reacted with 4-*t*-butylbenzylamine to synthesize amide compound 26-3.

#### 【SCHEME 27】




10 4-*t*-butylbenzoylchloride is reacted with 3-fluoro-4-methanesulfonylaminobenzylamine hydrochloride (3-4) to yield amide compound 27.

## 【SCHEME 28】



As depicted in the above Scheme 28, 3-fluoro-4-methanesulfonaminobenzyl  
amine hydrochloride 3-4 is reacted with 4-*t*-butylbenzyl bromide and carbon disulfide in  
5 the presence of cesium carbonate to yield compound 28.


## 【SCHEME 29】



As depicted in the above Scheme 29, 4-*t*-butylbenzylamine is reacted with  
10 triphosgene to prepare isocyanate, and 3-fluorophenethylamine is reacted therewith to  
afford compound 29.


## 【SCHEME 30】





As depicted in the above Scheme 30, 2-fluorobenzoyl chloride is reacted successively with KSCN and 4-t-butylbenzylamine to obtain final compound 30.


# 5 【SCHEME 31】



As depicted in the above Scheme 31, cyanoguanidine compounds are synthesized by two methods. As one method, 4-t-butylbenzylamine is reacted with dimethyl N-cyanodithioiminocarbonate or diphenyl cyanocarbonimidate, and then amine is reacted therewith to yield final compounds 31-1 ~ 31-6 (Example 173 ~ 178). And thiourea compound is reacted with lead cyanamide to give compounds 31-7 ~ 31-9

(Example 179 ~ 181).


## 【SCHEME 32】



5

As depicted in the above Scheme 32, tetralone is converted to oxime and the oxime is reduced with nickel catalyst and sodium borohydride to prepare amine compounds 32-1, 32-3 and 32-5. These compounds are reacted with various benzylisothiocyanates to give compounds 32-2, 32-4 and 32-6 ~ 32-10. And methoxy group of compounds 32-3 and 32-5 are treated with hydrobromic acid to form hydroxy group and the resulting compound are reacted with various benzylisothiocyanates in the presence of triethylamine to yield compounds 32-11 and 32-12.


## 【SCHEME 33】



As depicted in the above Scheme 33, 2-amino-3-formylchromone 33-1 or 3,5-dimethylpyrazole-1-methanol 33-3 is, respectively, reacted with 4-tert-butylbenzylisothiocyanate in the presence of base to give compounds 33-2 or 33-4.

5


#### 【SCHEME 34】



As depicted in the above Scheme 34, 4-tert-butylbenzaldehyde is reacted with phosphonate to prepare compound 34-2, and the compound 34-2 is reduced and

hydrolyzed to give 4-t-butylhydrocinnamic acid **34-4**. The obtained compound is reacted with compound **3-4** which is prepared according to the procedure as described in Example 13, to synthesize final compound **34-5**.


5     **【SCHEME 35】**



As depicted in the above Scheme 35,

N-t-butyloxycarbonyl-p-aminobenzylamine **8-1** is reacted with sulfamoyl chloride in basic condition to prepare compound **35-1**. The prepared compound **35-1** is  
 10 deprotected with trifluoroacetic acid to afford amine, and 4-t-butylbenzylisothiocyanate is subjected to condensation reaction therewith to yield thiourea compounds **35-2a**, **35-2b** and **35-2c**. 3-Nitro-4-aminobenzonitrile is mesylated to give compound **35-4**, and then nitrile group of the compound **35-4** is reduced with borane to afford amine. 4-t-Butylbenzylisothiocyanate is subjected to condensation reaction therewith to  
 15 synthesize thiourea compound **35-5**.

## 【SCHEME 36】



As depicted in the above Scheme 36, oxime 36-2, prepared from 4-aminoacetophenone as a starting material, is reduced to yield compound 36-3. Isothiocyanates are reacted therewith to give compounds 36-4 and 36-5. And compound 36-1 is reduced with methylamine to afford benzylamine derivatives, and 4-t-butylbenzylisothiocyanate is reacted therewith to synthesize compound 36-6.

The compound of formula (I) according to the present invention can be provided as a pharmaceutical composition containing pharmaceutically acceptable carriers, adjuvants, or diluents. For instance, the compounds of the present invention can be dissolved in oils, propylene glycol or other solvents which are commonly used to

produce an injection. Suitable examples of the carriers include physiological saline, polyethylene glycol, ethanol, vegetable oils, isopropyl myristate, etc., but are not limited to them. For topical administration, the compounds of the present invention can be formulated in the form of ointment or cream.

5           The pharmaceutical composition containing the compound of the present invention as an active ingredient can be used for preventing or treating pain, acute pain, chronic pain, neuropathic pain, post-operative pain, migraine, arthralgia, neuropathies, nerve injury, diabetic neuropathy, neurodegeneration, neurotic skin disorder, stroke, urinary bladder hypersensitiveness, irritable bowel syndrome, a respiratory disorder  
10 such as asthma or chronic obstructive pulmonary disease, irritation of skin, eye or mucous membrane, fervescence, stomach-duodenal ulcer, inflammatory bowel disease and inflammatory diseases.

Hereinafter, the formulating methods and kinds of excipients will be described,  
15 but the present invention is not limited to them.

The compound according to the present invention may also be used in the forms of pharmaceutically acceptable salts thereof, for example, alkali metals salts such as sodium salts, potassium salts and the like; alkali earth metals salts such as calcium salts, magnesium salts and the like; amines such as triethanolamine or ammonium salts, and

may be used either alone or in combination or in admixture with other pharmaceutically active compounds.

The compounds of the present invention may be formulated into injections by dissolving, suspending or emulsifying in water-soluble solvent such as saline and 5% dextrose, or in water-insoluble solvents such as vegetable oils, synthetic fatty acid glyceride, higher fatty acid esters and propylene glycol. The formulations of the invention may include any of conventional additives such as dissolving agents, isotonic agents, suspending agents, emulsifiers, stabilizers and preservatives.

The preferable dose level of the compounds according to the present invention depends upon a variety of factors including the condition and body weight of the patient, severity of the particular disease, dosage form, and route and period of administration, but may appropriately be chosen by those skilled in the art. The compounds of the present invention are preferably administered in an amount ranging from 0.001 to 100 mg/kg of body weight per day, and more preferably from 0.01 to 30 mg/kg of body weight per day. Doses may be administered once a day, or several times a day with each divided portions. The compounds of the present invention are used in a pharmaceutical composition in an amount of 0.0001 ~ 10% by weight, and preferably 0.001 ~ 1% by weight, based on the total amount of the composition.

The pharmaceutical composition of the present invention can be administered

to a mammalian subject such as rat, mouse, domestic animals, human being and the like via various routes. The methods of administration which may easily be expected include oral and rectal administration; intravenous, intramuscular, subcutaneous, intrauterine, duramatral and intracerebroventricular injections.


5

### Best Mode for Carrying Out the Invention

The present invention is more specifically explained by the following examples. However, it should be understood that the present invention is not limited to these examples in any manner.

10

#### Example 1: Synthesis of 1-(1H-indol-5-ylmethyl)-3-phenethylthiourea (1-5)



#### Step 1: synthesis of (1H-indol-5-yl)methylamine

To an ice cold suspension of aluminium chloride (126mg) in ether (1.5 ml) was added a suspension of lithium aluminium hydride (55 mg) in ether (1.5 ml), followed by stirring for 5 min. A solution of 5-cyanoindole (103 mg) in ether (5 ml) was added dropwise thereto. The mixture was stirred at room temperature for 6 hours, followed



by adding aqueous Rochel solution thereto and then stirring for 5 hours. The resulting mixture was basified with 1M aqueous sodium hydroxide solution, extracted twice with ethyl acetate (50 ml), washed with saturated aqueous sodium chloride solution, dried over magnesium sulfate and then filtered to yield (1H-indol-5-yl)methylamine (93 mg, 5 88 %).

$^1\text{H}$  NMR(300MHz,  $\text{CD}_3\text{OD}$ ) :  $\delta$  7.46(d, 1H,  $J=1.0\text{Hz}$ ), 7.29(d, 1H,  $J=8.3\text{Hz}$ ), 7.14(d, 1H,  $J=3.2\text{Hz}$ ), 7.02(dd, 1H,  $J=1.7, 8.3\text{Hz}$ ), 6.34(dd, 1H,  $J=0.7, 3.2\text{Hz}$ ), 3.89(s, 2H)


10 Step 2: synthesis of 1-(1H-indol-5-ylmethyl)-3-phenethylthiourea (1-5)

(1H-indol-5-yl)methylamine (8.5 mg) prepared in Step 1 was dissolved in dimethylformamide (100  $\mu\text{l}$ ) and the solution was diluted with dichloromethane (1 ml). To the diluted solution was added phenethylisothiocyanate (40  $\mu\text{l}$ ) and the mixture was stirred at room temperature for 2 hours. The resulting mixture was concentrated under 15 reduced pressure and the obtained residue was chromatographed on a silica gel column eluting with ethyl acetate/hexane (2/3) to yield 1-(1H-indol-5-ylmethyl)-3-phenethylthiourea (15 mg, 83 %).

$^1\text{H}$  NMR(300MHz,  $\text{CDCl}_3$ ) :  $\delta$  8.17(s, 1H), 7.53(s, 1H), 7.28(d, 1H,  $J=8.3\text{Hz}$ ), 7.11-7.19(m, 5H), 6.98-7.04(m, 2H), 6.46(t, 1H,  $J=2.2\text{Hz}$ ), 6.03(s, 1H), 5.59(s, 1H),

4.44(s, 2H), 3.66(m, 2H), 2.77(t, 2H,  $J=6.8\text{Hz}$ )

**Example 2: Synthesis of 1-(1H-indol-5-ylmethyl)-3-phenethylurea (1-6)**




5

(1H-indol-5-yl)methylamine (12.5 mg) was reacted with phenethylisocyanate (30  $\mu\text{l}$ ) according to the similar procedure as described in step 2 of Example 1, to give 1-(1H-indol-5-ylmethyl)-3-phenethylurea (1-6) (19 mg, 76 %).

$^1\text{H}$  NMR(300MHz,  $\text{CDCl}_3$ ) :  $\delta$  8.16(s, 1H), 7.44(s, 1H), 7.27(d, 1H,  $J=8.3\text{Hz}$ ),  
 10 7.02-7.21(m, 7H), 6.43-6.45(m, 1H), 4.48(t, 1H), 4.31(d, 2H,  $J=5.6\text{Hz}$ ), 4.22(m, 1H),  
 3.37(q, 2H,  $J=6.8\text{Hz}$ ), 2.71(t, 2H,  $J=6.8\text{Hz}$ )

**Example 3: Synthesis of 1-(4-t-butylbenzyl)-3-(1H-indol-5-ylmethyl)thiourea (1-7)**



15

Step 1: synthesis of 4-t-butylbenzylisothiocyanate

Di-2-pyridyl thionocarbonate (45 mg) was dissolved in methylenechloride (2 ml) and to the solution were added 4-t-butylbenzylamine (29 mg) and triethylamine (20  $\mu$ l), followed by stirring at room temperature for 2 hours. The reaction solution was concentrated under reduced pressure and the obtained residue was chromatographed on  
5 a silica gel column eluting with ethyl acetate/hexane (1/10) to yield 4-t-butylbenzylisothiocyanate (26 mg, 71 %).


$^1\text{H}$  NMR(300MHz,  $\text{CDCl}_3$ ) :  $\delta$  7.39(d, 2H,  $J=8.5\text{Hz}$ ), 7.23(d, 2H,  $J=8.3\text{Hz}$ ), 4.65(s, 2H), 1.30(s, 9H)

10 Step 2: Synthesis of 1-(4-t-butylbenzyl)-3-(1H-indol-5-ylmethyl)thiourea (1-7)  
(1H-indol-5-yl)methylamine (15 mg) was reacted with 4-t-butylbenzylisothiocyanate (20 mg) according to the similar procedure as described in Step 2 of Example 1, to synthesize 1-(4-t-butylbenzyl)-3-(1H-indol-5-ylmethyl)thiourea (1-7) (21 mg, 70 %).

15  $^1\text{H}$  NMR(300MHz,  $\text{CDCl}_3$ ) :  $\delta$  8.33(s, 1H), 7.48(s, 1H), 7.19-7.33(m, 4H), 7.03-7.10(m, 4H), 6.47(t, 1H), 6.18(s, 1H), 6.06(s, 1H), 4.58(d, 2H,  $J=13\text{Hz}$ ), 1.26(s, 9H)

**Example 4: Synthesis of 1-(4-t-butylbenzyl)-3-(4-methanesulfonylbenzyl)thiourea**

(1-8)



Lithium aluminum hydride (0.38 g) was dissolved in anhydrous ether (20 ml).

5 The solution was cooled to 0°C and 4-(methanesulfonyl)benzonitrile (1.81 g) was slowly added dropwise thereto. The mixture was stirred for 3 hours while allowed to slowly warm up to room temperature and the reaction was quenched with 20% aqueous sodium hydroxide solution and water. The water layer was washed with ether, and then the ether layer was mixed with the organic layer. The combined  
10 organic layer was dried over anhydrous magnesium sulfate and concentrated. The residue was purified by column-chromatography (acetone) to yield a liquid (0.3 g).


The obtained liquid was dissolved in dichloromethane (10 ml) and 4-*t*-butylbenzylisothiocyanate (0.33 g) was added thereto, followed by stirring at room temperature for 19 hours. The reaction mixture was concentrated and then  
15 purified by column-chromatography (hexane/ethyl acetate = 1/1) to yield compound 1-8 (0.02 g) as a white solid.

<sup>1</sup>H NMR(300MHz, CDCl<sub>3</sub>) : δ 7.85-7.81(m, 2H), 7.41-7.30(m, 4H),

7.27-7.23(m, 2H), 6.25(brs, 1H), 6.05(brs, 1H), 4.88(d, 2H, J= 6Hz), 4.60-4.55(m, 2H),  
3.01(s, 3H), 1.31(s, 9H)

**Example** **5:** **Synthesis** **of**

**5 1-(4-t-butylbenzyl)-3-[2-(1-methyl-1H-pyrrol-2-yl)ethyl]thiourea (1-9)**



Step 1: Synthesis of (1-methyl-1H-pyrrol-2-yl)ethylamine

1-methyl-2-pyrroleacetonitrile (2 g) was slowly added dropwise to a suspension  
10 of lithium aluminium hydride (695 mg) in ether (100 ml) while the temperature was  
adjusted to -78°C. The mixture was stirred for 1 hour, and then stirred for 3 hours at  
room temperature. After confirming the completion of the reaction using TLC, 15 %  
aqueous sodium hydroxide solution (10 ml) and water (20 ml) were added dropwise and  
the resulting mixture was stirred for 1 hour. The reaction mixture was extracted three  
15 times with ether. The organic layer was washed with saturated aqueous sodium  
chloride solution and concentrated under reduced pressure to yield amine compound.  
The amine compound, which was not purified, was used in the following reaction.

Step 2: Synthesis of


1-(4-t-butylbenzyl)-3-[2-(1-methyl-1H-pyrrol-2-yl)ethyl]thiourea (1-9)

Amine (250 mg) prepared in Step 1 and 4-t-butylbenzylisothiocyanate (420 mg) were dissolved in ethyl acetate (20 ml) and the solution was stirred at room temperature for 12 hours. The resulting mixture was concentrated under reduced pressure to remove the solvent and the residue was purified by column-chromatography (ethyl acetate/hexane = 1/3) to yield compound 1-9 (498 mg, 75 %) as a liquid.

$^1\text{H}$  NMR (300MHz,  $\text{CDCl}_3$ )  $\delta$  7.37(d, 2H), 7.19(d, 2H), 6.54(m, 1H), 6.01(m, 1H), 5.83(s, 1H), 4.46(brs, 2H), 3.72(brs, 2H), 2.841(t, 2H,  $J=6.9\text{Hz}$ ), 1.31(s, 9H)

Example 6: Synthesis of

1-(4-amino-3,5-dichlorobenzyl)-3-(4-t-butylbenzyl)thiourea (1-10)



15


4-amino-3,5-dichlorobenzonitrile (260 mg) was dissolved in methanol (20 ml) and a small amount of concentrated hydrochloric acid and 5 % palladium/carbon

catalyst was added thereto. After the mixture was stirred for 15 hours, the reaction mixture was filtered through celite and concentrated. The obtained mixture was dissolved in dichloromethane (10 ml), and 4-t-butylbenzylisothiocyanate (200 mg) and triethylamine (2 ml) was added thereto, followed by stirring at room temperature  
5 for 15 hours. The resulting mixture was extracted with water and dichloromethane, and the residue was purified by column-chromatography (hexane/ethyl acetate = 1/1) to yield compound 1-10 (72 mg, 13 %) as a liquid.

$^1\text{H}$  NMR (300MHz,  $\text{CDCl}_3$ )  $\delta$  7.40-7.00(m, 6H), 5.92(brs, 2H), 4.58(m, 2H), 4.45(m, 2H), 3.71(brs, 2H), 1.31(s, 9H)

10

**Example 7: Synthesis of 1-(4-t-butylbenzyl)-3-(pyrazin-2-yl-methyl)thiourea (1-11)**




Pyrazinecarbonitrile (500 mg) and 10 % palladium/carbon (450 mg) were  
15 dissolved in anhydrous methanol (30 ml) and the mixture was stirred under hydrogen atmosphere for 12 hours.

The resulting mixture was filtered, and then the filtrate was concentrated under

reduced pressure. The obtained compound (200 mg) and 4-t-butylbenzylisothiocyanate (330 mg) were dissolved in ethyl acetate (30 ml). The solution was stirred for 12 hours and then concentrated. The resulting residue was purified by column-chromatography (ethyl acetate/hexane = 3/1) to yield the compound 1-11 (271 mg, 53 %).

$^1\text{H}$  NMR (300MHz,  $\text{CDCl}_3$ )  $\delta$  8.51(s, 1H), 8.41(s, 1H), 8.16(s, 1H), 7.38(m, 2H), 7.29(m, 2H), 5.10(s, 2H), 4.86(d, 2H,  $J=2.25\text{Hz}$ ), 1.33(s, 9H)

**Example 8: Synthesis of 1-(4-t-butylbenzyl)-3-(3-cyanopyrazin-2-ylmethyl)thiourea (1-12)**




2,3-pyrazinedicarbonitrile (200 mg) and 10 % palladium/carbon (200 mg) were dissolved in anhydrous methanol (30 ml) and the mixture was stirred under hydrogen atmosphere for 12 hours. The resulting mixture was filtered, and then the filtrate was dried under reduced pressure to give an amine. The obtained amine (150 mg) and 4-t-butylbenzylisothiocyanate (180 mg) were dissolved in ethyl acetate (30 ml). The



solution was stirred for 12 hours to complete the reaction and purified by column-chromatography (ethyl acetate/hexane = 3/1) to yield the compound **1-12** (77 mg, 25 %) as a white solid.

$^1\text{H}$  NMR (300MHz,  $\text{CDCl}_3$ )  $\delta$  8.76(m, 1H), 8.67(m, 1H), 7.38(m, 4H), 5.38(s, 2H), 4.98(d, 2H,  $J=2.7\text{Hz}$ ), 1.32(s, 9H)

**Example 9: Synthesis of 1-(4-amino-2,5-difluorobenzyl)-3-(4-*t*-butylbenzyl)thiourea (1-13)**



10

**Step 1: Synthesis of 4-amino-2,5-difluorobenzylamine**

4-amino-2,5-difluorobenzonitrile (400 mg) and Raney nickel Catalyst were added to methanol (20 ml) and the mixture was stirred under hydrogen atmosphere at room temperature for 18 hours. After confirming the completion of the reaction, the resulting mixture was filtered through celite and the filtrate was concentrated under reduced pressure. The following procedure was carried out, using the concentrate which was not purified.

Step 2: Synthesis of 1-(4-amino-2,5-difluorobenzyl)-3-(4-t-butylbenzyl)thiourea


(1-13)

5 The compound (330 mg) obtained in Step 1 and 4-t-butylbenzylisothiocyanate (428 mg) were dissolved in ethyl acetate (40 ml) and the solution was stirred at room temperature for 6 hours. The mixture was concentrated under reduced pressure and the residue was purified by column-chromatography (ethyl acetate/hexane = 1/3) to yield the compound 1-13 (190 mg, 25 %).

10  $^1\text{H}$  NMR(300MHz,  $\text{CDCl}_3$ ) :  $\delta$  7.37(m, 2H), 7.22(m, 2H), 6.95(m, 1H), 6.43(m, 1H), 6.08(brs, 1H), 5.90(brs, 1H), 4.59(s, 2H), 4.57(s, 2H), 3.83(s, 2H), 1.31(s, 9H)

**Example 10: Synthesis of 1-phenethyl-3-(4-sulfamoylbenzyl)thiourea (2-5)**

15



Step 1: Synthesis of 4-iodo-1-sulfamoylbenzene (2-2)

Pipsylchloride (100 mg) was dissolved in 28 % ammonia solution (4 ml) and the solution was stirred at room temperature for 1 hours. The resulting mixture was extracted with ethyl acetate (20 ml), washed with water and saturated aqueous sodium chloride solution, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. The residue was chromatographed on column eluting with ethyl acetate/hexane (1/2) to yield the compound 2-2 (89 mg, 100 %).

$^1\text{H}$  NMR(300MHz,  $\text{CD}_3\text{OD}$ ) :  $\delta$  7.91(td, 1H,  $J=9.0\text{Hz}$ ), 7.63(td, 1H,  $J=9.0\text{Hz}$ )

#### Step 2: Synthesis of 4-cyano-1-sulfamoylbenzene (2-3)

The compound 2-2 (58 mg) prepared in Step 1 was dissolved in dimethylformamide (2 ml) and to the solution were added zinc cyanide [ $\text{Zn}(\text{CN})_2$ ] (58 mg) and tetrakis(triphenylphosphine) palladium (10 mg), followed by stirring at  $80^\circ\text{C}$  for 12 hours. The resulting mixture was basified with aqueous sodium bicarbonate solution, diluted with ethyl acetate (30 ml), washed with water and saturated aqueous sodium chloride solution, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. The obtained residue was chromatographed on silica gel column eluting with ethyl acetate/hexane (1/2) to yield the compound 2-3 (30 mg, 80 %).

$^1\text{H}$  NMR(300MHz,  $\text{CDCl}_3$ ) :  $\delta$  7.92-7.96 (m, 2H), 7.69-7.73 (m, 2H), 6.47 (s,

2H)

Step 3: Sythesis of 4-sulfamoylaminobenzene (2-4)

The compound 2-3 (52 mg) prepared in Step 2 was dissolved in methanol (2  
5 ml) and to the solution were added a catalytic amount of 10% palladium/carbon and  
concentrated hydrochloric acid (10  $\mu$ l), followed by stirring under hydrogen gas  
atmosphere at room temperature for 1 hour. The resulting mixture was diluted in ether,  
filtered through celite, neutralized with 1N aqueous sodium hyroxide solution, and then  
washed with water and saturate aqueous sodium chloride solution. The obtained  
10 residue was dried over anhydrous magnesium sulfate and then concentrated under  
reduced pressure to yield the compound 2-4 (26 mg, 50 %).

$^1\text{H-NMR}$ (300MHz,  $\text{CD}_3\text{OD}$ ) :  $\delta$  7.77 (dd, 2H,  $J = 1.7, 6.6$  Hz), 7.41 (d, 2H,  $J$   
= 8.5 Hz), 3.80 (s, 2H)

15 Step 4: Synthesis of 1-phenethyl-3-(4-sulfamoylbenzyl)thiourea (2-5)


The compound 2-4 (10 mg) prepared in Step 3 was dissolved in  
dimethylformamide (100  $\mu$ l). The solution was diluted with dichloromethane (2 ml)  
and to the solution was added phenethylisothiocyanate (1.0 ml), followed by stirring at  
room temperature for 2 hours. The reaction solution was concentrated under reduced

pressure and the obtained residue was chromatographed on a column eluting with ethyl acetate/hexane (1/1) to yield the compound **2-5** (11 mg, 59 %).

$^1\text{H}$  NMR(300MHz,  $\text{CD}_3\text{OD}$ ) :  $\delta$  7.82-7.85 (m, 2H), 7.42 (d, 2H,  $J = 8.5$  Hz), 7.16-7.30 (m, 5H), 4.78 (br s, 2H), 3.72 (br s, 2H), 2.88 (t, 2H,  $J = 7.1$  Hz)

5


**Example 11: Synthesis of 1-phenethyl-3-(4-sulfamoylbenzyl)urea (2-6)**



Compound **2-6** (13 mg, 79 %) was synthesized according to the same procedure as described in Step 4 of Example 10 except that compound **2-4** (9 mg) was reacted with phenethylisocyanate (100  $\mu\text{l}$ ).

$^1\text{H}$  NMR(300MHz,  $\text{CD}_3\text{OD}$ ) :  $\delta$  7.82-7.84 (m, 2H), 7.39 (d, 2H,  $J = 8.3$  Hz), 7.15-7.32 (m, 5H), 4.35 (s, 2H)

**Example 12: Synthesis of 1-(4-t-butylbenzyl)-3-(4-sulfamoylbenzyl)thiourea (2-7)**




15

Compound 2-7 (7 mg, 96 %) was synthesized according to the same procedure as described in Step 4 of Example 10 except that compound 2-4 (7 mg) and 4-t-butylbenzylisothiocyanate (10 mg) were used as reactants.

$^1\text{H}$  NMR(300MHz, acetone- $\text{d}_6$ ) :  $\delta$  7.81 (d, 2H,  $J = 8.3$  Hz), 7.48 (d, 2H,  $J = 8.3$  Hz), 7.36 (dd, 2H,  $J = 1.7, 6.3$  Hz), 7.26 (d, 2H,  $J = 8.3$  Hz), 4.91 (br s, 2H), 4.75 (br s, 2H), 1.29 (s, 9H)

**Example 13: Synthesis of 1-(4-t-butylbenzyl)-3-(3-fluoro-4-methanesulfonylaminobenzyl)thiourea (3-5)**



10

**Step 1: Synthesis of 2-fluoro-4-iodo-1-methanesulfonylaminobenzene (3-2)**

2-fluoro-4-iodophenylamine (1.50 g) was dissolved in dichloromethane (40 ml) and to the solution were added pyridine (1.02 ml) and methanesulfonylchloride (700  $\mu\text{l}$ ). The mixture was stirred at room temperature for 1 hour and 1.5 N aqueous hydrochloric acid was added thereto to quench the reaction. The resulting mixture was extracted with dichloromethane, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. The obtained residue was

column-chromatographed (ethyl acetate/hexane = 1/1) to yield the compound 3-2 (1.89 g, 95%).

$^1\text{H}$  NMR(300MHz,  $\text{CDCl}_3$ ) :  $\delta$  7.47(dd, 2H,  $J=1.2, 1.7\text{Hz}$ ) 7.30(t, 1H,  $J=8.3\text{Hz}$ ) 6.51(s, 1H) 3.01(s, 3H)

5

Step 2: Synthesis of 4-cyano-2-fluoromethanesulfonylaminobenzene (3-3)

The compound 3-2 (1.81 g) prepared in Step 1 was dissolved in dimethylformamide (10 ml) and to the solution were added zinc (II) cyanide (845 mg) and tetrakis(triphenylphosphine) palladium (187 mg), followed by stirring at 80-90°C for 10 1.5 hours. The resulting mixture was diluted with ethyl acetate (20 ml), washed with water and saturated aqueous sodium chloride solution, and then dried over anhydrous magnesium sulfate. The remaining liquid was concentrated under reduced pressure and the obtained residue was chromatographed on column eluting with ethyl acetate/hexane (1/2) to yield the compound 3-3 (1.03 g, 80 %).

15  $^1\text{H}$  NMR(300MHz,  $\text{CDCl}_3$ ) :  $\delta$  7.65(t, 1H,  $J=8.0\text{Hz}$ ) 7.41(d, 1H,  $J=9.8\text{Hz}$ ) 7.37(dd, 1H,  $J=9.5, 1.7\text{Hz}$ ) 6.83(s, 1H) 3.07(s, 3H)

Step 3: Synthesis of 3-fluoro-4-methanesulfonaminobenzylamine hydrochloride (3-4)

The compound 3-3 (1.03 g) prepared in Step 2 was dissolved in methanol (20 ml) and to the solution were added a catalytic amount of 10% palladium/carbon and concentrated hydrochloric acid (3 ml), followed by stirring at room temperature under hydrogen gas atmosphere for 1 hour. The resulting mixture was diluted in ether, filtered through celite, concentrated under reduced pressure, and then washed with ethyl acetate to yield the compound 3-4 (1.13 g, 92 %).

$^1\text{H}$  NMR(300MHz,  $\text{CD}_3\text{OD}$ ) :  $\delta$  7.57(t, 1H,  $J=8.3\text{Hz}$ ) 7.33(dd, 1H,  $J=9.8$ , 1.8Hz) 7.27(d, 1H,  $J=8.5\text{Hz}$ ) 4.11(s, 2H) 3.02(s, 3H)

Step 4: Synthesis of  
1-(4-t-butylbenzyl)-3-(3-fluoro-4-methanesulfonylaminobenzyl)thiourea (3-5)

Compound 3-4 (1.13 g) prepared in Step 3 was dissolved in dimethylformamide (6 ml) and the solution were diluted in dichloromethane (35 ml). To the diluted solution was added 4-t-butylbenzylisothiocyanate (1.09 g) and triethylamine (1.2 ml) in order, and then the mixture was stirred at room temperature for 2 hours. The resulting mixture was concentrated under reduced pressure, diluted with ethyl acetate (20 ml), and then washed with water and saturatated aqueous sodium chloride solution. The residue was dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The obtained residue was purified by chromatography on column eluting




with ethyl acetate/hexane (2/3) to yield the compound 3-5 (1.23 g, 65 %).

$^1\text{H}$  NMR(300MHz,  $\text{CDCl}_3$ ) :  $\delta$  7.41(t, 1H,  $J=8.2\text{Hz}$ ) 7.34(d, 2H,  $J=8.0\text{Hz}$ )  
7.20(d, 2H,  $J=8.0\text{Hz}$ ) 7.01(d, 1H,  $J=11.9\text{Hz}$ ) 6.97(d, 1H,  $J=9.8\text{Hz}$ ) 6.69(brs, 1H) 4.68(s,  
2H) 4.54(s, 2H) 2.97(s, 3H) 1.28(s, 9H)

5

**Example 14: Synthesis of**  
**1-phenethyl-3-(3-fluoro-4-methanesulfonaminobenzyl)urea (3-6)**




**3-6**

Compound 3-6 (17 mg, 36 %) was synthesized according to the same procedure  
as described in Step 4 of Example 13 except that compound 3-4 (28 mg) was reacted  
with phenethylisocyanate (38  $\mu\text{l}$ ).

$^1\text{H}$  NMR(300MHz,  $\text{CD}_3\text{OD}$ ) :  $\delta$  7.40(t, 1H,  $J=8.2\text{Hz}$ ) 7.28~7.06(m, 7H)  
4.69(s, 2H,  $\text{CH}_2$ ) 3.87 (t, 2H) 2.98(s, 3H) 2.87(t, 2H,  $J=7.1\text{Hz}$ )

**Example 15: Synthesis of**  
**1-phenethyl-3-(3-fluoro-4-methanesulfonylaminobenzyl)thiourea (3-7)**




Compound 3-7 (8.3 mg, 24 %) was synthesized according to the same procedure as described in Step 4 of Example 13 except that compound 3-4 (20 mg) and

5 phenethylisothiocyanate (27  $\mu$ l) were used as reactants.

$^1\text{H}$  NMR(300MHz,  $\text{CD}_3\text{OD}$ ) :  $\delta$  7.40(t, 1H,  $J=8.2\text{Hz}$ ) 7.29~7.14(m, 5H)  
7.10~7.03(m, 2H) 4.26(s, 2H) 3.36 (t, 2H) 2.95(s, 3H) 2.76(t, 2H,  $J=7.1\text{Hz}$ )




Compounds 3-8, 3-9 and 3-10 were synthesized according to the similar

10 procedure as described in the Example 13, and NMR data thereof are shown below.




Examp les	Compoun ds No.	R <sup>a</sup>	R <sup>b</sup>	Spectral data
--------------	-------------------	----------------	----------------	---------------

16	3-8	NHSO <sub>2</sub> Me	CH <sub>3</sub>	<sup>1</sup> H NMR(300MHz, CD <sub>3</sub> OD) : δ 7.32(d, 2H, J=8.0Hz) 7.30(d, 1H, J=8.3Hz) 7.17(d, 2H, J=8.3Hz) 7.10(s, 1H) 7.04(d, 1H, J=8.0Hz) 6.37(brs, 1H) 4.59(s, 2H) 4.55(s, 2H) 2.97(s, 3H) 2.25(s, 3H) 1.28(s, 9H)
17	3-9	NHSO <sub>2</sub> Me	Cl	<sup>1</sup> H NMR(300MHz, CDCl <sub>3</sub> ) : δ 7.50(d, 1H, J=8.3Hz) 7.37(d, 2H, J=8.3Hz) 7.35(d, 1H, J=2.0Hz) 7.23(d, 2H, J=8.3Hz) 7.13(d, 1H, J=7.1Hz) 6.92(brs, 1H) 4.69(s, 2H) 4.58(s, 2H) 2.978(s, 3H) 1.30(s, 9H)
18	3-10	NHSO <sub>2</sub> Me	CO <sub>2</sub> Me	<sup>1</sup> H NMR(400MHz, CDCl <sub>3</sub> ) : δ 10.38(brs, 1H) 7.99(s, 1H) 7.57(d, 1H, J=8.5Hz) 7.41(d, 1H, J=8.4Hz) 7.36(d, 2H, J=8.0Hz) 7.23(d, 2H, J=8.0Hz) 4.71(s, 2H) 4.62(s, 2H) 3.93(s, 3H) 2.84(s, 3H) 1.31(s, 9H)




**Example 19: Synthesis of**  
**1-(4-t-butylbenzyl)-3-(3-carboxyl-4-methanesulfonylaminobenzyl)thiourea (4-1)**



5           Compound 3-10 (1.08 g) prepared according to the procedure as described in Example 13 was dissolved in acetone (20 ml) and to the solution was added 2.5 M aqueous lithium hydroxide solution (15 ml). The mixture was stirred at room temperature for 5 hours and the solvent was removed therefrom. The residue was dissolved in ethyl acetate and then extracted to yield the compound 4-1 (980 mg, 94 %).

10           <sup>1</sup>H NMR(300MHz, CD<sub>3</sub>CD) : δ 8.07(d, 1H, J=2.2Hz) 7.63(d, 1H, J=8.5Hz) 7.51(d, 1H) 7.34(d, 2H, J=8.5Hz) 7.20(d, 2H, J=8.0Hz) 4.73(s, 2H) 4.66(s, 2H) 3.03(s, 3H) 1.29(s, 9H)


**Example 20: Synthesis of**  
 15   **1-(4-t-butylbenzyl)-3-((3-N-methoxyaminocarbonyl-4-methanesulfonylamino)benzyl)thiourea (4-2)**




Compound 4-1 (50 mg) prepared according to the procedure as described in Example 19 was dissolved in benzene (2 ml) and to the solution was added dropwise oxalyl chloride (100  $\mu$ l), followed by refluxing for 2 hours. The resulting mixture was concentrated under reduced pressure, and to the concentrate was added methoxylamine (92 mg). The mixture was dissolved in pyridine (2 ml), and the solution was stirred at room temperature for 24 hours and then concentrated under reduced pressure. To the concentrate was added ethyl ether, and the mixture was filtered and concentrated under reduced pressure. The obtained residue was chromatographed on column eluting ethyl acetate to yield the compound 4-2 (16 mg, 30 %).

$^1\text{H}$  NMR(300MHz,  $\text{CDCl}_3$ ) :  $\delta$  10.14(s, 1H) 9.38(s, 1H) 7.55(m, 3H) 7.32(m, 4H) 5.04(s, 2H) 5.01(s, 2H) 3.82(s, 3H) 3.00(s, 3H) 1.25(s, 9H)

Compound 4-3 was synthesized according to the similar procedure as described in the Example 20, and NMR data thereof are shown below.




Example	Compound No.	R'	R''	Spectral data
21	4-3	NHSO <sub>2</sub> Me	CONHOH	<sup>1</sup> H NMR(300MHz, CD <sub>3</sub> OD) : δ 8.09(d, 1H, J=2.0Hz) 7.51(d, 1H, J=8.3Hz) 7.44(dd, 1H, J=2.2, 8.6Hz) 7.31(m, 4H) 5.05(s, 4H) 2.92(s, 3H) 1.27(s, 9H)



5

**Example 22: Synthesis of 1-(4-t-butylbenzyl)-3-(3-hydrazido-4-methanesulfonylaminobenzyl)thiourea (4-4)**




10

Compound 4-1 (76 mg) prepared according to the procedure as described in

Example 19 was dissolved in benzene (3 ml) and to the solution was added dropwise oxalyl chloride (200  $\mu\text{l}$ ), followed by refluxing for 3 hours. The resulting mixture was concentrated under reduced pressure and to the concentrate was added hydrazine (55 mg). The mixture was dissolved in tetrahydrofuran (3 ml), and the solution was stirred at 0°C for 2 hours and then concentrated under reduced pressure. The obtained residue was chromatographed on silica gel column (ethyl acetate/hexane = 1/1) to yield the compound 4-4 (5 mg, 6 %).

$^1\text{H}$  NMR(300MHz, DMSO- $d_6$ ) :  $\delta$  10.9(s, 1H), 10.2(s, 1H), 7.75(s, 1H), 7.64(d, 1H), 7.55(d, 1H), 7.41(s, 4H), 5.04(s, 2H), 5.00(s, 2H), 3.14(s, 3H), 1.20(s, 9H)

Example 23: Synthesis of 1-(4-*t*-butylbenzyl)-3-(3-cyano-4-methanesulfonylaminobenzyl)thiourea (4-5)




Compound 4-1 (50 mg) prepared according to the procedure as described in Example 19 was dissolved in benzene (3 ml) and to the solution was added dropwise oxalyl chloride (100  $\mu\text{l}$ ), followed by refluxing for 3 hours. The resulting mixture was concentrated under reduced pressure and to the concentrate was added sulfamide

(106 mg). The mixture was dissolved in sulfolane (2 ml) and the solution was refluxed at 120°C for 3 hours. To the reaction mixture was added 1 N-aqueous sodium hydroxide solution to quench the reaction. The resulting mixture was extracted with ether, washed several times with water, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. The obtained residue was column-chromatographed (ethyl acetate/hexane = 1/1) to yield the compound 4-5 (8 mg, 16 %).

$^1\text{H}$  NMR(300MHz,  $\text{CDCl}_3$ ) :  $\delta$  10.8(s, 1H), 7.65(m, 2H), 7.58(m, 1H), 7.33(d, 4H), 5.05(s, 4H), 3.01(s, 3H), 1.24(s, 9H)

10






Compounds 4-6 ~ 4-13 were synthesized according to the similar procedure as described in the Example 13, and NMR data thereof are shown below.






Examples	Compounds No.	R <sup>c</sup>	R <sup>d</sup>	Spectral data
24	4-6	NHCO <sub>2</sub> Me	F	$^1\text{H}$ NMR(300MHz, $\text{CDCl}_3$ ) : $\delta$ 7.97(t, 1H), 7.35(d, 2H), 7.68(d, 2H), 6.95(d, 2H), 6.82(s, 1H), 4.62(s, 2H), 4.46(s, 2H), 3.76(s, 3H), 1.26(s, 9H)




25	4-7	NHCOCH <sub>2</sub> OMe	F	<sup>1</sup> H NMR(300MHz, CDCl <sub>3</sub> ) : δ 8.49(s, 1H), 8.07(t, 1H, J=8.0Hz), 7.36(d, 2H, J=8.0Hz) 7.23(d, 2H, J=8.0Hz), 7.03(d, 1H, J=11.2Hz), 6.93(d, 1H, J=8.3Hz) 6.66(brs, 1H) 4.67(s, 2H), 4.62(s, 2H), 3.49(s, 3H), 1.32(s, 9H)
26	4-8	NHCO <sub>2</sub> Et	F	<sup>1</sup> H NMR(300MHz, CDCl <sub>3</sub> ) : δ 7.95(s, 1H) 7.33(d, 2H, J=8.0Hz) 7.17(d, 2H, J=8.0Hz) 6.94(d, 2H) 6.77(s, 1H), 4.60(s, 2H) 4.55(s, 2H), 4.19(q, 2H, J=7.2Hz), 1.27(m, 12H)
27	4-9	NHCH <sub>2</sub> CO <sub>2</sub> Et	F	<sup>1</sup> H NMR(300MHz, CDCl <sub>3</sub> ) : δ 7.31(d, 2H, J=8.5Hz), 7.15(d, 2H, J=8.3Hz), 6.86(s, 1H), 6.83(s, 1H), 6.46(t, 1H, J=8.4Hz), 6.10(d, 1H), 4.53(s, 2H), 4.48(s, 2H), 4.20(q, 2H, J=7.1Hz), 3.75(s, 2H), 1.27(m, 12H)
28	4-10	NHCH <sub>2</sub> CO <sub>2</sub> Me	F	<sup>1</sup> H NMR(300MHz, CDCl <sub>3</sub> ) : δ 7.39(d, 2H, J=8.3Hz), 7.23(d, 2H, J=8.3Hz), 6.93(s, 1H), 6.90(s, 1H), 6.52(t, 1H, J=8.4Hz), 6.36(s, 1H), 4.60(s, 2H), 4.53(s, 2H), 3.83(s, 2H), 3.74(s, 3H), 1.34(s, 9H)
29	4-11	NHCH <sub>2</sub> CO <sub>2</sub> H	F	<sup>1</sup> H NMR(300MHz, CD <sub>3</sub> OD) : δ 7.32(d, 2H, J=8.5Hz), 7.18(d, 2H, J=8.3Hz), 6.90(m, 2H), 6.56(t, 1H, J=8.6Hz), 4.65(s, 2H), 4.55(s, 2H), 3.70(s, 2H), 1.28(s, 9H)
30	4-12	H	CO <sub>2</sub> Me	<sup>1</sup> H NMR(300MHz, CDCl <sub>3</sub> ) : δ 7.95-7.98(d, 2H, J=7.3Hz), 7.30-7.51(m, 4H), 7.20-7.25(d, 2H, J=8.3Hz), 4.75-4.79(d, 2H, J=5.4Hz), 4.61-4.64(d, 2H, J=4.4Hz), 3.92(s, 3H), 1.33(s, 9H)
31	4-13	H	CO <sub>2</sub> H	<sup>1</sup> H NMR(300MHz, CD <sub>3</sub> OD) : δ 7.97-7.98(s, 1H), 7.88-7.91(d, 1H, J=7.6Hz), 7.32-7.53(m, 4H), 7.18-7.22(d, 2H, J=8.0Hz), 4.79(s, 2H), 4.67(s, 2H), 1.28(s, 9H)





5

**Example 32: Synthesis of**  
**1-(4-t-butylbenzyl)-3-(2,3,5,6-tetrafluoro-4-methanesulfonylaminobenzyl)thiourea**  
**(5-4)**



10

## Step 1: Synthesis of

4-cyano-2,3,5,6-tetrafluoro-1-methanesulfonylaminobenzene

4-amino-2,3,4,5-tetrafluoronitrile (105 mg) was dissolved in tetrahydrofuran (4 ml) and the solution was cooled to 0°C. To the solution was added dropwise 1.6 M n-butyl lithium and the mixture was stirred for 10 minutes, followed by adding dropwise methanesulfonyl chloride (100  $\mu$ l). After 1 hour, the reaction was quenched with 1.5 N aqueous hydrochloric acid. The resulting mixture was extracted with ethyl acetate, and then concentrated under reduced pressure. The obtained residue was chromatographed on column eluting with ethyl acetate/hexane (1/1) to yield 4-cyano-2,3,5,6-tetrafluoro-1-methanesulfonylaminobenzene (20 mg, 10 %).

$^1\text{H}$  NMR(300MHz,  $\text{CDCl}_3$ ) :  $\delta$  6.84(brs, 1H) 3.08(s, 3H)

Step 2: Synthesis of 2,3,5,6-tetrafluoro-4-methanesulfonylaminobenzylamine hydrochloride

4-cyano-2,3,5,6-tetrafluoro-1-methanesulfonylaminobenzene (11 mg) prepared in Step 1 was dissolved in methanol (5 ml) and to the solution were added a catalytic amount of 10 % palladium/carbon and concentrated hydrochloric acid (300  $\mu$ l), followed by stirring at room temperature under hydrogen gas atmosphere for 1 hour. The resulting mixture was diluted in ether, filtered through celite, concentrated under

reduced pressure, and then washed with ethyl acetate to yield 2,3,5,6-tetrafluoro-4-methanesulfonylaminobenzylamine hydrochloride (7.0 mg, 59 %).

$^1\text{H}$  NMR(300MHz,  $\text{CD}_3\text{OD}$ ) :  $\delta$  4.32(s, 2H) 3.18(s, 3H)

5                    Step                    3:                    Synthesis                    of

1-(4-t-butylbenzyl)-3-(2,3,5,6-tetrafluoro-4-methanesulfonylaminobenzyl)thiourea (5-4)


2,3,5,6-tetrafluoro-4-methanesulfonylaminobenzylamine hydrochloride (20 mg)

prepared in Step 2 was dissolved in dimethylformamide (800  $\mu\text{l}$ ), and the solution was diluted with dichloromethane (6 ml). To the diluted solution were added

10 t-butylbenzylisothiocyanate (20 mg) and triethylamine (200  $\mu\text{l}$ ), and the mixture was stirred at room temperature for 2 hours. The mixture was concentrated under reduced pressure, diluted with ethyl acetate (20 ml), and then washed with water and saturated aqueous sodium chloride solution. The resulting mixture was dried over anhydrous magnesium sulfate and concentrated under reduced pressure, and the obtained residue  
15 was chromatographed on column eluting ethyl acetate/hexane (2/3) to yield the compound 5-4 (28 mg, 91 %).

$^1\text{H}$  NMR(300MHz,  $\text{CD}_3\text{OD}$ ) :  $\delta$  7.34(dd, 2H,  $J=1.8, 6.5\text{Hz}$ ) 7.20(d, 2H,  $J=8.3\text{Hz}$ ) 4.87(s, 2H) 4.63(s, 2H) 3.13(s, 3H) 1.29(s, 9H)

**Example 33: Synthesis of**  
**1-(4-t-butylbenzyl)-3-(2,5-difluoro-4-methanesulfonylaminobenzyl)thiourea (5-5)**



**Step 1: Synthesis of 2,5-difluoro-4-cyano-1-methanesulfonylaminobenzene**

5 To an ice-cold solution of 4-amino-2,5-difluorobenzonitrile (1.0 g) in anhydrous tetrahydrofuran (50 ml) was slowly added n-butyl lithium (2.6 ml) through an injector with stirring, followed by stirring 30 minutes. To the mixture was slowly added methanesulfonyl chloride (550  $\mu$ l), followed by stirring at room temperature for 24 hours. After confirming the completion of the reaction using TLC, the resulting

10 mixture was concentrated under reduced pressure, diluted with 1 N aqueous hydrochloric acid (100 ml), extracted with dichloromethane (50 ml  $\times$ 3). The combined organic layer was dried over magnesium sulfate, filtered, and then concentrated under reduced pressure. The obtained residue was purified by column-chromatography (ethyl acetate/hexane = 2/3) to yield

15 2,5-difluoro-4-cyano-1-methanesulfonylaminobenzene (1.2 g, 79.6 %).

$^1\text{H}$  NMR(300MHz,  $\text{CDCl}_3$ ) :  $\delta$  7.54(m, 1H), 7.40(m, 1H), 7.01(brs, 1H), 3.18(s, 3H)

Step 2: Sythesis of 2,5-difluoro-4-methanesulfonaminobenzyl hydrochloride

2,5-difluoro-4-cyano-1-methanesulfonylaminobenzene (250 mg), a catalytic amount of 10 % palladium/carbon catalyst and methanol (20 ml) were added to a  
5 reactor. The reactor was filled with hydrogen gas while the mixture was stirred. Concentrated hydrochloric acid (250  $\mu$ l) was slowly added thereto through an injector , followed by stirring for 18 hours. The reaction mixture was filtered through celite and the filtrate was concentrated under reduced pressure to afford a compound (250 mg, 85 %) as a solid. The obtained compound was washed with ether, and the following  
10 procedure was carried out using the washed compound.

Step 3: Synthesis of

1-(4-t-butylbenzyl)-3-(2,5-difluoro-4-methanesulfonaminebenzyl)thiourea (5-5)

2,5-difluoro-4-methanesulfonaminobenzyl hydrochloride (250 mg) prepared by  
15 Step 2 was dissolved in dimethylformamide (5 ml) and to the solution was added triethylamine (128  $\mu$ l) with stirring, followed by stirring for 30 minutes. To the mixture was added t-butylbenzylisothiocyanate (189 mg), followed by stirring for 6 hours. After the completion of the reaction, the resulting mixture was diluted with water (30 ml), and extracted with ethyl acetate (30 ml  $\times$  3). The organic layer was


dried over magnesium sulfate, filtered, and then concentrated under reduced pressure.

The obtained residue was purified by column-chromatography (ethyl acetate/hexane = 1/2) to yield the compound **5-5** (264 mg, 52.4 %).

$^1\text{H}$  NMR(300MHz,  $\text{CDCl}_3$ ) :  $\delta$  7.36(m, 2H), 7.31(m, 1H), 7.23(m, 2H),  
 5 7.17(m, 1H), 6.69(brs, 1H), 6.31(brs, 1H), 6.04(brs, 1H), 4.77(d, 2H,  $J=5.7\text{Hz}$ ), 4.53(d,  
 2H,  $J=4.8\text{Hz}$ ), 3.04(s, 3H), 1.31(s, 9H)

**Example 34: Synthesis of 1-(4-t-butylbenzyl)-3-[(5-methanesulfonylamino-2-pyridin-2-yl)methyl]thiourea (5-6)**

10



Step 1: Synthesis of 3-methanesulfonylamino-6-cyanopyridine

5-Amino-2-cyanopyridine (5 g) was dissolved in pyridine (30 ml). The solution was cooled to 0°C and to the solution was added dropwise methanesulfonyl  
 15 chloride (3.6 ml), followed by stirring at room temperature for 17 hours. The resulting mixture was concentrated under reduced pressure, extracted with water and dichloromethane, and then dried. The obtained residue was purified by



column-chromatography (hexane/ethyl acetate = 2/1) to yield an orange colored solid (6.4 g, 77 %).

$^1\text{H}$  NMR(300MHz,  $\text{CDCl}_3$ ) :  $\delta$  8.47-8.46(m, 1H), 7.84-7.69(m, 2H), 6.89(brs, 1H), 3.16(s, 3H)

5

Step 2: Synthesis of

1-(4-t-butylbenzyl)-3-[(5-methanesulfonylaminopyridin-2-yl)methyl]thiourea (5-6)


The compound (1.97 g) prepared in Step 1 was dissolved in methanol (50 ml) and to the solution were added concentrated hydrochloric acid (2 ml) and a catalytic amount of 5 % palladium/carbon, followed by stirring under hydrogen atmosphere for 21 hours. The mixture was filtered through celite and the filtrate was concentrated under reduced pressure to obtain foamy compound (3 g). Part (135 mg) of the obtained compound was dissolved in dimethylformamide (5 ml) and to the solution were added triethylamine (101 mg) and 4-t-butylbenzylisothiocyanate (100 mg), followed by stirring at room temperature for 20 hours. The mixture was concentrated under reduced pressure, extracted with water and dichloromethane, and then purified by column-chromatography (ethyl acetate) to yield the compound 5-6 (98 mg, 48 %) as a brown liquid.

$^1\text{H}$  NMR(300MHz,  $\text{CDCl}_3$ ) :  $\delta$  8.33-8.31(m, 1H), 7.66-7.62(m, 1H),

7.40-7.26(m, 5H), 6.99(brs, 1H), 6.76(brs, 1H), 4.77-4.60(m, 4H), 3.04(s, 3H), 1.32(s, 9H)

**Example 35: Synthesis of**

5 **1-(4-*t*-butylbenzyl)-3-(3,5-dichloro-4-methanesulfonylamino benzyl)thiourea (5-7)**



4-Amino-3,5-dichlorobenzonitrile (1 g) was dissolved in acetonitrile (50 ml) and to the solution were added triethylamine (890  $\mu\text{l}$ ) and methanesulfonyl chloride (670 mg), followed by refluxing for 8 hours. The mixture was extracted with water and dichloromethane, dried, concentrated, and then purified by column-chromatography (hexane/ethyl acetate = 4/1) to obtain a compound (80 mg) as a liquid. The obtained compound was dissolved in methanol (10 ml), and then the solution was stirred for 15 hours in the presence of a small amount of concentrated hydrochloric acid and 5% palladium/carbon catalyst to hydrogenate the compound. The reaction solution was filtered through celite and concentrated. The concentrate was dissolved in dichloromethane (5 ml) and to the solution were added 4-t-butylbenzylisothiocyanate


(54 mg) and triethylamine (500  $\mu\text{l}$ ), followed by stirring at room temperature for 15 hours. The resulting mixture was extracted with water and dichloromethane, and then purified by column-chromatography (hexane/ethyl acetate = 2/1) to yield the compound 5-7 (38 mg) as a liquid.

5

$^1\text{H}$  NMR(300MHz,  $\text{CDCl}_3$ ) :  $\delta$  7.42-7.23(m, 6H), 6.23(brs, 1H), 5.87(brs, 1H), 4.85-4.82(m, 2H), 4.58-4.56(m, 2H), 3.57(s, 3H), 1.31(s, 9H)

**Example 36: Synthesis of**

10 **1-(4-t-butylbenzyl)-3-(4-methanesulfonylaminophenethyl)thiourea (5-8)**



Step 1: Synthesis of 4-methanesulfonylaminobenzyl cyanide

To an ice-cold solution of 4-aminobenzyl cyanide (1 g) in dichloromethane (30 ml) were added dropwise triethylamine (1.58 ml) and methanesulfonyl chloride (700  $\mu\text{l}$ ), followed by stirring at room temperature for 12 hours. After confirming the

completion of the reaction using TLC, to the mixture was added 1 N aqueous hydrochloric acid (50 ml). The resulting mixture was extracted with dichloromethane (30 ml  $\times$  3), washed with saturated aqueous sodium chloride solution, dried over magnesium sulfate, and then filtered.

- 5           The filtrate was concentrated under reduced pressure and the obtained residue was purified by column-chromatography (ethyl acetate/hexane = 2/3) to yield 4-methanesulfonylaminobenzyl cyanide (1.35 g, 85 %).

$^1\text{H}$  NMR(300MHz,  $\text{CDCl}_3$ ) :  $\delta$ 7.34(d, 2H,  $J=8.4\text{Hz}$ ), 7.24(d, 2H,  $J=8.7\text{Hz}$ ), 6.51(bs, 1H), 3.74(s, 2H), 3.03(s, 3H)

10

#### Step 2: Synthesis of 4-methanesulfonaminophenethylamine

- 4-Methanesulfonylbenzyl cyanide (200 mg) and Raney nickel (catalytic amount) were added to methanol (15 ml) and the mixture was stirred for 6 hours with the reactor filled with hydrogen gas. After confirming the completion of the reaction,
- 15 the resulting mixture was filtered through celite and the filtrate was concentrated under reduced pressure. The following procedure was carried out using the concentrate which was not purified.

Step

3:

Synthesis


of

## 1-(4-t-butylbenzyl)-3-(4-methanesulfonylaminophenethyl)thiourea (5-8)

4-Methanesulfonaminophenethylamine (200 mg) prepared in Step 2 and 4-t-butylbenzylisothiocyanate (190 mg) were dissolved in ethyl acetate (30 ml) and the solution was subjected to reaction for 6 hours. After the completion of the reaction, the resulting mixture was concentrated under reduced pressure and the obtained residue was purified by column-chromatography (ethyl acetate/hexane = 1/2) to yield the compound 5-8 (210 mg, 53 %).

$^1\text{H}$  NMR(300MHz,  $\text{CDCl}_3$ ) :  $\delta$ 7.38(d, 2H,  $J=8.4\text{Hz}$ ), 7.21(d, 2H,  $J=8.4\text{Hz}$ ), 7.14(s, 4H), 6.56(s, 1H), 6.05(brs, 1H), 5.69(brs, 1H), 4.51(brs, 2H), 3.72(d, 2H,  $J=4.8\text{Hz}$ ), 2.99(s, 3H), 2.86(t, 2H,  $J=6.9\text{Hz}$ ), 1.32(s, 9H)

Example 37: Synthesis of 1-(4-t-butylbenzyl)-3-(2-methanesulfonylaminophenethyl)thiourea (5-9)



15

## Step 1: Synthesis of (2-methanesulfonylaminophenyl)acetonitrile

To an ice-cold solution of 2-aminophenylacetonitrile (500 mg) in

dichloromethane (20 ml) were added triethylamine (330  $\mu\text{l}$ ) and methanesulfonyl chloride (530  $\mu\text{l}$ ) and the mixture was stirred for 16 hours, under argon gas atmosphere. After confirming the completion of the reaction using TLC, the resulting mixture was diluted with 1 N aqueous hydrochloric acid solution (30 ml), and extracted with  
5 dichloromethane (50 ml  $\times$  3). The organic layer was washed with brine, dried over magnesium sulfate, and then filtered. The filtrate was concentrated under reduced pressure and the obtained residue was purified by column-chromatography (ethyl acetate/hexane = 1/2) to yield (2-methanesulfonylaminophenyl)acetonitrile (573 mg, 72 %).

10  $^1\text{H}$  NMR(300MHz,  $\text{CDCl}_3$ ) :  $\delta$  7.56(m, 1H), 7.37(m, 3H), 6.55(brs, 1H), 3.99(s, 2H), 3.06(s, 3H)

#### Step 2: Synthesis of 2-methanesulfonylaminophenethylamine

(2-Methanesulfonylaminophenyl)acetonitrile (300 mg) was mixed with 10 %  
15 palladium/carbon (catalytic amount) in methanol (20 ml) and the mixture was stirred under hydrogen gas atmosphere for 48 hours. After confirming the completion of the reaction using TLC, the resulting mixture was filtered through celite and the filtrate was concentrated under reduced pressure. The following procedure was carried out using the concentrate which was not purified.

Step 3: Synthesis of

1-(4-t-butylbenzyl)-3-(2-methanesulfonylaminophenethyl)thiourea (5-9)


2-Methanesulfonylaminophenethylamine (200 mg) prepared in Step 2 and  
 5 t-butylbenzeneisothiocyanate (192 mg) were dissolved in ethyl acetate (20 ml) and the  
 solution was stirred for 6 hours. After confirming the completion of the reaction, the  
 resulting mixture was concentrated under reduced pressure and the concentrate was  
 purified by column-chromatography (ethyl acetate/hexane = 2/3) to yield the compound  
 5-9 (165 mg, 42 %).

10  $^1\text{H}$  NMR(300MHz,  $\text{CDCl}_3$ ) :  $\delta$ 7.28(m, 8H), 6.38(brs, 1H), 4.74(s, 1H), 4.72(s,  
 1H), 3.79(m, 2H), 3.14(m, 4H), 3.01(s, 3H), 1.31(s, 9H)

Example 38: Synthesis of

1-(4-t-butylbenzyl)-3-(4-methanesulfanylcarbonylaminobenzyl)thiourea (6-5)

15



Step 1: Synthesis of (4-nitrobenzyl)carbamic acid t-butyl ester (6-2)

4-Nitrobenzylamine hydrochloride (110 mg) was dissolved in dichloromethane (2 ml) and to the solution were added dimethylaminopyridine (14 mg) and di-t-butyl dicarbonate (382 mg), followed by adding triethylamine (200  $\mu\text{l}$ ) thereto and stirring at room temperature for 3 hours. After the completion of the reaction, the resulting mixture was concentrated under reduced pressure and the obtained residue was chromatographed on column eluting with ethyl acetate/hexane (1/3) to yield the compound 6-2 (88.3 mg, 66 %).

$^1\text{H}$  NMR(300MHz,  $\text{CDCl}_3$ ) :  $\delta$  8.18 (d, 2H,  $J=8.5\text{Hz}$ ), 7.43 (d, 2H,  $J=8.8\text{Hz}$ )  
4.40 (d, 2H,  $J=6.3\text{Hz}$ ), 1.45 (s, 9H)

10

Step 2: Synthesis of (4-methylsulfanylcarbonylaminobenzyl)carbamic acid t-butyl ester (6-3)

The compound 6-2 (88.3 mg) prepared in Step 1 was dissolved in methanol (2 ml) and to the solution was added catalytic amount of 10 % palladium/carbon, followed by stirring at room temperature under hydrogen gas atmosphere for 30 minutes. The resulting mixture was diluted with ether, and filtered through celite. The filtrate was concentrated under reduced pressure to yield compound (76 mg). The obtained compound, which was not purified, was dissolved in dichloromethane (1 ml) and to the solution were added methylchlorothiolformate (100  $\mu\text{l}$ ) and pyridine (49  $\mu\text{l}$ ). After



stirring the mixture at room temperature for 1 hour, the resulting mixture was extracted with dichloromethane, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. The obtained residue was column-chromatographed (ethyl acetate/hexane = 1/1) to yield the compound 6-3 (22 mg, 22 %).

5 <sup>1</sup>H NMR(300MHz, CDCl<sub>3</sub>) : δ 7.36 (d, 1H, *J*=8.5Hz), 7.20-7.25 (m, 2H), 7.03 (d, 1H, *J*=8.3Hz), 4.25 (s, 2H), 2.40 (s, 3H), 1.44 (s, 9H)

Step 3: Synthesis of 4-methylsulfanylcarbonylaminobenzylamine hydrochloride  
(6-4)

10 The compound 6-3 (22 mg) prepared in Step 2 was dissolved in ethyl acetate (1 ml) and to the solution was added 5 N aqueous hydrochloric acid (1 ml). The mixture was stirred at 60°C for 1 hour and concentrated under reduced pressure to yield the compound 6-4 (15 mg, 100 %).

<sup>1</sup>H NMR(300MHz, CD<sub>3</sub>OD) : δ 7.65 (d, 1H, *J*=8.5Hz), 7.57 (d, 1H, *J*=8.3Hz),  
15 7.49 (d, 1H, *J*=8.5Hz), 7.38 (d, 1H, *J*=8.8Hz), 4.05(s, 2H) 2.35(s, 3H)


Step 4: Synthesis of 1-(4-t-butylbenzyl)-3-(4-methylsulfonylaminobenzyl)thiourea (6-5)

The compound 6-4 (15 mg) prepared in Step 3 was diluted in dichloromethane

(1 ml) and to the solution were added 4-t-butylisothiocyanate (20 mg) and triethylamine (100  $\mu$ l), followed by stirring at room temperature for 1 hour. The resulting mixture was concentrated under reduced pressure and the obtained residue was chromatographed on column eluting with ethylacetate/hexane (1/3) to yield the compound 6-5 (20 mg, 83 %).

$^1\text{H}$  NMR(300MHz,  $\text{CDCl}_3$ ) :  $\delta$  7.16-7.35 (m, 8H), 4.56 (br, 4H), 2.35 (s, 3H), 1.26 (s, 9H)

**Example 39: Synthesis of 1-(4-t-butylbenzyl)-3-(4-guanidinobenzyl)thiourea (7-6)**



10

Step 1: Synthesis of 4-(1,3-bis(t-butoxycarbonyl)-2-guanidino)phenyliodide (7-2)

4-Iodoaniline 7-1 (100 mg) was dissolved in dimethylformamide (2 ml) and to the solution were added 1,3-bis(t-butoxycarbonyl)-2-methyl-2-thiopseudourea (200 mg), mercury (II) chloride (186 mg) and triethylamine (200  $\mu$ l), followed by stirring for 1 hour. After the completion of the reaction, the resulting mixture was concentrated

under reduced pressure at the temperature not more than 50°C and the obtained residue was chromatographed eluting with ethyl acetate/hexane (1/3) to yield the compound 7-2 (137 mg, 66 %).

$^1\text{H}$  NMR(300MHz,  $\text{CDCl}_3$ ) :  $\delta$  11.60 (br, 1H) 10.33 (br, 1H), 7.58-7.63 (d, 2H,  $J=8.8\text{Hz}$ ), 7.35-7.38 (d, 2H,  $J=8.8\text{Hz}$ ), 1.51 (s, 9H), 1.48 (s, 9H)

Step 2: Synthesis of 4-[1,3-bis(t-butoxycarbonyl)-2-guanidino]benzonitrile (7-3)

The compound 7-2 (137 mg) prepared in Step 1 was dissolved in dimethylformamide (2 ml) and to the solution were added zinc (II) cyanide (40 mg) and tetrakis(triphenylphosphine) palladium (14 mg), followed by stirring at 80°C for 1 hour. The reaction was quenched with water. The resulting mixture was extracted with ethyl acetate, and the organic phase was dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. The obtained residue was chromatographed on column eluting with ethyl acetate/hexane (1/3) to yield the compound 7-3 (95 mg, 89 %).

$^1\text{H}$  NMR(300MHz,  $\text{CDCl}_3$ ) :  $\delta$  11.58 (br, 1H) 10.62 (br, 1H), 7.76-7.79 (d, 2H,  $J=8.8\text{Hz}$ ), 7.58-7.61 (dd, 2H,  $J=2.0, 6.8\text{Hz}$ ), 1.52 (s, 9H), 1.50 (s, 9H)

## Step 3: Synthesis of

1-(4-t-butylbenzyl)-3-[4-{1,3-bis(t-butoxycarbonyl)-2-guanidino}benzyl]thiourea (7-5)

The compound 7-3 (20 mg) prepared in Step 2 was dissolved in methanol (2 ml) and to the solution was added catalytic amount of palladium/carbon, followed by stirring at room temperature under hydrogen gas atmosphere for 30 minutes. The resulting mixture was diluted with ether, filtered through celite, and then concentrated under reduced pressure to give the compound 7-4. The compound 7-4 was diluted with dichloromethane (3ml). To the solution was added 4-t-butylbenzylisothiocyanate (40 mg) and the mixture was stirred at room temperature for 1 hour. The resulting mixture was concentrated under reduced pressure and the obtained residue was chromatographed eluting with ethyl acetate/hexane (1/3) to yield the compound 7-5 (35 mg, 95 %).

$^1\text{H}$  NMR(300MHz,  $\text{CD}_3\text{OD}$ ) :  $\delta$  7.18-7.49 (m, 8H), 4.66-4.69 (br, 4H), 1.56 (s, 9H), 1.45 (s, 9H), 1.29 (s, 9H)


## Step 4: Synthesis of 1-(4-t-butylbenzyl)-3-(4-guanidinobenzyl)thiourea (7-6)

The compound 7-5 (35 mg) prepared in Step 3 was dissolved in ethyl acetate (1.0 ml) and to the solution was added 5 N aqueous hydrochloric acid (1 ml). The mixture was stirred at 60°C for 1 hour and concentrated under reduced pressure to yield

the compound 7-6 (18 mg, 100 %).

$^1\text{H}$  NMR(300MHz, acetone- $d_6$ ) :  $\delta$  7.07-7.37 (m, 8H), 4.73(s, 2H), 4.66 (s, 2H), 1.17 (s, 9H)

5      **Example**                                      **40:**                                      **Synthesis**                                      **of**  
 1-[2-(1-methyl-1H-pyrrol-2-yl)ethyl]-3-(4-methanesulfonylaminoethyl)thiourea  
 (8-4)



10                      Step 1: Synthesis of (4-aminobenzyl)carbamic acid t-butyl ester (8-1)

4-Aminobenzylamine (1.02 g) was dissolved in anhydrous tetrahydrofuran (10 ml) and to the solution was added di-t-butyl dicarbonate (2.002 g), followed by stirring at room temperature for 2 hours. The resulting mixture was concentrated under reduced pressure to remove the solvent. The obtained residue was purified by  
 15 column-chromatography (ethyl acetate/hexane = 2/3) to yield the compound 8-1 (1.78 g, 96 %) as a yellow solid.

$^1\text{H}$  NMR (300MHz,  $\text{CDCl}_3$ ):  $\delta$  7.09-7.05 (m, 2H), 6.6-6.62 (m, 2H), 4.70 (brs,

1H), 4.18(d, 2H, J = 5.7Hz), 3.64(brs, 2H), 1.45 (s, 9H)

Step 2: Synthesis of (4-methanesulfonylaminobenzyl)carbamic acid t-butyl ester (8-2)

5           Compound 8-1 (1 g) was dissolved in anhydrous dichloromethane and the solution was cooled to 0°C. To the solution was added triethylamine (630  $\mu\ell$ ) and methanesulfonyl chloride (350  $\mu\ell$ ) in order and the mixture was stirred at room temperature for 24 hours. After confirming the completion of the reaction using TLC, the resulting mixture was neutralized with hydrochloric acid solution, diluted with water, 10 and then extracted three times with dichloromethane. The extracted organic layer was washed with water and saturated aqueous sodium chloride solution, dried over magnesium sulfate, and then dried under reduced pressure. The obtained residue was purified by column-chromatography (hexane/ethyl acetate = 2/1) to yield the compound 8-2 (1.28 g, 95 %) as a white solid.

15            $^1\text{H}$  NMR (300MHz,  $\text{CDCl}_3$ ):  $\delta$  7.1-7.3 (m, 4H), 6.77 (s, 1H), 4.88 (brs, 1H), 4.28 (d, 2H), 2.99 (s, 3H), 1.46 (s, 9H)

Step 3: Synthesis of 4-methanesulfonylaminobenzylammonium trifluoroacetate (8-3)

(4-Methanesulfonylaminobenzyl)carbamic acid t-butyl ester **8-2** (500 mg) was dissolved in anhydrous dichloromethane (30 ml) and the solution was cooled to 0°C, followed by slowly adding trifluoroacetic acid (5 ml) thereto. The mixture was stirred at 0°C for 1 hour and 30 minutes and then, after confirming the completion of the reaction using TLC, concentrated under reduced pressure to yield an orange colored residue. The residue was washed with ether and filtered to yield the compound **8-3** (420 mg, 80 %) as a pink solid.

<sup>1</sup>H NMR (300MHz, DMSO-d<sub>6</sub>): δ 8.14 (brs, 3H), 7.39 (d, 2H), 7.22 (d, 2H), 3.97 (s, 2H), 2.99 (s, 3H)

10

Step 4: Synthesis of  
1-[2-(1-methyl-1H-pyrrol-2-yl)ethyl]-3-(4-methanesulfonylaminobenzyl)thiourea (**8-4**)


Compound **8-3** (500 mg) was dissolved in dimethylformamide (2 ml) and to the solution was added triethylamine (230 μl), followed by stirring for 1 hour. To the mixture was added 2-(2-isothiocyanatoethyl)-1-methyl-1H-pyrrole (280 mg), followed by adding ethyl acetate (10 ml) thereto. The mixture was stirred for 12 hours, filtered under reduced pressure, and then purified by column-chromatography (ethyl acetate/hexane =4/1) to yield the compound **8-4** (146 mg, 25 %) as a red solid.

<sup>1</sup>H NMR (300MHz, CH<sub>3</sub>COCH<sub>3</sub>-d<sub>6</sub>): δ 7.32(m, 4H), 7.16(m, 1H), 6.42(d, 1H,

J=2.1Hz), 6.02(d, 1H, J=1.95Hz), 4.76(m, 2H), 3.89(m, 2H), 3.81(m, 2H), 3.01(m, 2H), 2.96(s, 3H)

**Example 41: Synthesis of 1-(4-aminobenzyl)-3-(4-t-butylbenzyl)thiourea (9a)**

5



4-t-Butylbenzylisothiocyanate (100 mg) was dissolved in dichloromethane (3 ml) and then cooled to 0 °C. To the solution was added 4-nitrobenzylamine (75 mg), followed by stirring at room temperature for 6 hours. After the completion of the reaction, dichloromethane was evaporated therefrom under reduced pressure and the residue was dissolved in methanol (3 ml). To the solution was added catalytic amount of 5 % platinum/carbon and the mixture was subjected to hydrogenation reaction under atmospheric pressure. After the completion of the reaction, the methanol was evaporated under reduced pressure and the obtained residue was column-chromatographed (hexane/ethyl acetate = 1/1) to yield the compound **9a** (137 mg, 85 %) as a white solid.

<sup>1</sup>H NMR (300MHz,CDCl<sub>3</sub>): δ 6.70-7.40(m, 8H), 6.00-6.40(br, 2H), 4.55(br,




2H), 4.45(br, 2H), 1.28(s, 9H)

MS (EI) m/e 327 [M<sup>+</sup>]

**Example 42: Synthesis of 1-(4-acetylamino benzyl)-3-(4-t-butylbenzyl)thiourea (9b)**

5




Compound 9a (100 mg) and triethylamine (50 mg) were dissolved in dichloromethane (3 ml) and cooled to 0 °C. To the solution was added anhydrous acetic acid (35 mg). After the completion of the reaction, dichloromethane was  
10 evaporated under reduced pressure and the obtained residue was column-chromatographed (hexane/ethyl acetate = 1/1) to yield the compound 9b (107 mg, 95 %) as a white solid.

<sup>1</sup>H NMR (300MHz, DMSO-d<sub>6</sub>): δ 8.31(s, 1H), 7.87(br, 2H), 7.50(d, 2H, J=8.40 Hz), 7.32(d, 2H, J=8.25 Hz), 7.16-7.17(m, 4H), 4.59(br, 4H), 2.01(s, 3H), 1.25(s,  
15 9H)

MS (EI) m/e 369 [M<sup>+</sup>]


Example 43: Synthesis of

1-(4-(N,N-dimethanesulfonyl)aminobenzyl)-3-(4-t-butylbenzyl)thiourea (9c)





4-t-Butylbenzylisothiocyanate (100 mg) was dissolved in dichloromethane (3  
 5 ml) and cooled to 0 °C. To the solution was added  
 (N,N-dimethylsulfonyl-4-amino)benzylamine (136 mg), followed by stirring at room  
 temperature for 6 hours. After the completion of the reaction, dichloromethane was  
 evaporated under reduced pressure and the obtained residue was  
 column-chromatographed (hexane/ethyl acetate = 1/1) to yield the compound **9c** (184  
 10 mg, 75 %) as a white solid.




<sup>1</sup>H NMR (300MHz, CDCl<sub>3</sub>): δ 7.00-7.35(m, 8H), 6.30(br, 2H), 4.66(s, 2H),  
 4.49(s, 2H), 3.26(s, 6H), 1.22(s, 9H); MS (EI) m/e 469 [M<sup>+</sup>]



Examples	Compound No.	R <sup>D</sup> R <sup>E</sup>	Spectral data
----------	-----------------	----------------------------------	---------------

44	9d	H- CH <sub>3</sub> SO <sub>2</sub> -	<sup>1</sup> H NMR(300MHz, CDCl <sub>3</sub> ) : δ 7.37 (d, 2H), 7.1-7.3 (m, 6H), 6.39 (s, 1H), 5.99 (brs, 1H), 4.66 (d, 2H), 4.56 (m, 2H), 3.00 (s, 3H), 1.31 (s, 9H) MS (EI) m/e 405 [M+]
45	9e	H- CF <sub>3</sub> SO <sub>2</sub> -	<sup>1</sup> H NMR(300MHz, DMSO-d <sub>6</sub> ) : δ 7.90(br, 1H), 7.25(m, 8H), 4.50-4.70(br, 4H), 1.25(s, 9H) MS (EI) m/e 459 [M+]
46	9f	-H -CHO	<sup>1</sup> H NMR(300MHz, CDCl <sub>3</sub> ) : δ 8.20-8.40(br, 2H), 8.05(s, 1H), 6.80-7.30(m, 8H), 4.52(br, 4H), 1.19(s, 9H) MS (EI) m/e 355 [M+]
47	9g	-H -C(=S)NH <sub>2</sub>	<sup>1</sup> H NMR(300MHz, DMSO-d <sub>6</sub> ) : δ 9.64(s, 1H), 7.86(br, 2H), 7.20-7.40(m, 8H), 4.61(br, 4H), 1.26(s, 9H) MS (EI) m/e 386 [M+]
48	9h	-H -CO <sub>2</sub> Et	<sup>1</sup> H NMR(300MHz, DMSO-d <sub>6</sub> ) : δ 9.56(s, 1H), 7.81(br, 2H), 7.15-7.45(m, 8H), 4.58(br, 4H), 4.10(q, 2H, J=7.05 Hz), 1.25(s, 9H), 1.23(t, 3H, J=7.05 Hz) MS (EI) m/e 399 [M+]






5      **Example**                                      **49:**                                      **Synthesis**                                      **of**

**1-(4-t-butylbenzyl)-3-[2-hydroxy-4-(N-t-butoxycarbonyl)aminobenzyl]thiourea**

**(10-4)**




2-Hydroxy-4-nitrobenzaldehyde (1.67 g), t-butyldiphenylsilylchloride (TBDPSCI) (2.65 g) and imidazole (681 mg) were dissolved in dichloromethane (100 ml) and the solution was stirred at room temperature for 18 hours. The precipitate was filtered off and the filtrate was concentrated under reduced pressure. The obtained  
5 residue was purified by column-chromatography (hexane/ethyl acetate = 3/1) to yield the compound 10-1 (4.00 g, 99 %). The compound 10-1 (3.00 g) was reduced in the presence of palladium/carbon catalyst to yield an amine. The amine was dissolved in tetrahydrofuran (15 ml) and to the solution was added  $\text{Boc}_2\text{O}$  (950 mg), followed by stirring at room temperature for 18 hours. To the mixture were added water (20 ml)  
10 and ethyl acetate (10 ml). From the mixture, an organic layer was separated and an aqueous layer was extracted with ethyl acetate (10 ml  $\times$ 2). The combined organic layer was washed with brine, dried over magnesium sulfate and then concentrated under reduced pressure. The obtained residue was purified by column-chromatography (hexane/ethyl acetate = 3/1) to yield the compound 10-2 (380 mg, 20 %) and 10-3 (764  
15 mg, 41 %). The compound 10-2 was dissolved in ethyl acetate (10 ml) and to the solution was added t-butylbenzylisothiocyanate (150 mg), followed by stirring at room temperature for 18 hours. The resulting mixture was concentrated under reduced pressure and the obtained residue was purified by column-chromatography (hexane/ethyl acetate = 3/1) to yield thiourea compound (300 mg, 56 %). The

compound (300 mg) was dissolved in THF (5.0 ml) and to the solution was added tetrabutylammonium fluoride (131 mg), followed by stirring at room temperature for 45 minutes. The reaction was quenched with saturated sodium bicarbonate and an aqueous solution layer was extracted with ethyl acetate (10 ml  $\times$ 2). The combined  
5 organic layer was washed with saturated aqueous sodium chloride solution, dried over magnesium sulfate, and then concentrated under reduced pressure. The obtained residue was purified by column-chromatography (hexane/ethyl acetate = 1/1) to yield the compound 10-4 (52 mg, 27 %).

$^1\text{H}$  NMR (300MHz,  $\text{CDCl}_3$ ):  $\delta$  7.35(d,  $J=8.4\text{Hz}$ , 2H), 7.20(d,  $J=8.4\text{Hz}$ , 2H),  
10 7.07(dd,  $J=2.7$ , 8.4Hz, 1H), 6.94(d,  $J=8.4\text{Hz}$ , 1H), 6.89(d,  $J=2.7\text{Hz}$ , 1H), 6.01(bs, 1H),  
5.19(bs, 1H), 4.83(d,  $J=5.7\text{Hz}$ , 2H), 4.15(d,  $J=6.6\text{Hz}$ , 2H), 1.44(s, 9H), 1.30(s, 9H)

**Example 50: Synthesis of**  
**1-(4-t-butylbenzyl)-3-[2-hydroxy-4-methanesulfonylaminobenzyl]thiourea (10-6)**

15



Step 1: Synthesis of

2-(N-t-butyloxycarbonylamino)methyl-4-methanesulfonylamino-1-t-butyldiphenylsilyloxybenzene (10-5)

The compound 10-3 (700 mg) prepared by Example 49 was dissolved in dichloromethane (10 ml) and the solution was cooled to 0°C, followed by adding  
5 trifluoroacetic acid (2.0 ml) thereto. The mixture was stirred for 2 hours and concentrated under reduced pressure. The obtained residue (186 mg) was dissolved in  
1 THF (2.0 ml) and to the solution was added triethylamine (90  $\mu$ l), followed by stirring for 12 hours. To the solution was added Boc<sub>2</sub>O (68 mg) and the mixture was stirred at room temperature for 10 hours. To the resulting mixture were added water (10 ml)  
10 and ethyl acetate (10 ml). The organic layer was separated and the aqueous layer was extracted with ethyl acetate (10 ml  $\times$ 2). The combined organic layer was washed with saturated aqueous sodium chloride solution, dried over magnesium sulfate, and then concentrated under reduced pressure. The obtained residue was purified by column-chromatography (hexane/ethyl acetate = 1/2) to yield an alkylamine  
15 intermediate (100 mg, 69 %), protected with Boc group. The intermediate and triethylamine (40  $\mu$ l) were dissolved in dichloromethane (2.0 ml) and the solution was cooled to 0°C. To the solution was added methanesulfonyl chloride (20  $\mu$ l) and the mixture was stirred at room temperature for 2 hours. The water was added thereto to quench the reaction. An organic layer was separated, dried over magnesium sulfate,

and then concentrated under reduced pressure. The obtained residue was purified by column-chromatography (hexane/ethyl acetate = 3/2) to yield the compound 10-5 (69 mg, 60 %).

<sup>1</sup>H NMR (300MHz, CDCl<sub>3</sub>): δ 7.68(m, 4H), 7.40(m, 6H), 7.12(d, *J*=3.0Hz, 1H), 6.73(dd, *J*=3.0, 8.7Hz, 1H), 6.40(d, *J*=8.7Hz, 1H), 6.04(s, 1H), 4.94(bs, 1H), 4.46(d, *J*=5.4Hz, 2H), 2.90(s, 3H), 1.48(s, 9H), 1.11(s, 9H).

Step 2: Synthesis of

1-(4-t-butylbenzyl)-3-[2-hydroxy-4-methanesulfonylaminobenzyl]thiourea (10-6)


Compound 10-5 (90 mg) was dissolved in THF (2.0 ml) and to the solution was added tetrabutylammoniumfluoride (200 μl), followed by stirring at room temperature for 45 minutes. The reaction was quenched with saturated aqueous sodium bicarbonate solution and the aqueous layer was extracted with ethyl acetate (10 ml ×2). The combined organic layer was washed with saturated aqueous sodium chloride solution, dried over magnesium sulfate, and then concentrated under reduced pressure. The obtained residue was purified by column-chromatography (hexane/ethyl acetate = 1/1) to yield a phenol compound (38 mg, 71 %). The compound was dissolved in dichloromethane (3.0 ml) and the solution was cooled to 0°C. To the solution was added trifluoroacetic acid (500 μl), and the mixture was stirred for 2 hours and



concentrated under reduced pressure. The concentrate was dissolved in ethyl acetate (2.0 ml) and to the solution was added triethylamine (16  $\mu\text{l}$ ), followed by stirring for 1 hour. To the solution was slowly added a solution of t-butylbenzylisothiocyanate (25 mg) in ethyl acetate (1.0 ml), and the mixture was stirred at room temperature for 18 hours and concentrated under reduced pressure. The obtained residue was purified by column-chromatography (hexane/ethyl acetate = 1/3) to yield the compound 10-6 (37 mg, 73 %).

$^1\text{H}$  NMR (300MHz,  $\text{CDCl}_3$ ):  $\delta$  7.35(d,  $J=8.1\text{Hz}$ , 2H), 7.19(d,  $J=8.1\text{Hz}$ , 2H), 7.06(d,  $J=2.4\text{Hz}$ , 1H), 7.00(dd,  $J=2.4$ , 8.4Hz, 1H), 6.89(d,  $J=8.4\text{Hz}$ , 1H), 6.31(bs, 1H), 6.23(bs, 1H), 4.80(d,  $J=6.3\text{Hz}$ , 2H), 4.49(bs, 2H), 2.94(s, 3H), 1.30(s, 9H)

**Example 51: Synthesis of 1-(4-t-butylbenzyl)-3-(2,6-difluoro-3-methanesulfonylaminobenzyl)thiourea (11-2)**



15

Step 1: Synthesis of 2,4-difluoro-3-[N-(t-butoxycarbonylamino)methyl]aniline

(11-1)

2,6-Difluoro-3-nitrobenzonitrile (921 mg) and 10 % palladium/carbon (200 mg) were mixed in methanol (15 ml) and to the mixture was added c-HCl (900  $\mu$ l), followed by stirring under hydrogen atmosphere for 1 day. The mixture was diluted with ethyl acetate (30 ml) and filtered through celite pad. The filtrate was neutralized with 1 N aqueous sodium hydroxide solution and the organic layer was separated. The aqueous layer was extracted with ethyl acetate (10 ml  $\times$ 2). The combined organic layer was washed with saturated aqueous sodium chloride solution, dried over magnesium sulfate, and then concentrated under reduced pressure. The residue was purified by column-chromatography (methanol/ethyl acetate = 2/1) to yield an amine salt (580 mg, 50 %). The obtained amine salt was dissolved in tetrahydrofuran (5.0 ml) and to the solution was added triethylamine (700  $\mu$ l), followed by stirring at room temperature for 12 hours. To the solution was added Boc<sub>2</sub>O (548 mg) and the mixture was stirred at room temperature for 10 hours. To the resulting mixture were added water (10 ml) and ethyl acetate (10 ml) and then the organic layer was separated. The aqueous layer was extrated with ethyl acetate (10 ml  $\times$ 2). The combined organic layer was washed with saturated aqueous sodium chloride solution, dried over magnesium sulfate, and then concentrated under reduced pressure. The obtained residue was purified by column-chromatography (hexane/ethyl acetate = 1/1) to yield intermediate material 11-1 (531 mg, 82 %) protected with Boc.


$^1\text{H}$  NMR (300MHz,  $\text{CDCl}_3$ )  $\delta$  6.67(m, 2H), 4.86(bs, 1H), 4.39(d,  $J=4.8\text{Hz}$ , 2H), 3.59(bs, 2H), 1.44(s, 9H)

Step 2: Synthesis of  
5 1-(4-t-butylbenzyl)-3-(2,6-difluoro-3-methanesulfonylaminobenzyl)thiourea (11-2)

Compound 11-1 (531 mg) was mesylated and treated with trifluoroacetic acid to remove Boc group therefrom. 4-t-butylbenzylisothiocyanate was reacted therewith to yield the compound 11-2 (145 mg, 16 %).

$^1\text{H}$  NMR (300MHz,  $\text{CDCl}_3$ ):  $\delta$  7.50(dt,  $J=5.7, 9.0\text{Hz}$ , 1H), 7.38(d,  $J=8.1\text{Hz}$ , 2H), 7.22(d,  $J=8.1\text{Hz}$ , 2H), 6.90(dt,  $J=1.8, 9.0\text{Hz}$ , 1H), 6.41(bs, 1H), 6.14(bs, 1H), 6.02(bs, 1H), 4.79(d,  $J=5.7\text{Hz}$ , 2H), 4.55(bs, 2H), 3.00(s, 3H), 1.32(s, 9H)

Example 52: Synthesis of  
15 1-(4-t-butylbenzyl)-3-(3-methanesulfonylaminobenzyl)thiourea (12-3b)



Step 1: Synthesis of 3-aminomethyl-phenylamine (12-1b)

3-Nitrobenzaldehyde (1.51 g) and hydroxylamine hydrochloride (1.29 g) were dissolved in methanol (100 ml), and to the solution was slowly added pyridine (2.37 g) at room temperature, followed by stirring for 18 hours. The resulting mixture was concentrated under reduced pressure. The residue was dissolved in ethyl acetate (30 ml), washed with water (10 ml  $\times$  2) and saturated aqueous copper sulfate solution (10 ml), dried over magnesium sulfate, concentrated under reduced pressure, and then the residue was purified by column-chromatography (hexane/ethyl acetate = 3/1) to yield oxime (1.66 g). The obtained oxime was dissolved in methanol (20 ml) and to the solution was added 10 % palladium/carbon (414 mg), followed by stirring at room temperature under hydrogen atmosphere for 3 days. The reaction mixture was filtered to remove the precipitate and the filtrate was concentrated under reduced pressure to yield the compound **12-1b** (643 mg, 53 %).

$^1\text{H}$  NMR(300MHz, DMSO- $d_6$ ):  $\delta$  7.08(t,  $J=8.1\text{Hz}$ , 1H), 6.66(m, 2H), 6.55(d,  $J=8.1\text{Hz}$ , 1H), 2.40 (bs, 2H)


Step 2: Synthesis of  
1-(4-*t*-butylbenzyl)-3-(3-methanesulfonylaminobenzyl)thiourea (**12-3b**)

Compound **12-1b** (643 mg) was dissolved in tetrahydrofuran (6.0 ml) and to the solution was slowly added  $\text{Boc}_2\text{O}$  (1.26 g) at room temperature, followed by stirring for

18 hours. The resulting mixture was concentrated under reduced pressure and the obtained residue was purified by column-chromatography (hexane/ethyl acetate = 2/1) to yield an intermediate compound (622 mg) protected with Boc group. The intermediate compound and triethylamine (500  $\mu\text{l}$ ) were dissolved in dichloromethane (20 ml) and the solution was cooled to 0°C. To the solution was added methanesulfonyl chloride (300  $\mu\text{l}$ ) and the mixture was stirred at room temperature for 50 minutes. The water was added thereto to quench the reaction. The organic layer was separated, dried over magnesium sulfate, concentrated under reduced pressure, and then the residue was purified by column-chromatography (hexane/ethylacetate = 1/1) to yield the compound **12-2b** (871 mg, 47 %). The compound **12-2b** was dissolved in dichloromethane (15 ml) and the solution was cooled to 0°C, followed by adding trifluoroacetic acid (3.0 ml) thereto and stirring for 2 hours. The resulting mixture was concentrated under reduced pressure and the residue was dissolved in ethyl acetate (10 ml), followed by adding triethylamine (140  $\mu\text{l}$ ) thereto and stirring for 1 hour. To the solution was slowly added a solution of t-butylbenzylisothiocyanate (421 mg) in ethyl acetate (2 ml) and the mixture was stirred at room temperature for 18 hours. The resulting mixture was concentrated under reduced pressure and the obtained residue was purified by column-chromatography (hexane/ethyl acetate = 1/1) to yield the compound **12-3b** (385 mg, 95 %).




$^1\text{H}$  NMR (300MHz,  $\text{CDCl}_3$ ):  $\delta$  7.33(d,  $J=8.4\text{Hz}$ , 2H), 7.25(t,  $J=8.1\text{Hz}$ , 1H), 7.18(d,  $J=8.4\text{Hz}$ , 2H), 7.13(m, 2H), 7.03(d,  $J=7.5\text{Hz}$ , 1H), 6.31(bs, 2H), 4.66(d,  $J=5.1\text{Hz}$ , 2H), 4.58(d,  $J=4.8\text{Hz}$ , 2H), 2.95(s, 3H), 1.29(s, 9H).




5 Compounds **12-3a** and **12-3c** ~ **12-3g** of Example 53 ~ Example 59 were synthesized according to the synthesizing procedure as described above.



Examples	Compound No.	$\text{R}^{\text{F}}=$ $\text{R}^{\text{G}}=$	Spectral data
53	<b>12-3a</b>	H 2-NHMs	$^1\text{H}$ NMR(300MHz, $\text{CDCl}_3$ ): $\delta$ 8.13(bs, 1H), 7.46(d, $J=8.1\text{Hz}$ , 1H), 7.31(m, 2H), 7.31(d, $J=8.4\text{Hz}$ , 2H), 7.17(d, $J=5.4\text{Hz}$ , 1H), 7.16(d, $J=8.4\text{Hz}$ , 2H), 6.34(m, 2H), 4.87(d, $J=6.0\text{Hz}$ , 2H), 4.47(bs, 2H), 2.99(s, 3H), 1.28(s, 9H).
54	<b>12-3c</b>	H 2-NMs <sub>2</sub>	$^1\text{H}$ NMR(300MHz, $\text{CDCl}_3$ ): $\delta$ 7.62(d, $J=7.5\text{Hz}$ , 1H), 7.47(t, $J=7.5\text{Hz}$ , 1H), 7.40(t, $J=8.4\text{Hz}$ , 1H), 7.34(d, $J=8.4\text{Hz}$ , 3H), 7.17(d, $J=8.4\text{Hz}$ , 2H), 6.49(bs, 1H), 6.31(bs, 1H), 4.86(d, $J=4.2\text{Hz}$ , 2H), 4.50(bs, 2H), 3.43(s, 6H), 1.29(s, 9H).
55	<b>12-3d</b>	H 3-NMs <sub>2</sub>	$^1\text{H}$ NMR(300MHz, $\text{CDCl}_3$ ): $\delta$ 7.43(d, $J=7.2\text{Hz}$ , 1H), 7.38(m, 1H), 7.38(d, $J=8.4\text{Hz}$ , 2H), 7.31(m, 1H), 7.29(m, 1H), 7.22(d, $J=8.4\text{Hz}$ , 2H), 6.16(bs, 1H), 6.04(bs, 1H), 4.78(d, $J=5.7\text{Hz}$ , 2H), 4.57(bs, 2H), 3.40(s, 6H), 1.30(s, 9H).


56	12-3e	4-F 3-NHMs	<sup>1</sup> H NMR(300MHz, CDCl <sub>3</sub> ): δ 7.46(d, <i>J</i> =8.1Hz, 1H), 7.47(d, <i>J</i> =8.4Hz, 2H), 7.22(d, <i>J</i> =8.4Hz, 2H), 7.08(d, <i>J</i> =8.1Hz, 2H), 6.50(bs, 1H), 6.12(bs, 1H), 5.97(bs, 1H), 4.71(d, <i>J</i> =5.4Hz, 2H), 4.57(d, <i>J</i> =4.8Hz, 2H), 3.03(s, 3H), 1.31(s, 9H).
57	12-3f	4-F 3-NMs <sub>2</sub>	<sup>1</sup> H NMR(300MHz, CDCl <sub>3</sub> ): δ 7.37(d, <i>J</i> =8.4Hz, 2H), 7.36(m, 2H), 7.24(d, <i>J</i> =8.4Hz, 2H), 7.15(d, <i>J</i> =9.3Hz, 1H), 6.20(bs, 1H), 6.04(bs, 1H), 4.74(d, <i>J</i> =5.4Hz, 2H), 4.55(d, <i>J</i> =5.1Hz, 2H), 3.43(s, 6H), 1.31(s, 9H).
58	12-3g	6-F 3-NHMs	<sup>1</sup> H NMR(300MHz, CDCl <sub>3</sub> ): δ 7.36(d, <i>J</i> =8.1Hz, 2H), 7.28(dd, <i>J</i> =2.4, 6.4Hz, 1H), 7.21(d, <i>J</i> =8.1Hz, 2H), 7.08(m, 1H), 7.00(t, <i>J</i> =9.2Hz, 1H), 6.88(bs, 1H), 6.34(bs, 1H), 6.18(bs, 1H), 4.76(d, <i>J</i> =5.7Hz, 2H), 4.55(d, <i>J</i> =4.5Hz, 2H), 2.97(s, 3H), 1.30(s, 9H).





5      **Example**                                      **59:**                                      **Synthesis**                                      **of**

**1-(4-t-butyl-2-methoxybenzyl)-3-(4-methanesulfonylaminobenzyl)thiourea (13-4a)**



### Step 1: Synthesis of 4-t-butyl-2-methoxybenzonitrile (13-2a)

10 4-t-Butyl-2-hydroxybenzonitrile (1.16 g) and potassium carbonate (376 mg)



were dissolved in dimethylformamide (4 ml) and to the solution was added dropwise iodomethane (226  $\mu\text{l}$ ), followed by stirring at 50°C for 2 hours. The resulting mixture was filtered to remove the remaining potassium carbonate and concentrated under reduced pressure. The obtained residue was purified by column-chromatography (hexane/ethyl acetate = 10/1) to yield the compound 13-2a (167 mg, 97 %).

$^1\text{H}$  NMR(300MHz,  $\text{CDCl}_3$ ) :  $\delta$ 7.45(d, 1H,  $J=8.0\text{Hz}$ ), 7.01(dd, 1H,  $J=1.7$ , 8.2Hz), 6.94(d, 1H,  $J=1.5\text{ Hz}$ ), 3.92(s, 3H), 1.31(s, 9H)

#### Step 2: Synthesis of 4-t-butyl-2-methoxybenzylamine (13-3a)

Lithium aluminium hydride (50 mg) was suspended in ether (2 ml) and the suspension was cooled to 0°C. To the suspension was added dropwise a solution of the compound 13-2a (167 mg) prepared by Step 1 in ether (2 ml) and the mixture was refluxed for 2 hours. After the completion of the reaction, the reaction solution was basified with 5 N aqueous sodium hydroxide solution. Then, aqueous Rochel solution was added thereto and stirred for 1 hour, at room temperature. Then, resulting mixture was extracted with ether (50 ml  $\times$  3) and concentrated under reduced pressure to yield the compound 13-3a (120 mg, 71 %). The following Step 3 was proceeded using the compound 13-3a which was not purified.


Step 3: Synthesis of  
1-(4-t-butyl-2-methoxybenzyl)-3-(4-methanesulfonylaminobenzyl)thiourea (**13-4a**)

The compound **13-3a** (132 mg) prepared according to the same procedure as described in Step 2 was dissolved in dichloromethane (5 ml) and to the solution were  
5 added triethylamine (143  $\mu$ l) and 4-methanesulfonaminobenzylisothiocyanate (165 mg) in order, followed by stirring at room temperature for 3 hours. The reaction solution was evaporated under reduced pressure and the obtained residue was purified by column-chromatography (hexane/ethyl acetate = 2/1) to yield the compound **13-4a** (190 mg, 70 %),

10  $^1\text{H}$  NMR(300MHz,  $\text{CDCl}_3$ ) :  $\delta$  7.11-7.32(m, 5H), 6.96(d, 1H,  $J=7.0\text{Hz}$ ), 6.82(s, 1H), 4.67(s, 2H), 4.45(s, 2H), 3.62(s, 3H), 3.00(s, 3H), 1.2(s, 9H) ; MS (FAB) m/e 436[ $\text{M}^++1$ ]

Compounds of Example 60 ~ 69 are shown in the Scheme 13. In Step 1 of the  
15 Examples, compounds **13-2b** ~ **13-2k** were synthesized according to the similar procedure as described in Step 1 of Example 59, and properties and spectral data thereof are shown in below table. And in Step 2 of the respective examples, amines were synthesized according to the similar procedure as described in Step 2 of Example 59, and the following Step 3 were proceeded using the obtained amine compounds which

was not purified. In the Example 60 ~ 69, the final compounds 13-4b ~ 13-4k were synthesized according to the similar procedure as described in Step 3 of Example 59 except that amines prepared by Step 2 were used, and properties and spectral data thereof are shown in below table.




13-2b ~ 13-2k

5

Examples -step	Compounds	R <sup>H</sup>	Spectral data
60-1	13-2b	ethyl	<sup>1</sup> H NMR(300MHz, CDCl <sub>3</sub> ) : δ7.45(d, 1H, J=8.1Hz), 6.98(dd, 1H, J=1.7, 8.1Hz), 6.92(d, 1H, J=1.5Hz), 4.15(q, 2H, J=6.8Hz), 1.46(t, 3H, J=7.1Hz), 1.30(s, 9H); MS (FAB) m/e 450 [M <sup>+</sup> +1]
61-1	13-2c	n-propyl	<sup>1</sup> H NMR(300MHz, CDCl <sub>3</sub> ): δ7.45(d, 1H, J=8.3Hz), 6.98(dd, 1H, J=1.7, 8.2Hz), 6.91(d, 1H, J=1.7Hz), 4.02(t, 2H, J=6.6Hz), 1.78-1.92(m, 2H), 1.30(s, 9H), 1.07(t, 3H, J=7.3Hz)
62-1	13-2d	n-butyl	<sup>1</sup> H NMR(300MHz, CDCl <sub>3</sub> ): δ7.44(d, 1H, J=8.0Hz), 6.98(dd, 1H, J=1.7, 8.0Hz), 6.92(d, 1H, J=1.5Hz), 4.04(t, 2H, J=3.4Hz), 1.70-1.88(m, 2H), 1.40-1.62(m, 2H), 1.30(s, 9H), 0.97(t, 3H, J=7.3Hz)
63-1	13-2e	n-pentyl	<sup>1</sup> H NMR(300MHz, CDCl <sub>3</sub> ): δ7.44(d, 1H, J=8.0Hz), 6.98(dd, 1H, J=1.7, 8.0Hz), 6.91(d, 1H, J=1.7Hz), 4.05(t, 2H, J=6.6Hz), 1.84(m, 2H, J=6.8Hz), 1.34-1.53(m, 4H), 1.30(s, 9H), 0.92(t, 3H, J=7.1Hz)

64-1	13-2f	isopropyl	$^1\text{H}$ NMR(300MHz, $\text{CDCl}_3$ ): $\delta$ 7.44(d, 1H, $J=8.0\text{Hz}$ ), 6.97(dd, 1H, $J=1.7, 8.0\text{Hz}$ ), 6.94(d, 1H, $J=1.7\text{Hz}$ ), 4.65(m, 1H, $J=5.9\text{Hz}$ ), 1.38(d, 6H, $J=6.1\text{Hz}$ ), 1.29(s, 9H)
65-1	13-2g	isobutyl	$^1\text{H}$ NMR(300MHz, $\text{CDCl}_3$ ) : $\delta$ 7.45(d, 1H, $J=8.3\text{Hz}$ ), 6.8(dd, 1H, $J=1.7, 8.0\text{Hz}$ ), 6.90(d, 1H, $J=1.5\text{Hz}$ ), 3.81(d, 2H, $J=6.4\text{Hz}$ ), 2.08-2.20(m, 1H), 1.30(s, 9H), 1.06(d, 6H, $J=6.8\text{Hz}$ )
66-1	13-2h	neo-pentyl	$^1\text{H}$ NMR(300MHz, $\text{CDCl}_3$ ) : $\delta$ 7.45(d, 1H, $J=8.0\text{Hz}$ ), 6.98(dd, 1H, $J=1.7, 8.0\text{Hz}$ ), 6.89(d, 1H, $J=1.7\text{Hz}$ ), 3.68(s, 2H), 1.30(s, 9H), 1.08(s, 9H)
67-1	13-2i	MOM	$^1\text{H}$ NMR(400MHz, $\text{CDCl}_3$ ) : $\delta$ 7.51(d, 1H, $J=8.1\text{Hz}$ ), 7.19(dd, 1H, $J=1.5, 5.2\text{Hz}$ ), 7.10(d, 1H, $J=1.6\text{Hz}$ ), 5.31(s, 2H), 3.56(s, 3H), 1.34(s, 9H)
68-1	13-2j	methoxyethoxymethyl	$^1\text{H}$ NMR(300MHz, $\text{CDCl}_3$ ) : $\delta$ 7.45(d, 1H, $J=7.8\text{Hz}$ ), 7.02(d, 1H, $J=1.7\text{Hz}$ ), 6.99(dd, 1H, $J=1.7, 3.0\text{Hz}$ ), 4.23(t, 2H, $J=4.6\text{Hz}$ ), 3.80(t, 2H, $J=4.5\text{Hz}$ ), 3.47(s, 3H), 1.29(s, 9H)
69-1	13-2k	benzyl	$^1\text{H}$ NMR(300MHz, $\text{CDCl}_3$ ) : $\delta$ 7.50-7.27(m, 6H), 7.02(d, 1H, $J=0.7\text{Hz}$ ), 6.98(dd, 1H, $J=1.7, 5.3\text{Hz}$ ), 5.21(s, 2H), 1.25(s, 9H), 3.47(s, 3H)











5



Examples -step	Compounds	$\text{R}^{\text{H}}$	Spectral data
-------------------	-----------	-----------------------	---------------

60-3	13-4b	ethyl	<sup>1</sup> H NMR(300MHz, CDCl <sub>3</sub> ) : $\delta$ 7.01-7.10(m, 5H), 6.91(d, 1H, $J$ =7.6Hz), 6.77(s, 1H), 4.64(s, 2H), 4.42(s, 2H), 3.87(q, 2H, $J$ =7.1Hz), 2.94(s, 3H), 1.15-1.24(m, 12H); MS (FAB) m/e 450 [ $M^+$ +1]
61-3	13-4c	n-propyl	<sup>1</sup> H NMR(300MHz, CDCl <sub>3</sub> ) : $\delta$ 7.06-7.20(m, 5H), 6.95(dd, 1H, $J$ =1.7, 7.9Hz), 6.1(d, 1H, $J$ =1.5Hz), 4.68(s, 2H), 4.44(s, 2H), 3.80(t, 2H, $J$ =6.6Hz), 2.98(s, 3H), 1.52-1.74(m, 2H), 1.29(s, 9H), 0.95(t, 3H, $J$ =7.6Hz); MS (FAB) m/e 464 [ $M^+$ +1]
62-3	13-4d	n-butyl	<sup>1</sup> H NMR(300MHz, CDCl <sub>3</sub> ) : $\delta$ 7.08-7.33(m, 5H), 6.96(d, 1H, $J$ =7.8Hz), 6.83(s, 1H), 4.68(s, 2H), 4.47(s, 2H), 3.85(t, 2H, $J$ =6.8Hz), 2.98(m, 3H), 1.39-1.80(m, 4H), 1.29(s, 9H), 0.91(t, 3H, $J$ =7.3Hz); MS (FAB) m/e 478 [ $M^+$ +1]
63-3	13-4e	n-pentyl	<sup>1</sup> H NMR(300MHz, CDCl <sub>3</sub> ) : $\delta$ 8.05-7.35(m, 5H), 6.75-7.00(m, 2H), 4.61(s, 2H), 4.49(s, 2H), 2.96(s, 3H), 1.55-1.70(m, 2H), 1.10-1.48(m, 13H), 0.92(t, 3H, $J$ =7.1Hz); MS (FAB) m/e 492 [ $M^+$ +1]
64-3	13-4f	isopropyl	<sup>1</sup> H NMR(300MHz, CDCl <sub>3</sub> ) : $\delta$ 7.06-7.37(m, 5H), 6.95(dd, 1H, $J$ =1.7, 7.8Hz), 4.69(s, 2H), 4.33-4.60(m, 3H), 2.97(s, 3H), 1.29(s, 9H), 1.23(d, 6H, $J$ =6.1Hz); MS (FAB) m/e 464 [ $M^+$ +1]
65-3	13-4g	isobutyl	<sup>1</sup> H NMR(300MHz, CDCl <sub>3</sub> ) : $\delta$ 7.06-7.33(m, 5H), 6.95(d, 1H, $J$ =8.0Hz), 6.81(d, 1H, $J$ =1.7Hz), 4.68(s, 2H), 4.48(s, 2H), 3.62(d, 2H, $J$ =6.3Hz), 2.98(s, 3H), 1.30(s, 9H), 0.96(d, 6H, $J$ =6.8Hz); MS (FAB) m/e 478 [ $M^+$ +1]
66-3	13-4h	neo-pentyl	<sup>1</sup> H NMR(300MHz, CDCl <sub>3</sub> ) : $\delta$ 7.04-7.21(m, 5H), 6.95(d, 1H, $J$ =8.1Hz), 6.82(d, 1H, $J$ =1.7Hz), 4.68(s, 2H), 4.53(s, 2H), 3.54(s, 2H), 2.97(s, 3H), 1.30(s, 9H), 0.99(s, 9H); MS (FAB) m/e 492 [ $M^+$ +1]
67-3	13-4i	MOM	<sup>1</sup> H NMR(300MHz, CDCl <sub>3</sub> ) : $\delta$ 6.96-7.30(m, 7H), 5.06(s, 2H), 4.66(s, 2H), 4.51(s, 2H), 3.39(s, 3H), 2.98(s, 3H), 1.28(s, 9H); MS (FAB) m/e 466 [ $M^+$ +1]
68-3	13-4j	methoxyethoxymethyl	<sup>1</sup> H NMR(300MHz, CDCl <sub>3</sub> ) : $\delta$ 7.10-7.37(m, 5H), 6.98(d, 1H, $J$ =7.8Hz), 6.85(s, 1H), 4.68(s, 2H), 4.61(s, 2H), 4.00-4.15(m, 2H), 3.60-3.75(m, 2H), 3.30(s, 3H), 2.97(s, 3H), 1.28(s, 9H); MS (FAB) m/e 480 [ $M^+$ +1]

69-3	13-4k	benzyl	$^1\text{H}$ NMR(400MHz, $\text{CDCl}_3$ ) : $\delta$ 7.50-6.95(m, 12H), 5.01(s, 2H), 4.68-4.40(m, 4H), 3.00(s, 3H), 1.33(s, 9H); MS (FAB) m/e 512 $[\text{M}^++1]$
------	-------	--------	---








**Example**                      **70:**                      **Synthesis**                      **of**

- 5    **1-(2-acetoxymethyl-4-t-butylbenzyl)-3-(4-methanesulfonylaminobenzene)thiourea**  
**(13-9a)**



Step 1: Synthesis of 4-t-butyl-2-trifluoromethanesulfonyloxybenzonitrile (13-5)

4-t-butyl-2-hydroxybenzonitrile (800 mg) was dissolved in dichloromethane



(16 ml) and cooled to 0 °C. To the solution were added triethylamine (663  $\mu\text{l}$ ) and trifluoromethanesulfonic anhydride (764  $\mu\text{l}$ ) in order, followed by stirring for 1 hour.

The reaction solution was evaporated under reduced pressure and the obtained residue was purified by column-chromatography (hexane/ethyl acetate = 10/1) to yield the

5 compound 13-5 (1.30 g, 93 %).

$^1\text{H}$  NMR(300MHz,  $\text{CDCl}_3$ ) :  $\delta$ 7.67(d, 1H,  $J=8.0\text{Hz}$ ), 7.49(dd, 1H,  $J=1.7$ , 8.3Hz), 7.43(d, 1H,  $J=1.5\text{Hz}$ ), 1.34(s, 9H)

#### Step 2: Synthesis of methyl 5-t-butyl-2-cyanobenzoate (13-6)

10 The compound 13-5 (1.30 g) prepared according to the same procedure as described in Step 1 was mixed with palladium acetate (28 mg) and 1,1'-bis(diphenylphosphino)ferrocene (141 mg), and the atmosphere of the reactor was brought into an atmosphere of carbon monoxide. To the mixture was added dimethylsulfoxide (25 ml) to dissolve the mixture. To the solution was added

15 triethylamine (1.77 ml) and methanol (3.42 ml) successively with stirring and the mixture was stirred at 50°C for 4 hours. The resulting mixture was filtered to remove the catalyst and the filtrate was evaporated under reduced pressure. The obtained residue was purified by column-chromatography (hexane/ethyl acetate = 20/1) to yield the compound 13-6 (400 mg, 44 %).

<sup>1</sup>H NMR(300MHz, CDCl<sub>3</sub>) : δ 8.13(d, 1H, *J*=2.0Hz), 7.72(d, 1H, *J*=8.1Hz), 7.64(dd, 1H, *J*=2.2, 8.2Hz), 3.99(s, 3H), 1.34(s, 9H)

### Step 3: Synthesis of (2-aminomethyl-5-t-butylphenyl)methanol (13-7)

5           Lithium aluminium hydride (105 mg) was suspended in ether (3 ml) and the suspension was cooled to 0°C. To the suspension was added dropwise a solution of the compound 13-6 (140 mg) prepared by Step 2 in ether (4 ml) and the mixture was refluxed for 2 hours. After the completion of the reaction, the reaction mixture was basified with 5 N aqueous sodium hydroxide solution, followed by adding aqueous  
10 Rochel solution thereto and then stirring for 1 hour. Then, the resulting mixture was extracted with ether (50 ml × 3) and concentrated under reduced pressure to yield the compound 13-7 (320 mg, 90 %). The following Step 4 was proceeded using the compound 13-7 which was not purified

15	Step	4:	Synthesis	of
			1-(4-t-butyl-2-hydroxymethylbenzyl)-3-(4-methanesulfonylaminobenzyl)thiourea	
			(13-8)	

The compound **13-7a** (320 mg) prepared according to the same procedure as described in Step 3 was dissolved in dichloromethane (7 ml) and to the solution were

added triethylamine (231  $\mu\text{l}$ ) and 4-methanesulfonaminobenzylisothiocyanate (401 mg) successively, followed by stirring at room temperature for 3 hours. The reaction solution was evaporated under reduced pressure and the obtained residue was purified by column-chromatography (hexane/ethyl acetate = 1/1) to yield the compound 13-8 (460 mg, 64 %).

$^1\text{H}$  NMR(300MHz,  $\text{CDCl}_3$ ) :  $\delta$ 7.38-7.00 (m, 7H), 4.75-4.60(m, 4H), 4.50(s, 2H), 2.92(s, 3H), 1.25(s, 9H)

	Step	5:	Synthesis	of
10	1-(2-acetoxymethyl-4-t-butylbenzyl)-3-(4-methanesulfonylaminobenzene)thiourea (13-9a)			


1,3-Dicyclohexylcarbodiimide (68 mg) was dissolved in dichloromethane (1 ml), and the solution was stirred and cooled to 0°C. To the solution were added dropwise a mixed solution of the compound 13-8 (130 mg) prepared according to the same procedure as described in Step 4 and 4-(dimethylamino)pyridine (4 mg) in dichloromethane (3 ml), followed by adding acetic acid (34  $\mu\text{l}$ ) thereto. The mixture was stirred at room temperature for 12 hours and concentrated under reduced pressure. The obtained residue was purified by column-chromatography (hexane/ethyl acetate = 3/2) to yield the compound 13-9a (52 mg, 37 %).

$^1\text{H}$  NMR(300MHz,  $\text{CDCl}_3$ ) :  $\delta$ 7.40-7.06(m, 7H), 5.10(s, 2H), 4.68(s, 4H),

2.30(s, 3H), 2.01(s, 3H), 1.30(s, 9H) ; MS (FAB) m/e 478 [ $\text{M}^+$ +1]

**Example 71: Synthesis of**

5 **1-(2-trimethylacetoxymethyl-4-t-butylbenzyl)-3-(4-methanesulfonylaminobenzene) thiourea (13-9b)**




Compound **13-9b** (110 mg, 71 %) was synthesized by reacting compound **13-8** (130 mg) with trimethylacetic acid (45 mg) according to the similar procedure as  
10 described in Step 5 of Example 70.

$^1\text{H}$  NMR(300MHz,  $\text{CDCl}_3$ ) :  $\delta$ 7.43-7.07(m, 7H), 5.10(s, 2H), 4.72(s, 2H),

4.66(s, 2H), 2.97(s, 3H), 1.29(s, 9H), 1.12(s, 9H) ; MS (FAB) m/e 520 [ $\text{M}^+$ +1]

**Example 72: Synthesis of 1-(4-t-butylbenzyl)-3-(4-methylthiobenzyl)thiourea (14-3)**



Step 1: Synthesis of 2-(4-methylthiobenzyl)isoindol-1,3-dione (**14-1**)

(4-methylthio)benzylalcohol (1.54 g) was dissolved in anhydrous tetrahydrofuran (10 ml) and to the solution were added phthalimide (1.47 g) and  
 5 triphenylphosphine (2.62 g). To the mixture was slowly added dropwise a solution of diisopropylazodicarboxylate (DIAD) (2.02 g) in anhydrous tetrahydrofuran (4 ml), while the mixture was stirred at room temperature. After 18 hours, the reaction mixture was concentrated and the residue was purified by column-chromatography (hexane/ethyl acetate = 5/1) to yield a white solid (2.00 g, 71 %).

10  $^1\text{H}$  NMR(300MHz,  $\text{CDCl}_3$ ) :  $\delta$  7.86-7.68(m, 4H), 7.38-7.35(m, 2H), 7.22-7.18(m, 2H), 4.79(s, 2H), 2.44(s, 3H)


Step 2: Synthesis of 1-(4-t-butylbenzyl)-3-(4-methylthiobenzyl)thiourea (**14-3**)

2-(4-methylthiobenzyl)isoindol-1,3-dione (**14-1**) (1.67 g) was dissolved in  
 15 ethanol (10 ml) and to the solution was added hydrazine hydrate (300 mg), followed by refluxing. After 24 hours, the resulting mixture was diluted with dichloromethane (50 ml) and washed with 2 N hydrochloric acid solution. An organic layer was washed

with aqueous sodium chloride solution, dried over anhydrous magnesium sulfate, concentrated under reduced pressure. The residue was purified by column-chromatography to obtain a liquid (0.8 g). The obtained liquid mixture (400 mg) was dissolved in dichloromethane (20 ml) and to the solution was added  
5 4-t-butylbenzylisothiocyanate (0.54 g), followed by stirring at room temperature for 24 hours. The reaction mixture was concentrated and the residue was purified by column-chromatography (dichloromethane) to yield the compound 14-3 (0.52 g, 56 %) as a white solid.

$^1\text{H}$  NMR(300MHz,  $\text{CDCl}_3$ ) :  $\delta$  7.37-7.15(m, 8H), 6.00(brs, 2H), 4.60-4.50(m,  
10 4H), 2.47(s, 3H), 1.31(s, 9H)

**Example 73: Synthesis of**  
**1-(4-t-butylbenzyl)-3-[2-(4-methylthiazol-5-yl)ethyl]thiourea (14-6)**



15

Step 1: Synthesis of 5-(2-methylsulfonyloxyethyl)-4-methylthiazole

2-(4-methylthiazol-5-yl)ethanol (5.01 g) was dissolved in dichloromethane (100

ml) and to the solution was added triethylamine (5.06 g), followed by adjusting the temperature of reactor to 0°C. To the obtained solution was added dropwise methanesulfonyl chloride (4.58 g), and the mixture was stirred for 21 hours while allowed to warm up to room temperature. The reaction solution was washed with  
5 water, concentrated under reduced pressure, and then purified by column-chromatography (hexane/ethyl acetate = 1/3) to yield 5-(2-methylsulfonyloxyethyl)-4-methylthiazole (5.18 g, 67 %) as a pale yellow liquid.

<sup>1</sup>H NMR(300MHz, CDCl<sub>3</sub>) : δ 8.63(s, 1H), 4.37(t, 3H, J= 6Hz), 3.23(t, 3H, J= 6Hz), 2.97(s, 3H), 2.43(s, 3H)

10

Step 2: Synthesis of 2-[2-(4-methylthiazol-5-yl)ethyl]isoindol-1,3-dione (14-4)

5-(2-methylsulfonyloxyethyl)-4-methylthiazole (4.17 g) was dissolved in dimethylformamide (20 ml) and to the solution was added potassium phthalimide (3.84 g), followed by stirring at 70°C for 5 hours. The mixture was concentrated under  
15 reduced pressure and water was added thereto to form precipitate. The resulting mixture was filtered to collect the precipitate. The obtained precipitate was dissolved in dichloromethane. The solution was dried over anhydrous magnesium sulfate, concentrated, and then crystallized (dichloromethane/petroleum ether) to yield the compound 14-4 (3.77 g, 74 %) as a pale yellow solid.

$^1\text{H}$  NMR(300MHz,  $\text{CDCl}_3$ ) :  $\delta$  8.57(s, 1H), 7.86-7.70(m, 4H), 3.91(t, 3H, J=6Hz), 3.18(t, 3H, J= 6Hz), 2.38(s, 3H)

	Step	3:	Synthesis	of
5	1-(4-t-butylbenzyl)-3-[2-(4-methylthiazol-5-yl)ethyl]thiourea (14-6)			

2-[2-(4-methylthiazol-5-yl)ethyl]isoindol-1,3-dione (3 g) was dissolved in a mixture of methanol (10 ml) and tetrahydrofuran (10 ml) and to the solution was added dropwise hydrazine hydrate (610 mg), followed by stirring for 20 hours. To the obtained solution was added 2 N aqueous hydrochloric acid solution (6 ml), and the mixture was stirred for 3 hours and concentrated under reduced pressure to obtain reaction mixture (3.5 g) as a yellow solid. The obtained mixture (140 mg) was dissolved in dimethylformamide (5 ml) and to the solution were added 4-t-butylbenzylisothiocyanate (0.2 g) and a small amount of triethylamine, followed by stirring at room temperature for 21 hours. The resulting mixture was diluted with dichloromethane, washed with water, dried, concentrated under reduced pressure, and then purified by column-chromatography (hexane/ethyl acetate = 1/1) to yield the compound 14-6 (0.07 g) as a liquid.


$^1\text{H}$  NMR(300MHz,  $\text{CDCl}_3$ ) :  $\delta$  8.53(s,1H), 7.38-7.18(m, 4H), 6.25(brs, 1H), 5.77(brs, 1H), 4.49(s,2H), 3.78-3.73(m, 2H), 3.08(t, 2H, J=6Hz), 2.36(s, 3H), 1.31(s,



9H)

**Example 74: Synthesis of**  
**1-(4-t-butylbenzyl)-3-((2-chloro-5-pyridinyl)methyl)thiourea (14-9)**

5

**14-9**

Step 1: Synthesis of ((2-chloro-5-pyridinyl)methyl)isoindol-1,3-dione (14-7)

2-chloro-5-chloromethylpyridine (5 g) was dissolved in dimethylformamide (60 ml) and to the solution was added phthalimide (6.29 g), followed by stirring at room temperature for 17 hours. The solvent of the reaction solution was removed under reduced pressure and the residue was extracted with water and dichloromethane to yield a white solid (6.2 g, 74 %).

15


<sup>1</sup>H NMR(300MHz, CDCl<sub>3</sub>) : δ 8.50-8.49(m, 1H), 7.88-7.72(m, 5H), 7.30-7.26(m, 1H), 4.83(s, 2H), 2.44(s, 3H)

**Step 2: Synthesis of**  
**1-(4-t-butylbenzyl)-3-((2-chloro-5-pyridinyl)methyl)thiourea (14-9)**

((2-chloro-5-pyridinyl)methyl)isindol-1,3-dione (4.7 g) was dissolved in methanol (100 ml) and to the solution was added hydrazine hydrate (7.7 ml), followed by stirring at room temperature for 2 hours. The reaction solution was extracted with water and dichloromethane and concentrated under reduced pressure to obtain a liquid (1.4 g). The obtained liquid mixture (66 mg) was dissolved in dichloromethane (5 ml) and to the solution was added 4-t-butylbenzylisothiocyanate (95 mg), followed by stirring at room temperature for 24 hours. The reaction mixture was concentrated and purified by column-chromatography (hexane/ethyl acetate = 2/1) to yield the compound 14-9 (45 mg, 28 %) as a white solid.

<sup>1</sup>H NMR(300MHz, CDCl<sub>3</sub>) : δ 8.16-8.15(m, 1H), 7.61-7.57(m, 1H), 7.38-7.18(m, 4H), 6.48(brs, 2H), 6.21(brs, 2H), 4.74(d, 2H, J=5.7Hz), 4.54(d, 2H, J=4.5Hz), 1.29(s, 9H)

**Example 75: Synthesis of**  
15 **1-(4-t-butylbenzyl)-3-(2-(thiomorpholin-4-yl)ethyl)thiourea (15-3)**

**15-3**

Step 1: Synthesis of 2-(2-thiomorpholin-4-yl)ethyl)isoindol-1,3-dione (**15-1**)

Thiomorpholine (3.75 g) was dissolved in acetone (100 ml) and to the solution were added anhydrous potassium carbonate (5.52 g) and 2-(bromoethyl)phthalimide (9.22 g), followed by refluxing for 26 hours. The obtained mixture was filtered, concentrated, and then dissolved in dichloromethane. The solution was washed with water, dried, concentrated under reduced pressure, and then purified by column-chromatography (hexane/ethyl acetate = 1/1) to yield the compound **15-1** (2 g, 20 %) as a yellow solid.

$^1\text{H}$  NMR(300MHz,  $\text{CDCl}_3$ ) :  $\delta$  7.87-7.70(m, 4H), 3.80(t, 2H,  $J=6.6\text{Hz}$ ), 2.79-2.57(m, 10H)


Step 2: Synthesis of  
1-(4-t-butylbenzyl)-3-(2-(thiomorpholin-4-yl)ethyl)thiourea (**15-3**)

2-(2-thiomorpholin-4-ylethyl)isoindol-1,3-dione **15-1** (2.76 g) was dissolved in a mixture of methanol (20 ml) and tetrahydrofuran (20 ml) and to the solution was added dropwise hydrazine hydrate (550 mg), followed by stirring for 21 hours. To the obtained solution was added 2 N aqueous hydrochloric acid solution (6 ml), and the mixture was stirred for 3 hours and then concentrated under reduced pressure. To the concentrate was added water (15 ml) and the undissolved material was filtered off.

The filtrate was concentrated to obtain reaction mixture (1.62 g) as a solid. The obtained mixture (150 mg) was dissolved in dimethylformamide (5 ml) and to the solution was added 4-t-butylbenzylisothiocyanate (210 mg) and a small amount of triethylamine, followed by stirring at room temperature for 23 hours. The resulting mixture was diluted with dichloromethane, washed with water, and concentrated under reduced pressure. The residue was purified by column-chromatography (hexane/ethyl acetate = 1/3) to the compound **15-3** (0.12 g) as a white solid.

$^1\text{H}$  NMR(300MHz,  $\text{CDCl}_3$ ) :  $\delta$  7.42-7.26(m, 4H), 6.32(brs, 1H), 4.60(s, 2H), 3.40(s, 2H), 2.62-2.20(m, 10H), 1.32(s, 9H)

**Example 76: Synthesis of 1-(furan-2-ylmethyl)-3-(4-methoxybenzyl)thiourea (16-1)**




**16-1**

Furan-2-ylmethylamine (190 mg) was dissolved in dimethylformamide (5 ml) and to the solution were added triethylamine (200 mg) and 4-methoxybenzylisothiocyanate (360 mg), followed by stirring at room temperature for 24 hours. Then, the resulting mixture was diluted with ethyl acetate, washed with water, dried, and concentrated under reduced pressure. The residue was purified by

column-chromatography (hexane/ethyl acetate = 1/1) to yield the compound 16-1 (0.5 g, 90 %) as a liquid.

$^1\text{H}$  NMR(300MHz,  $\text{CDCl}_3$ ) :  $\delta$  7.33-7.32(m, 1H), 7.23-7.19(m, 2H),  
6.89-6.85(m, 2H), 6.32-6.23(m, 2H), 6.20(brs,1H), 6.05(brs,1H), 4.67-4.64(m, 2H),  
5 4.55-4.53(m, 2H), 3.80(s, 3H)

**Example 77: Synthesis of 1-(4-t-butylbenzyl)-3-(furan-2-ylmethyl)thiourea (16-2)**




Furan-2-ylmethylamine (0.58 g) was dissolved in dichloromethane (50 ml) and  
10 to the solution was added 4-t-butylbenzylisothiocyanate (1.23 g), followed by stirring at  
room temperature for 8 hours. Then, the resulting mixture was diluted with ethyl  
acetate, washed with water, dried, and concentrated under reduced pressure. The  
residue was purified by column-chromatography (dichloromethane) to yield the  
compound 16-2 (1.57 g, 87 %) as a liquid.

15  $^1\text{H}$  NMR(300MHz,  $\text{CDCl}_3$ ) :  $\delta$  7.37-7.20(m, 5H), 6.31-6.29(m, 1H),  
6.21-6.19(m, 1H), 6.10(brs,1H), 4.65-4.63(m, 2H), 4.58-4.50(m, 2H), 1.30(s, 9H)









## Example 78 ~ Example 121








Compounds of Example 78 ~ Example 121 are shown in the Scheme 16. The compounds were synthesized according to the similar procedure as described in Example 76 or Example 77, and properties and spectral data are shown in below table.





5






Examples	Compounds	R=	Types	Spectral data
78	16-3		B	<sup>1</sup> H NMR(300MHz, CDCl <sub>3</sub> ) : δ 7.34-7.18(m, 6H), 6.31-6.28(m, 1H), 6.21-6.20(m, 1H), 5.92(brs, 2H), 4.60-4.50(m, 2H), 3.75-3.65(m, 2H), 2.91(t, 2H, J=6.6Hz)
79	16-4		A	<sup>1</sup> H NMR(300MHz, CDCl <sub>3</sub> ) : δ 8.41-8.39(m, 1H), 7.70-7.64(m, 1H), 7.38-7.17(m, 6H), 4.73(m, 2H), 4.64(m, 2H), 1.31(s, 9H)
80	16-5		B	<sup>1</sup> H NMR(300MHz, CDCl <sub>3</sub> ) : δ 8.41-8.38(m, 1H), 7.72-7.66(m, 1H), 7.34-7.05(m, 9H), 4.69(m, 2H), 3.77(m, 2H), 2.96(t, 2H, J=6.9Hz)
81	16-6		A	<sup>1</sup> H NMR(300MHz, CDCl <sub>3</sub> ) : δ 8.52-8.48(m, 2H), 7.63-7.59(m, 1H), 7.39-7.35(m, 2H), 7.24-7.20(m, 3H), 6.22(brs, 1H), 5.95(brs, 1H), 4.79-4.76(m, 2H), 4.57-4.55(m, 2H), 1.31(s, 9H)
82	16-7		A	<sup>1</sup> H NMR(300MHz, CDCl <sub>3</sub> ) : δ 8.51-8.49(m, 2H), 7.40-7.37(m, 2H), 7.25-7.21(m, 2H), 7.10-7.07(m, 2H), 6.30(brs, 1H), 6.00(brs, 1H), 4.80-4.77(m, 2H), 4.58-4.56(m, 2H), 1.31(s, 9H)
83	16-8		A	<sup>1</sup> H NMR(300MHz, CDCl <sub>3</sub> ) : δ 8.16-8.14(m, 1H), 7.62-7.55(m, 1H), 7.37-7.22(m, 4H), 7.16-7.05(m, 2H), 4.54(m, 2H), 3.91(m, 2H), 3.04(t, 2H, J=6Hz), 1.32(s, 9H)
84	16-9		B	<sup>1</sup> H NMR(300MHz, CDCl <sub>3</sub> ) : δ 8.41-8.38(m, 1H), 7.66-7.60(m, 1H), 7.33-7.13(m, 7H), 6.31(br, 2H), 3.87(m, 2H), 3.66(m, 2H), 3.04(t, 2H, J=6Hz), 2.92(t, 2H, J=6.9Hz),
85	16-10		A	<sup>1</sup> H NMR(300MHz, CDCl <sub>3</sub> ) : δ 7.37-7.19(m, 6H), 7.12-6.99(m, 2H), 6.11(brs, 1H), 6.01(brs, 1H), 4.75-4.73(m, 2H), 4.57-4.55(m, 2H), 1.31(s, 9H)

**16-3****16-4****16-5****16-6****16-7****16-8****16-9****16-10**







Examples	Compounds	R=	Types	Spectral data
86	16-11		A	$^1\text{H}$ NMR(300MHz, $\text{CDCl}_3$ ) : $\delta$ 7.38-6.88(m, 8H), 6.14(brs, 1H), 5.96(brs, 1H), 4.70-4.67(m, 2H), 4.57-4.55(m, 2H), 1.31(s, 9H)
87	16-12		A	$^1\text{H}$ NMR(300MHz, $\text{CDCl}_3$ ) : $\delta$ 7.37-7.33(m, 2H), 7.20-7.16(m, 4H), 7.01-6.95(m, 2H), 6.07(brs, 1H), 6.00(brs, 1H), 4.63-4.54(m, 4H), 1.31(s, 9H)
88	16-13		A	$^1\text{H}$ NMR(300MHz, $\text{CDCl}_3$ ) : $\delta$ 7.39-7.35(m, 2H), 7.23-7.19(m, 2H), 7.10-6.90(m, 4H), 6.08(brs, 1H), 5.85(brs, 1H), 4.69-4.66(m, 2H), 4.56-4.53(m, 2H), 1.31(s, 9H)
89	16-14		A	$^1\text{H}$ NMR(300MHz, $\text{CDCl}_3$ ) : $\delta$ 7.40-7.37(m, 2H), 7.24-7.21(m, 3H), 6.73-6.66(m, 2H), 6.24(brs, 1H), 5.90(brs, 1H), 4.74-4.71(m, 2H), 4.56-4.54(m, 2H), 1.31(s, 9H)
90	16-15		A	$^1\text{H}$ NMR(300MHz, $\text{CDCl}_3$ ) : $\delta$ 7.39-7.36(m, 2H), 7.24-7.22(m, 2H), 7.02-6.94(m, 3H), 6.16(brs, 1H), 5.92(brs, 1H), 4.78-4.76(m, 2H), 4.56-4.54(m, 2H), 1.31(s, 9H)
91	16-16		A	$^1\text{H}$ NMR(300MHz, $\text{CDCl}_3$ ) : $\delta$ 7.38-7.20(m, 5H), 6.90-6.74(m, 2H), 6.10(brs, 1H), 5.91(brs, 1H), 4.75-4.72(m, 2H), 4.55-4.50(m, 2H), 1.31(s, 9H)
92	16-17		A	$^1\text{H}$ NMR(300MHz, $\text{CDCl}_3$ ) : $\delta$ 7.38-7.34(m, 2H), 7.27-7.20(m, 3H), 6.91-6.85(m, 2H), 6.05(brs, 1H), 6.02(brs, 1H), 4.71-4.70(m, 2H), 4.61-4.60(m, 2H), 1.31(s, 9H)


























Examples	Compounds	R=	Types	Spectral data
93	16-18		A	<sup>1</sup> H NMR(300MHz, CDCl <sub>3</sub> ) : δ 7.39-7.35(m, 2H), 7.25-7.20(m, 3H), 7.15-7.05(m, 1H), 6.95-6.85(m, 1H), 6.16(brs, 1H), 5.88(brs, 1H), 4.80-4.78(m, 2H), 4.53-4.51(m, 2H), 1.31(s, 9H)
94	16-19		A	<sup>1</sup> H NMR(300MHz, CDCl <sub>3</sub> ) : δ 7.39-7.35(m, 2H), 7.25-7.06(m, 3H), 6.86-6.78(m, 1H), 6.14(brs, 1H), 5.95(brs, 1H), 4.79-4.76(m, 2H), 4.56-4.50(m, 2H), 1.31(s, 9H)
95	16-20		A	<sup>1</sup> H NMR(300MHz, CDCl <sub>3</sub> ) : δ 7.39-7.35(m, 2H), 7.26-6.98(m, 6H), 5.97(brs, 1H), 5.68(brs, 1H), 4.51-4.49(m, 2H), 3.75-3.74(m, 2H), 2.94(t, 2H, J=6.6Hz), 1.32(s, 9H)
96	16-21		A	<sup>1</sup> H NMR(300MHz, CDCl <sub>3</sub> ) : δ 7.38-7.19(m, 6H), 6.92-6.84(m, 2H), 6.03(brs, 1H), 5.59(brs, 1H), 4.46(m, 2H), 3.78(m, 2H), 2.89(t, 2H, J=6.6Hz), 1.32(s, 9H)
97	16-22		A	<sup>1</sup> H NMR(300MHz, CDCl <sub>3</sub> ) : δ 7.37-6.92(m, 8H), 5.94(brs, 1H), 5.58(brs, 1H), 4.46(m, 2H), 3.73(m, 2H), 2.85(t, 2H, J=6Hz), 1.32(s, 9H)
98	16-23		A	<sup>1</sup> H NMR(300MHz, CDCl <sub>3</sub> ) : δ 7.40-7.35(m, 2H), 7.19-7.16(m, 2H), 7.10-6.83(m, 3H), 6.08(brs, 1H), 5.58(brs, 1H), 4.47-4.44(m, 2H), 3.77-3.70(m, 2H), 2.84(t, 2H, J=6.9Hz), 1.31(s, 9H)










**16-18****16-19****16-20****16-21****16-22****16-23**









Examples	Compounds	R=	Types	Spectral data
99	16-24		A	$^1\text{H NMR}$ (300MHz, $\text{CDCl}_3$ ) : $\delta$ 7.38-7.34(m, 2H), 7.19-7.16(m, 2H), 7.08-7.04(m, 2H), 6.84-6.80(m, 2H), 5.90(brs, 1H), 5.62(brs, 1H), 4.48-4.46(m, 2H), 3.79(s, 3H), 3.70-3.68(m, 2H), 2.81(t, 2H, $J=6.6\text{Hz}$ ), 1.31(s, 9H)
100	16-25		A	$^1\text{H NMR}$ (300MHz, $\text{CDCl}_3$ ) : $\delta$ 7.37-7.33(m, 2H), 7.22-7.15(m, 3H), 6.79-6.71(m, 3H), 5.93(brs, 1H), 5.64(brs, 1H), 4.47-4.45(m, 2H), 3.79(s, 3H), 3.78-3.72(m, 2H), 2.85(t, 2H, $J=6.6\text{Hz}$ ), 1.31(s, 9H)
101	16-26		A	$^1\text{H NMR}$ (300MHz, $\text{CDCl}_3$ ) : $\delta$ 7.39-7.35(m, 2H), 7.25-7.18(m, 3H), 7.10-7.07(m, 1H), 6.92-6.87(m, 1H), 6.82-6.79(m, 1H), 6.23(brs, 1H), 6.04(brs, 1H), 4.60-4.59(m, 2H), 3.61(s, 3H), 3.61-3.50(m, 2H), 2.89(t, 2H, $J=6.9\text{Hz}$ ), 1.32(s, 9H)
102	16-27		A	$^1\text{H NMR}$ (300MHz, $\text{CDCl}_3$ ) : $\delta$ 7.36-7.33(m, 2H), 7.18-7.15(m, 2H), 6.79-6.75(m, 1H), 6.69-6.66(m, 2H), 6.03(brs, 1H), 5.77(brs, 1H), 4.48-4.46(m, 2H), 3.84(s, 3H), 3.83(s, 3H), 3.72-3.70(m, 2H), 2.81(t, 2H, $J=6.9\text{Hz}$ ), 1.30(s, 9H)
103	16-28		A	$^1\text{H NMR}$ (300MHz, $\text{CDCl}_3$ ) : $\delta$ 7.37-7.33(m, 2H), 7.20-7.17(m, 2H), 6.48(s, 2H), 6.00(brs, 2H), 4.60-4.55(m, 4H), 3.82-3.79(m, 9H), 1.30(s, 9H)











**16-28**

Examples	Compounds	R=	Types	Spectral data
104	16-29		A	<sup>1</sup> H NMR(300MHz, CDCl <sub>3</sub> ) : δ 7.83-7.79(m, 2H), 7.39-7.18(m, 6H), 6.13(brs, 1H), 5.71(brs, 1H), 4.85(s, 2H), 4.50(m, 2H), 3.80-3.75(m, 2H), 2.97(t, 2H, J=7.2Hz), 1.31(s, 9H)
105	16-30		A	<sup>1</sup> H NMR(300MHz, CDCl <sub>3</sub> ) : δ 7.40-7.35(m, 2H), 7.20-7.16(m, 2H), 6.78-6.75(m, 1H), 6.66-6.65(m, 1H), 6.58-6.54(m, 1H), 5.94(brs, 1H), 5.67(brs, 1H), 4.48-4.46(m, 2H), 3.65-3.64(m, 2H), 2.74(t, 2H, J=6.6Hz), 1.31(s, 9H)
106	16-31		C	<sup>1</sup> H NMR(300MHz, CDCl <sub>3</sub> ) : δ 7.56(brs, 1H), 7.41-7.25(m, 4H), 6.63(brs, 1H), 4.86(d, 2H, J=6Hz), 3.90-3.86(m, 2H), 3.63-3.55(m, 2H), 2.98-2.93(m, 2H), 2.67-2.60(m, 2H), 1.33(s, 9H)
107	16-32		A	<sup>1</sup> H NMR(300MHz, CDCl <sub>3</sub> ) : δ 7.29-7.32 (m, 2H), 7.21 (d, 2H, J = 8.0 Hz), 6.39 (br s, 1H), 4.55 (br s, 2H), 2.86-2.94 (m, 6H), 2.42 (t, 2H, J = 5.4 Hz), 2.29 (t, 2H, J = 4.7 Hz), 1.24 (s, 9H)
108	16-33		B	<sup>1</sup> H NMR(300MHz, CDCl <sub>3</sub> ) : δ 7.34-7.20(m, 5H), 6.29(s, 1H), 3.80-3.70(m, 2H), 3.60-3.50(m, 4H), 3.40-3.30(m, 2H), 2.96(t, 2H, J=6.9Hz), 2.51-2.35(m, 6H)
109	16-34		A	<sup>1</sup> H NMR(300MHz, CDCl <sub>3</sub> ) : δ 7.40-7.26(m, 4H), 6.40(brs, 1H), 4.63(m, 2H), 3.50-3.30(m, 6H), 2.52-2.36(m, 6H), 1.31(s, 9H)
110	16-35		A	<sup>1</sup> H NMR(300MHz, CDCl <sub>3</sub> ) : δ 7.37-7.26(m, 4H), 6.40(brs, 1H), 4.68(m, 2H), 3.34(m, 2H), 2.42(t, 2H, J=5.1Hz), 2.30(m, 4H), 1.60(m, 2H), 1.30(s, 9H), 1.29-1.09(m, 4H)
111	16-36		A	<sup>1</sup> H NMR(300MHz, CD <sub>3</sub> OD) : δ 7.57 (d, 1H, J = 1.0 Hz), 7.32-7.36 (m, 2H), 7.21 (d, 1H, J = 8.6 Hz), 4.63 (br s, 2H), 3.72 (br s, 2H), 2.83 (t, 2H, J = 7.1 Hz), 1.29 (s, 9H)
112	16-37		A	<sup>1</sup> H NMR(300MHz, CDCl <sub>3</sub> ) : δ 7.97(brs, 1H), 7.59-7.56(m, 1H), 7.38-7.09(m, 8H), 6.96(brs, 1H), 5.85(brs, 1H), 5.72(brs, 1H), 4.40(m, 2H), 3.79(m, 2H), 3.04(t, 2H, J=6.6Hz), 1.30(s, 9H)




Examples	Compounds	R=	Types	Spectral data
113	16-38		B	<sup>1</sup> H NMR(300MHz, CDCl <sub>3</sub> ) : δ 8.03(brs, 1H), 7.60-7.05(m, 9H), 5.67(brs, 1H), 5.51(brs, 1H), 3.68(m, 2H), 3.54(m, 2H), 3.03(t, 2H, J=6.6Hz), 2.75(t, 2H, J=6.6Hz)
114	16-39		A	<sup>1</sup> H NMR(300MHz, CDCl <sub>3</sub> ) : δ 7.52-7.15(m, 9H), 5.10-4.90(m, 2H), 4.60-4.55(m, 2H), 2.67(brs, 2H), 1.25(s, 3H)
115	16-40		A	<sup>1</sup> H NMR(300MHz, CDCl <sub>3</sub> ) : δ 8.70(brs, 1H), 8.14-8.09(m, 1H), 7.38-7.20(m, 5H), 6.42-6.30(m, 2H), 5.91(brs, 1H), 4.58(m, 2H), 3.79-3.66(m, 4H), 1.30(s, 9H)
116	16-41		A	<sup>1</sup> H-NMR(300MHz, CDCl <sub>3</sub> ) : δ 7.37-7.47 (m, 2H), 7.21-7.24 (d, 2H, J= 8.3Hz), 6.70-6.78 (m, 3H), 5.98 (s, 2H), 4.57-4.60 (br, 4H), 1.35 (s, 9H)
117	16-42		A	<sup>1</sup> H-NMR(300MHz, acetone-d <sub>6</sub> ) : δ 7.50 (s, 1H), 7.32 (dd, 2H, J= 1.9, 6.3 Hz), 7.22 (d, 2H, J= 8.5 Hz), 7.05 (s, 1H), 6.86 (s, 1H), 4.66 (br s, 2H), 4.01 (t, 2H, J=7.1 Hz), 3.50 (t, 2H, J= 6.6 Hz), 1.99-2.08 (m, 2H), 1.24 (s, 9H)
118	16-43		A	<sup>1</sup> H-NMR(300MHz, CDCl <sub>3</sub> ) : δ 7.32-7.35 (m, 2H), 7.11-7.18 (m, 3H), 6.88 (dd, 1H, J= 3.4, 5.1 Hz), 6.74 (d, 1H, J= 2.9 Hz), 6.09 (br s, 1H), 5.75 (br s, 1H), 4.44 (br s, 2H), 4.08 (t, 2H, J= 7.3 Hz), 3.07 (t, 2H, J= 6.6 Hz), 1.29 (s, 9H)
119	16-44		A	<sup>1</sup> H-NMR(300MHz, CDCl <sub>3</sub> ) : δ 7.36-7.39 (m, 2H), 7.21-7.26 (m, 3H), 6.94-6.96 (m, 2H), 6.24 (br s, 1H), 6.04 (br s, 1H), 4.88 (d, 2H, J= 4.8 Hz), 4.57 (br s, 2H), 1.33 (s, 9H)
120	16-45		A	<sup>1</sup> H NMR (CDCl <sub>3</sub> ) δ 7.37(m, 2H), 7.23(m, 2H), 4.45(bs, 2H), 3.50(m,2H), 2.73(m, 2H), 2.50(bs, 1H), 2.21(s, 3H), 2.13(m, 1H), 1.88(m, 3H), 1.68(m, 4H), 1.30(s, 9H)





5 **Example 121: Synthesis of 1-(4-t-butylbenzyl)-3-(2-pyridinyl)thiourea (16-46)**



2-aminopyridine (86 mg) was dissolved in acetonitrile (10 ml) and to the solution were added 4-t-butylbenzylisothiocyanate (190 mg) and triethylamine (140  $\mu$ l),

10 followed by refluxing for 27 hours. The resulting mixture was extracted with water




and dichloromethane, dried, concentrated under reduced pressure, and then crystallized (dichloromethane/petroleum ether) to yield the compound (90 mg, 33 %) as a white solid.

$^1\text{H}$  NMR(300MHz,  $\text{CDCl}_3$ ) :  $\delta$  11.99(brs, 1H), 8.13-8.11(m, 1H), 7.67-7.61(m, 1H), 7.41-7.27(m, 4H), 6.96-6.92(m, 1H), 6.68-6.64(m, 1H), 4.99-4.96 (m, 2H), 1.32(s, 9H)

**Example 122: Synthesis of 1-(4-t-butylbenzyl)-3-((2-hydroxy-1-methyl-2-phenyl)ethyl)thiourea (16-47)**

10




Phenylpropanolamine hydrochloride (100 mg) was dissolved in dimethylformamide (5 ml) and to the solution was added triethylamine (80  $\mu\text{l}$ ), followed by stirring for 30 minutes. To the obtained reaction mixture was added t-butylbenzeneisothiocyanate (135 mg), and the mixture was stirred for 4 hours, diluted with water (20 ml), extracted with dichloromethane (30 ml  $\times$ 3), dried over magnesium sulfate, and then filtered. The filtrate was concentrated under reduced pressure and the

obtained residue was purified by column-chromatography (ethyl acetate/hexane = 1/3) to yield the compound 16-47 (159 mg, 83.7 %).

<sup>1</sup>H NMR(300MHz, CDCl<sub>3</sub>) : δ7.32(m, 9H), 6.65(brs, 1H), 5.69(d, 1H, J=7.8Hz), 4.92(s, 1H), 4.57(s, 2H), 2.66(s, 1H), 1.58(s, 1H), 1.31(s, 9H), 0.98(d, 3H, J=6.9Hz)

**Example 123: Synthesis of 1-(4-t-butylbenzyl)-3-(1H-pyrrol-2-ylmethyl)thiourea (17-1)**



10

**Step 1: Synthesis of 1H-pyrrol-2-carboxaldehyde oxime**

Pyrrole-3-carboxaldehyde (120.4 mg) was dissolved in methanol (4 ml) and to the solution were added hydroxylamine hydrochloride (106 mg) and sodium acetate (127 mg), followed by stirring for 1 hour. The resulting mixture was extracted with ethyl acetate, and then dried over anhydrous magnesium sulfate. The filtrate was concentrated under reduced pressure, and then column-chromatographed (ethyl acetate/hexane = 1/3) to yield the compound (122 mg, 100 %).

15

$^1\text{H}$  NMR(300MHz,  $\text{CD}_3\text{OD}$ ) :  $\delta$  7.19(s, 1H), 6.92 (t, 1H,  $J = 2.1$  Hz), 6.52 (q, 1H,  $J = 3.7$  Hz), 6.15 (q, 1H,  $J = 3.7$  Hz)

Step 2: Synthesis of (1H-pyrrol-2-yl)methylamine hydrochloride

5        1H-pyrrol-2-carboxaldehyde oxime (60 mg) prepared according to the same procedure as described in Step 1 was dissolved in methanol (2 ml) and to the solution were added a catalytic amount of 10 % palladium/carbon and concentrated hydrochloric acid (100  $\mu\text{l}$ ), followed by stirring at room temperature under hydrogen gas atmosphere for 1 hour. The resulting mixture was diluted with ether, and then filtered through  
10 celite. The filtrate was concentrated under reduced pressure to yield (1H-pyrrol-2-yl)methylamine hydrochloride (60 mg, 100 %).

$^1\text{H}$  NMR(300MHz,  $\text{CD}_3\text{OD}$ ) :  $\delta$  6.78 (q, 1H,  $J = 4.2$  Hz), 6.23 (s, 1H), 6.10 (q, 1H,  $J = 5.9$  Hz), 4.08 (s, 2H)


15        Step 3: Synthesis of 1-(4-t-butylbenzyl)-3-(1H-pyrrol-2-ylmethyl)thiourea (17-1)

(1H-pyrrol-2-yl)methylamine hydrochloride (60 mg) prepared according to the same procedure as described in Step 2 was dissolved in dichloromethane (2 ml) and to the solution was added 4-t-butylbenzylisothiocyanate (155 mg), followed by stirring at room temperature for 1 hour. The resulting mixture was concentrated under reduced

pressure and the obtained residue was column-chromatographed (ethyl acetate/hexane = 1/3) to yield the compound 17-1 (120 mg, 65 %).

$^1\text{H-NMR}$ (300MHz,  $\text{CD}_3\text{OD}$ ) :  $\delta$  7.23-7.35 (t, 2H,  $J = 7.4$  Hz), 7.18-7.21 (d, 2H,  $J = 8.5$  Hz), 6.65 (d, 1H,  $J = 2.2$  Hz), 5.97-5.98 (d, 2H,  $J = 2.0$  Hz), 4.61 (br, 4H),  
5 1.29 (s, 9H)

**Example 124: Synthesis of**  
**1-(4-t-butylbenzyl)-3-(1-methyl-1H-pyrrol-2-yl)methylthiourea (17-2)**



**17-2**

10

Step 1: Synthesis of methyl-1H-pyrrol-2-carboxaldehyde oxime

Methyl-2-pyrrolecarboxaldehyde (5 g), hydroxylamine hydrochloride (9.55 g) and sodium acetate (11.28 g) were dissolved in methanol (100 ml) and the solution was refluxed for 12 hours. After confirming the completion of the reaction using TLC, the  
15 resulting mixture was purified by column-chromatography (ethyl acetate/hexane = 3/1) to yield the compound (5.01 g, 88 %) as a brown solid.

$^1\text{H NMR}$  (300MHz,  $\text{CDCl}_3$ ):  $\delta$  7.40(s, 1H), 7.31(m, 1H), 6.70(m, 1H), 6.23(m,

1H), 3.74(s, 3H)

Step 2: Synthesis of (1-methyl-1H-pyrrol-2-yl)methylamine

Sodium borohydride (310 mg) was dried under vacuum and anhydrous  
5 tetrahydrofuran (30 ml) was added thereto through an injector, followed by adjusting  
the temperature down to -15°C. To the mixture at -15°C was added a solution of  
methyl-1H-pyrrol-2-carboxaldehyde oxime (500 mg) and nickel (II) chloride  
hexahydrate (catalytic amount) in anhydrous methanol (30 ml) and the mixture was  
stirred, followed by stirring at room temperature for 12 hours. After confirming the  
10 completion of the reaction, the resulting mixture was filtered and the obtained brown oil  
was purified by column-chromatography (ethyl acetate) to yield  
(1-methyl-1H-pyrrol-2-yl)methylamine (275 mg, 62 %) as solid.

<sup>1</sup>H NMR (300MHz, CDCl<sub>3</sub>): δ 6.63(m, 1H), 6.11(m, 2H), 3.94(m, 2H),  
3.72(brs, 2H), 3.64(s, 3H)


15

Step 3: Synthesis of  
1-(4-t-butylbenzyl)-3-(1-methyl-1H-pyrrol-2-yl)methylthiourea (17-2)  
(1-methyl-1H-pyrrol-2-yl)methylamine (65 mg) and  
4-t-butylbenzylisothiocyanate (120 mg) were dissolved in ethyl acetate (30 ml) and the

solution was stirred for 12 hours. After the completion of the reaction, the resulting mixture was purified by column-chromatography (ethyl acetate/hexane = 1/3) to yield the compound 17-2 (140 mg, 75 %)

<sup>1</sup>H NMR (300MHz, CDCl<sub>3</sub>): δ 7.36(m, 2H), 7.19(m, 2H), 6.58(m, 1H),  
5 6.18(brs, 1H), 6.01(m, 2H), 5.69(brs, 1H), 4.63(d, 2H, J=2.1Hz), 4.52(d, 2H, J=2.4Hz),  
3.52(s, 3H), 1.31(s, 9H)

**Example 125: Synthesis of 1-(1-methyl-1H-pyrrol-2-ylmethyl)-3-phenethylthiourea (17-3)**




10

(1-methyl-1H-pyrrol-2-yl)methylamine (65 mg) and  
(2-isothiocyanatoethyl)benzene (100 mg) were dissolved in ethyl acetate (20 ml) and  
the solution was stirred for 12 hours. After the completion of the reaction, the  
resulting mixture was purified by column-chromatography (ethyl acetate/hexane = 1/3)  
15 to yield the compound 17-3 (97 mg, 60 %) as a brown liquid.

<sup>1</sup>H NMR (300MHz, CDCl<sub>3</sub>): δ 7.25(m, 5H), 6.60(m, 1H), 6.02(m, 1H), 5.97(s,  
1H), 4.51(brs, 2H), 3.69(brs, 2H), 2.87(t, 2H, J=6.9Hz)

Example 126: Synthesis of

1-(4-t-butylbenzyl)-3-(5-nitrothiophen-2-ylmethyl)thiourea (17-4)



5 Step 1: Synthesis of 5-nitrothiophen-2-carboxaldehyde oxime

5-Nitrothiophen-2-carboxaldehyde oxime (yield: 85 %, pale yellow solid) was synthesized according to the similar procedure as described in Step 1 of Example 124 except that 5-nitrothiophen-2-carboxaldehyde was used as a starting material.

<sup>1</sup>H NMR (300MHz, CDCl<sub>3</sub>): δ 8.21(s, 1H), 7.91(d, 1H, J=2.1Hz), 7.85(d, 1H, J=2.25Hz), 7.76(s, 1H), 7.26(s, 1H), 7.11(d, 1H, J=2.1Hz)

Step 2: Synthesis of (5-nitrothiophen-2-yl)methylamine

Sodium borohydride (132 mg) was dried under vacuum and then anhydrous tetrahydrofuran (30 ml) was added thereto through an injector, followed by adjusting the temperature down to -15°C. To the mixture at -15°C was added a solution of 5-nitrothiophen-2-carboxaldehyde oxime (200 mg; synthesized in Step 1) and nickel chloride (II) hexahydrate (catalytic amount) in anhydrous methanol (20 ml), and the

mixture was stirred for 12 hours. After confirming the completion of the reaction, the resulting mixture was filtered to obtain the compound as a brown liquid.


Step 3: Synthesis of 1-(4-t-butylbenzyl)-3-(5-nitrothiophen-2-ylmethyl)thiourea

5 (17-4)

The compound 17-4 (yield: 40 %, yellow solid) was synthesized by reacting the compound prepared in Step 2 with 4-t-butylbenzylisothiocyanate according to the similar procedure as described in Step 3 of Example 124.

<sup>1</sup>H NMR (300MHz, CDCl<sub>3</sub>): δ 7.71(d, 1H, J=1.95Hz), 7.37(m, 2H), 7.23(m, 2H), 6.85(d, 1H, J=1.95Hz), 6.59(brs, 1H), 6.30(brs, 1H), 4.96(d, 2H, J=3Hz), 4.55(brs, 2H), 1.29(s, 9H)

Example 127: Synthesis of 1-(4-t-butylbenzyl)-3-(2-methyl-pyridin-3-ylmethyl)thiourea (18-5)



15

Step 1: Synthesis of (2-methylpyridin-3-yl)methanol (18-2)

Ethyl 2-methylnicotinate 18-1 (257 mg) was mixed with dichloromethane (4



ml) and to the mixture at -78°C was added dropwise 1 M diisobutyl aluminium hydride (4 ml), followed by stirring for 1 hour. The reaction was quenched with methanol and to the mixture was added aqueous Rochel solution (20 ml), followed by stirring for 2 hours. The resulting mixture was extracted with dichloromethane, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was column-chromatographed (ethyl acetate/hexane = 1/1) to yield the compound 18-2 (166 mg, 87 %).

$^1\text{H}$  NMR(300MHz,  $\text{CDCl}_3$ ) :  $\delta$  8.34 (d, 1H,  $J = 3.4$  Hz), 7.74 (d, 1H,  $J = 7.6$  Hz), 7.15 (dd, 1H,  $J = 5.1$  Hz,  $J = 7.8$  Hz), 4.70 (s, 2H), 3.21 (br, 1H), 2.51 (s, 3H)

10

#### Step 2: Synthesis of (2-methylpyridin-3-yl)methylaminophthalimide (18-3)

Compound 18-2 (166 mg) prepared in Step 1 was dissolved in tetrahydrofuran (4 ml) and to the solution were added phthalimide (401 mg) and triphenylphosphine (716 mg), followed by adding diethylazodicarbonate (0.24 ml) thereto and stirring for 30 minutes. After the completion of the reaction, the resulting mixture was concentrated under reduced pressure and the obtained residue was column-chromatographed (ethyl acetate/hexane = 1/1) to yield the compound 18-3 (300 mg, 88 %).

$^1\text{H}$  NMR(300MHz,  $\text{CDCl}_3$ ) :  $\delta$  8.40 (dd, 1H,  $J = 1.7$  Hz,  $J = 3.2$  Hz),

7.87-7.83 (m, 2H), 7.76-7.72 (m, 2H), 7.61 (d, 1H,  $J = 6.6$  Hz), 7.10 (dd, 1H,  $J = 4.9$  Hz,  $J = 7.8$  Hz) 4.80 (s, 2H), 2.72 (s, 3H)

Step 3: Synthesis of


5 1-(4-t-butylbenzyl)-3-(2-methylpyridin-3-ylmethyl)thiourea (18-5)

The compound 18-3 (19 mg) prepared in Step 2 was dissolved in ethanol and to the solution was added a drop of methylamine. After stirring the mixture at 55°C for 30 hours, t-butylbenzylisothiocyanate (62 mg) was added thereto, and the mixture was stirred at room temperature for 1 hour. The resulting mixture was concentrated under  
10 reduced pressure and the obtained residue was column-chromatographed (methanol/dichloromethane = 1/10) to yield the compound 18-5 (26.2 mg, 100 %).

$^1\text{H}$  NMR(300MHz,  $\text{CDCl}_3$ ) :  $\delta$  8.56-8.55 (m, 1H), 8.37-8.30 (m, 1H), 7.75-7.67(m, 1H), 7.40-7.10 (m, 4H), 4.74 (s, 2H), 4.44 (s, 2H), 3.05 (s, 3H), 1.30 (s, 9H)

15

**Example 128: Synthesis of 1-(1H-indazol-5-yl)-3-phenethylthiourea (19-1)**



**Step 1: Synthesis of 5-amino-1H-indazole**

5-Nitro-1H-indazole (20 mg) was dissolved in methanol (1 ml) and to the solution was added a catalytic amount of palladium/carbon, followed by stirring at room temperature under hydrogen gas atmosphere for 30 minutes. The resulting mixture  
5 was diluted with ether, filtered through celite, and then concentrated under reduced pressure to yield 5-amino-1H-indazole (16 mg, 100 %).


$^1\text{H}$  NMR(300MHz,  $\text{CD}_3\text{OD}$ ) :  $\delta$  7.78 (s, 1H), 7.32 (d, 1H,  $J = 8.7$  Hz),  
7.01-6.95 (m, 2H)

**10 Step 2: Synthesis of 1-(1H-indazol-5-yl)-3-phenethylthiourea (19-1)**

5-Amino-1H-indazole (9 mg) prepared according to the same procedure as described in Step 1 was dissolved in dichloromethane (1 ml) and the solution was stirred at room temperature for 3 hours. The resulting mixture was concentrated under reduced pressure and the obtained residue was column-chromatographed eluting with  
15 ethyl acetate/hexane (1/2) to yield the compound **19-1** (10 mg, 60 %).

$^1\text{H}$  NMR(300MHz,  $\text{CD}_3\text{OD}$ ) :  $\delta$  7.99 (d, 1H,  $J = 1.0$  Hz), 7.51-7.47 (m, 2H),  
7.27-7.13 (m, 6H), 3.78 (t, 2H,  $J = 6.8$  Hz), 2.90 (t, 2H,  $J = 7.3$  Hz)


**Example 129: Synthesis of 1-(4-t-butylbenzyl)-3-(1H-indazolyl)thiourea (19-2)**



Compound **19-2** (25 mg, 65 %) was synthesized using 5-amino-1H-indazole (15 mg) and t-butylbenzylisothiocyanate (30 mg) according to the similar procedure as described in Step 2 of Example 128.

$^1\text{H}$  NMR(300MHz,  $\text{CD}_3\text{OD}$ ) :  $\delta$  7.99(s, 1H), 7.65 (s, 1H), 7.50 (d, 1H,  $J = 8.8$  Hz), 7.33-7.21 (m, 5H), 4.73 (brs, 2H), 1.27 (s, 9H)

Example	130:	Synthesis	of
10	<b>1-(4-t-butylbenzyl)-3-(2-fluoro-4-methanesulfonyloxybenzyl)thiourea (20-2a)</b>		



Step 1: Synthesis of 3-fluoro-4-(N-t-butyloxycarbonylaminomethyl)phenol (**20-1a**) and 3-fluoro-4-(N-t-butyloxycarbonylaminomethyl)phenol t-butyloxycarbonyl ether (**20-1b**)

2-Fluoro-4-hydroxybenzonitrile (686 mg), nickel chloride (II) (1.18 g) and Boc<sub>2</sub>O (2.18 mg) were dissolved in methanol (40 ml) and the solution was cooled to 0°C. To the solution was slowly added sodium borohydride (1.32 g), and the mixture was stirred at 0°C for 10 minutes and then at room temperature for 24 hours. The resulting mixture was concentrated under reduced pressure and to the concentrate were added ethyl acetate (60 ml) and sodium borohydride (300 mg), followed by filtering. The filtrate was extracted twice with ethyl acetate. The total filtrate was concentrated under reduced pressure, and then purified by column-chromatography (hexane/ethyl acetate = 3/1) to yield the compound **20-1a** (134 mg, 11 %) and **20-1b** (710 mg, 42 %).

**20-1a:** <sup>1</sup>H NMR (300MHz, CDCl<sub>3</sub>) δ 7.11(t, *J*=8.2Hz, 1H), 6.62(bs, 1H), 6.61(d, *J*=9.6Hz, 2H), 4.91(bs, 1H), 4.24(d, *J*=4.8Hz, 2H), 1.46(s, 9H)

**20-1b:** <sup>1</sup>H NMR (300MHz, CDCl<sub>3</sub>) δ 7.37(t, *J*=8.3Hz, 1H), 6.93(m, 2H), 4.88(bs, 1H), 4.32(d, *J*=5.7Hz, 2H), 1.55(s, 9H), 1.44(s, 9H)


Step 2: Synthesis of 1-(4-*t*-butylbenzyl)-3-(2-fluoro-4-methanesulfonyloxybenzyl)thiourea (**20-2a**)

Compound **20-1a** (134 mg) prepared in Step 1 was dissolved in dichloromethane (2 ml) and to the solution at 0°C were added dropwise methanesulfonyl chloride (44 μl) and pyridine (45 μl), followed by stirring at room

temperature for 24 hours. The resulting mixture was concentrated under reduced pressure and the obtained residue was purified by column-chromatography (hexane/ethyl acetate = 3/1) to obtain methanesulfonyl compound (55 mg, 31 %). The obtained compound was dissolved in dichloromethane (2.0 ml) and the solution was  
5 cooled to 0°C, followed by adding trifluoroacetic acid (100  $\mu$ l) thereto and stirring for 2 hours. The resulting mixture was concentrated under reduced pressure and dissolved in dimethylformamide (5.0 ml). To the solution was added triethylamine (30  $\mu$ l) and the mixture was stirred for 1 hour. To the obtained solution was added 4-t-butylbenzylisothiocyanate (40 mg) and the mixture was stirred at room temperature  
10 for 18 hours. The resulting mixture was concentrated under reduced pressure and the obtained residue was purified by column-chromatography (hexane/ethyl acetate = 2/1) to yield the compound **20-2a** (61 mg, 85 %).

$^1\text{H}$  NMR (300MHz,  $\text{CDCl}_3$ )  $\delta$  7.43(t,  $J=8.7\text{Hz}$ , 1H), 7.37(d,  $J=8.1\text{Hz}$ , 2H), 7.22(d,  $J=8.1\text{Hz}$ , 2H), 7.02(m, 2H), 6.20(bs, 1H), 6.00(bs, 1H), 4.79(d,  $J=5.4\text{Hz}$ , 2H),  
15 4.53(d,  $J=4.2\text{Hz}$ , 2H), 3.16(s, 3H), 1.31(s, 9H).

**Example 131: Synthesis of 1-(4-t-butylbenzyl)-3-(2-fluoro-4-hydroxy)thiourea (20-2b)**



The compound **20-1b** (710 mg) prepared in Step 1 of Example 130 was dissolved in dichloromethane (10 ml) and the solution was cooled to 0°C, followed by adding trifluoroacetic acid (1.0 ml) thereto and stirring for 2 hours. The resulting mixture was concentrated under reduced pressure and part (211 mg) of the obtained residue was dissolved in dimethylformamide (5.0 ml). To the solution was added triethylamine (120  $\mu$ l) and the mixture was stirred for 1 hour. To the obtained solution was slowly added 4-*t*-butylbenzylisothiocyanate (170 mg) and the mixture was stirred at room temperature for 18 hours. The resulting mixture was concentrated under reduced pressure and purified by column-chromatography (hexane/ethyl acetate = 1/1) to yield the compound **20-2b** (196 mg, 68 %).

$^1\text{H}$  NMR (300MHz,  $\text{CDCl}_3$ ):  $\delta$  7.35(d,  $J=8.4\text{Hz}$ , 2H), 7.20(d,  $J=8.4\text{Hz}$ , 2H), 7.13(t,  $J=8.4\text{Hz}$ , 1H), 6.54(m, 2H), 6.08(bs, 1H), 6.02(bs, 1H), 5.75(bs, 1H), 4.59(m, 4H), 1.31(s, 9H)

15

Example


132:

Synthesis

of

**1-(4-*t*-butylbenzyl)-3-[(6-methanesulfonylaminopyridin-2-yl)methyl]thiourea**

(21-7)



### Step 1: Synthesis of 2,2-dimethyl-N-(6-methyl-2-pyridinyl)propanamide

(21-1)

5            2-amino-6-picoline (26 g) was dissolved in dichloromethane (280 ml) and the reactor was cooled to 0°C, followed by adding triethylamine (30 g) thereto. To the obtained solution was slowly added dropwise a solution of trimethylacetylchloride (31.8 g) in dichloromethane (20 ml) and the mixture was stirred at room temperature for 3 hours. The resulting mixture was filtered, washed with water, dried over anhydrous  
10    magnesium sulfate, concentrated under reduced pressure and then crystallized (dichloromethane/petroleum ether) to yield a pale yellow solid (38 g, 82 %).

Step	2:	Synthesis	of
N-[6-(bromomethyl)-2-pyridinyl]-2,2-dimethylpropaneamide ( <b>21-2</b> )			

15 2,2-dimethyl-N-(6-methyl-2-pyridinyl)propaneamide (21-1) (32 g) and N-bromosuccinimide (29.6 g) were added to carbon tetrachloride (300 ml) and to the mixture was added AIBN (15 mg), followed by refluxing for 20 hours under light



emitted by 500W lamp. The resulting mixture was cooled to room temperature, filtered, and concentrated under reduced pressure. The residue was purified by column-chromatography (hexane/ethyl acetate = 10/1) to yield the compound **21-2** (1.94 g, 5 %) as a pure white solid.

5  $^1\text{H}$  NMR(300MHz,  $\text{CDCl}_3$ ) :  $\delta$  8.20-8.17(m, 1H), 8.00(brs, 1H), 7.72-7.66(m, 1H), 7.16-7.13(m, 1H), 4.42(s, 2H), 1.34(s, 9H)

Step 3: Synthesis of  
N-[6-((1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)methyl)-2-pyridinyl]-2,2-dimethylprop  
10 aneamide (**21-3**)

N-[6-(bromomethyl)-2-pyridinyl]-2,2-dimethylpropaneamide (**21-2**) (1.9 g) was dissolved in dimethylformamide (20 ml) and to the solution was added potassium phthalimide (1.43 g), followed by stirring at room temperature for 24 hours. The resulting mixture was concentrated under reduced pressure and extrated with water and  
15 dichloromethane. An organic layer was concentrated under reduced pressure to yield the compound **21-3** (2.27 g, 96 %) as a bright yellow solid.

$^1\text{H}$  NMR(300MHz,  $\text{CDCl}_3$ ) :  $\delta$  8.15-8.12(m, 1H), 7.92-7.74(m, 4H), 7.66-7.60(m, 1H), 7.00-6.97(m, 1H), 4.90(s, 2H), 1.29(s, 9H)

Step 4: Synthesis of

2-[(2-amino-6-pyridinyl)methyl]-1H-isoindol-1,3(2H)-dione (21-4)

N-[6-[(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)methyl]-2-pyridinyl]-2,2-dimethylpropaneamide 21-3 was dissolved in ethanol (20 ml) and to the solution was added concentrated sulfuric acid (2 ml), followed by refluxing for 6 hours. The obtained solution was basified with ammonia solution, extracted with dichloromethane, and then dried over anhydrous magnesium sulfate. The residue was concentrated under reduced pressure and purified by column-chromatography (hexane/ethyl acetate = 1/1) to yield the compound 21-4 (400 mg, 23 %) as a pale yellow solid.

<sup>1</sup>H NMR(300MHz, CDCl<sub>3</sub>) : δ 7.90-7.71(m, 4H), 7.38-7.32(m, 1H), 6.59-6.56(m, 1H), 6.37-6.33(m, 1H), 4.83(s, 2H), 4.36(brs, 2H)

Step 5: Synthesis of

2-[(2-methanesulfonylamino-6-pyridinyl)methyl]-1H-isoindol-1,3(2H)-dione (21-5)

The compound 21-4 (200 mg) prepared in Step 4 was dissolved in dichloromethane (10 ml) and to the solution were added triethylamine (130 μl) and methanesulfonyl chloride (67 μl), followed by stirring at room temperature for 24 hours. The resulting mixture was extracted with water and dichloromethane, dried, concentrated under reduced pressure, and then crystallized (dichloromethane/petroleum

ether) to yield the compound **21-5** (260 mg, 99 %) as a white solid.

Step 6: Synthesis of

1-(4-t-butylbenzyl)-3-[(2-methanesulfonylamino-6-pyridinyl)methyl]thiourea (**21-7**)


5 The compound **21-5** (220 mg) prepared in Step 5 was dissolved in methanol (5 ml) and to the solution was added hydrazine hydrate (270  $\mu$ l), followed by stirring at room temperature for 2 hours. The obtained reaction solution was concentrated under reduced pressure to obtain the compound **21-6**. The compound **21-6** (690 mg) was dissolved in dimethylformamide (20 ml) and to the solution was added

10 4-t-butylbenzylisothiocyanate (370 mg), followed by stirring at 100°C for 7 hours. The reaction mixture was concentrated and purified by column-chromatography (hexane/ethyl acetate = 1/2) to yield the compound **21-7** (58 mg, 23 %) as a green foamy solid.

$^1\text{H}$  NMR(300MHz,  $\text{CDCl}_3$ ) :  $\delta$  7.69-7.63(m, 1H), 7.42-7.38(m, 2H),

15 7.31-7.25(m, 3H), 7.04-6.65(m, 3H), 4.76-4.60(m, 4H), 3.07(s, 3H), 1.31(s, 9H)

**Example 133: Synthesis of (4-t-butylbenzyl)thiocarbamic acid (1-methyl-4-nitro-1H-pyrrol-2-yl)methyl ester (22-3)**



Step 1: Synthesis of N-methyl-4-nitro-pyrrole-2-carboxaldehyde (22-1)

N-methylpyrrole-2-carboxaldehyde (5 g) was dissolved in anhydrous acetic acid (50 ml), and to an ice-cold of the solution was slowly added dropwise nitric acid (1.84 ml) with stirring. The mixture was stirred at this temperature for 1 hour, and then at room temperature for 18 hours. After confirming the completion of the reaction, to the mixture was added an ice-water (200 ml), followed by slowly adding solid sodium hydroxide (20 g) thereto and stirring for 1 hour. The obtained mixture was extracted with ether (150 ml ×3). The obtained organic layer was washed with aqueous sodium bicarbonate solution and saturated aqueous sodium chloride solution, dried over sodium sulfate, and then filtered. The filtrate was concentrated under reduced pressure and purified by column-chromatography (ethyl acetate/hexane = 1/4) to yield the compound 22-1 (3.5 g, 49.6 %).

<sup>1</sup>H NMR(300MHz, CDCl<sub>3</sub>) : δ9.63(s, 1H), 7.68(s, 1H), 7.43(s, 1H), 4.03(s, 3H)

Step 2: Synthesis of 2-hydroxymethyl-N-methyl-4-nitro-pyrrole (22-2)

Compound 22-1 (550 mg) was dissolved in anhydrous tetrahydrofuran (30 ml) and cooled to 0 °C. To the solution was slowly added dropwise 1M borane-tetrahydrofuran (3.25 ml), followed by refluxing at 80°C for 3 hours. After the completion of the reaction, the solvent was evaporated under reduced pressure to be removed, and then the residue was purified by column-chromatography (ethyl acetate/hexane = 2/1) to yield the compound 22-2 (500 mg, 90 %).

<sup>1</sup>H NMR(300MHz, CDCl<sub>3</sub>) : δ 7.51(s, 1H), 6.65(s, 1H), 4.59(s, 2H), 3.75(s, 3H)

Step 3: Synthesis of (4-t-butylbenzyl)thiocarbamic acid (1-methyl-4-nitro-1H-pyrrol-2-yl)methyl ester (22-3)

Compound 22-2 (100 mg) was dissolved in anhydrous tetrahydrofuran (15 ml) and cooled to 0 °C. To the solution was slowly added sodium hydride (190 mg) with stirring, followed by stirring for 30 minutes. To the mixture was added t-butylbenzylisothiocyanate (130 mg), followed by stirring for 6 hours. The solvent was evaporated under reduced pressure to be removed, and then the residue was diluted with water (20 ml). The obtained mixture was extracted with ethyl acetate (20 ml ×3), dried over magnesium sulfate, and then filtered. The filtrate was evaporated under reduced pressure and the obtained residue was purified by column-chromatography


(ethyl acetate/hexane = 1/3) to yield the compound **22-3** (130 mg, 56.2 %).

$^1\text{H}$  NMR(300MHz,  $\text{CDCl}_3$ ) :  $\delta$  7.51(m, 1H), 7.31(m, 3H), 7.10(m, 1H), 6.83(m, 1H), 6.47(brs, 1H), 5.44(s, 2H), 4.71(d, 2H,  $J=5.7\text{Hz}$ ), 3.68(s, 3H), 1.31(s, 9H)

5      **Example**                                      **134:**                                      **Synthesis**                                      **of**

**1-(4-*t*-butylbenzyl)-3-(4-methanesulfonylamino-1-methyl-1H-pyrrol-2-yl)thiourea**

**(22-9)**



**22-9**

Step 1: Synthesis of 2-cyano-N-methylpyrrole (**22-4**)

10            N-methyl-2-pyrrolcarboxaldehyde (5 g) and hydroxylamine hydrochloride (3.82 g) were mixed in 1-methyl-2-pyrrolidinone (50 ml) and the mixture was refluxed at 110°C for 2 hours. After confirming the completion of the reaction, to the reaction mixture was slowly added an ice-water (200 ml) and the resulting mixture was extracted with ethyl acetate (150 ml  $\times$  3), washed with brine, dried over sodium sulfate, and then

15    filtered. The filtrate was concentrated under reduced pressure and the obtained residue was purified by column-chromatography (ethyl acetate/hexane = 1/4) to yield the compound **22-4** (3.5 g, 72 %).

$^1\text{H}$  NMR(300MHz,  $\text{CDCl}_3$ ) :  $\delta$  6.79(m, 2H), 6.16(m, 1H), 3.78(s, 3H)

Step 2: Synthesis of 4-nitro-2-cyano-N-methylpyrrole (22-5)

Compound 22-4 (1 g) was dissolved in anhydrous acetic acid (100 ml), and  
5 cooled to 0 °C. To the solution was slowly added dropwise nitric acid (380  $\mu\text{l}$ ) with  
stirring, followed by stirring at the same temperature for 1 hour and subsequently at  
room temperature for 18 hours. After confirming the completion of the reaction, to the  
mixture was added an ice-water (200 ml), followed by slowly adding solid sodium  
hydroxide (20 g) thereto and stirring for 1 hour. The obtained mixture was extracted  
10 with ether (50 ml  $\times$ 3). The obtained organic layer was washed with aqueous sodium  
bicarbonate solution and saturated aqueous sodium chloride solution, dried over sodium  
sulfate, and then filtered. The filtrate was concentrated under reduced pressure and  
purified by column-chromatography (ethyl acetate/hexane = 1/3) to yield the compound  
22-5 (1.05 g, 73.7 %).

15  $^1\text{H}$  NMR(300MHz,  $\text{CDCl}_3$ ) :  $\delta$  7.65(s, 1H), 7.32(s, 1H), 3.88(s, 3H)

Step 3: Synthesis of 2-cyano-4-amino-N-methylpyrrole (22-6)

Compound 22-5 (500 mg) and 10 % palladium/carbon (50 mg) were poured  
into the reactor and dissolved in methanol (10 ml), and then reacted under hydrogen gas

atmosphere for 2 hours. After confirming the completion of the reaction, the resulting mixture was filtered through celite, and the filtrate was concentrated under reduced pressure and purified by column-chromatography (ethyl acetate/hexane = 3/1) to yield the compound **22-6** (310 mg, 77.4 %).

5  $^1\text{H}$  NMR(300MHz,  $\text{CDCl}_3$ ) :  $\delta$  6.36(d, 1H,  $J=2.1\text{Hz}$ ), 6.30(d, 1H,  $J=4.2\text{Hz}$ ), 3.66(s, 3H)

Step 4: Synthesis of 4-methanesulfonylamino-2-cyano-N-methylpyrrole (**22-7**)

Compound **22-6** (310 mg) was dissolved in dichloromethane (30 ml) and  
10 cooled to 0 °C. To the solution were added triethylamine (430  $\mu\text{l}$ ) and methanesulfonyl chloride (210  $\mu\text{l}$ ) successively through an injector, followed by stirring at room temperature for 24 hours. The resulting mixture was diluted with 1 N aqueous hydrochloric acid, and an organic layer was dried over magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure and the obtained residue  
15 was purified by column-chromatography (ethyl acetate/hexane = 1/1) to yield the compound **22-7** (400 mg, 78.5 %)

$^1\text{H}$  NMR(300MHz,  $\text{CDCl}_3$ ) :  $\delta$  6.78(d, 1H,  $J=1.8\text{Hz}$ ), 6.53(d, 1H,  $J=1.8\text{Hz}$ ), 5.95(brs, 1H), 3.92(s, 3H), 2.97(s, 3H)



Step 5: Synthesis of

(4-methanesulfonylamino-1-methyl-1H-pyrrol-2-yl)methylamine (22-8)

Compound 22-7 (150 mg) and 10 % palladium/carbon (catalytic amount), together with methanol (10 ml), were poured into reactor and the reactor was filled with hydrogen gas, followed by stirring at room temperature for 24 hours. After the completion of the reaction, the resulting mixture was filtered through celite and concentrated under reduced pressure. The following procedure was carried out using the obtained residue which was not purified.

Step 6: Synthesis of

1-(4-t-butylbenzyl)-3-(4-methanesulfonylamino-1-methyl-1H-pyrrol-2-yl)thiourea (22-9)


The compound 22-8 (95 mg) prepared in Step 5 and 4-t-butylbenzylisothiocyanate (96 mg) were added to ethyl acetate (20 ml) and the mixture was stirred for 16 hours. The resulting mixture was concentrated under reduced pressure and the obtained residue was purified by column-chromatography (ethyl acetate/hexane = 3/2) to yield the compound 22-9 (105 mg, 55 %).

<sup>1</sup>H NMR(300MHz, CDCl<sub>3</sub>) : δ7.37(d, 2H, J=8.1Hz), 7.22(d, 2H, J=8.1Hz), 6.61(d, 1H, J=1.8Hz), 5.95(d, 1H, J=2.1Hz), 6.26(brs, 1H), 5.87(brs, 1H), 5.77(brs, 1H),

4.64(d, 2H, J=4.8Hz), 4.54(d, 2H, J=3.9Hz), 3.48(s, 3H), 2.91(s, 3H), 1.31(s, 9H)

**Example 135: Synthesis of**

**1-(4-*t*-butylbenzyl)-3-[(4-methanesulfonylaminomethyl)phenyl]thiourea (23-2)**



5

Step 1: Synthesis of (4-methanesulfonylaminomethyl)-1-nitrobenzene (**23-1**)

4-nitrobenzylamine hydrochloride (3.77 g) was dissolved in dichloromethane (20 ml) and to the solution at 0°C was added triethylamine (6.14 ml), followed by adding dropwise methanesulfonyl chloride (1.7 ml) thereto and stirring at room temperature for 23 hours. After the completion of the reaction, the resulting mixture was extracted with water and dichloromethane, concentrated under reduced pressure, and then crystallized (dichloromethane/petroleum ether) to yield an ochreous solid (1.2 g, 26 %).

15                      Step                      2:                      Synthesis                      of

**1-(4-*t*-butylbenzyl)-3-[(4-methanesulfonylaminomethyl)phenyl]thiourea (23-2)**


The compound **23-1** prepared in Step 1 was dissolved in ethyl acetate (30 ml)







and to the solution was added tin (II) chloride dihydrate (6.1 g), followed by refluxing at 50 °C for 2 hours. After allowed to cool down to room temperature, the resulting mixture was basified with saturated aqueous sodium bicarbonate solution, washed with water and brine, dried, and then concentrated under reduced pressure to obtain a yellow solid (610 mg, 59 %). The obtained compound (107 mg), which was not purified, was dissolved in acetonitrile (10 ml) and to the solution were added triethylamine (100  $\mu$ l) and 4-t-butylbenzylisothiocyanate (110 mg), followed by refluxing for 24 hours. The resultant mixture was concentrated under reduced pressure and purified by column-chromatography (hexane/ethyl acetate = 1/2) to yield the compound 23-2 (73 mg, 34 %) as a solid.


$^1\text{H}$  NMR(300MHz,  $\text{CDCl}_3$ ) :  $\delta$  7.84(brs, 1H), 7.46-7.18(m, 8H), 6.26(brs, 1H), 5.00-4.81(m, 3H), 4.31-4.28(m, 2H), 2.92(s, 3H), 1.29(s, 9H)






#### Example 136 ~ Example 141

Compounds of Example 136 ~ Example 141, which are shown in the Scheme 24, were synthesized according to the similar procedure as described in Example 76 or Example 77, and properties and spectral data thereof are shown in below table.




Examples	Compounds	R=	Types	Spectral data
136	24-1		A	<sup>1</sup> H NMR(300MHz, CDCl <sub>3</sub> ) : δ 7.39-7.26(m, 9H), 5.55(brs, 1H), 4.81(d, 2H, J=4.8Hz), 3.83-3.79(m, 4H), 3.53(s, 2H), 2.51-2.47(m, 4H), 1.32(s, 9H)
137	24-2		B	<sup>1</sup> H NMR(300MHz, CDCl <sub>3</sub> ) : δ 7.33-7.19(m, 10H), 5.40(brs, 1H), 3.97-3.90(m, 2H), 3.72-3.69(m, 4H), 3.52(s, 2H), 2.94(t, 2H, J= 6.9Hz), 2.46-2.42(m, 4H), 1.32(s, 9H)
138	24-3		A	<sup>1</sup> H NMR(300MHz, CDCl <sub>3</sub> ) : δ 8.34-8.32(m, 1H), 7.40-7.26(m, 5H), 6.55(t, 1H, J=4.5Hz), 5.57(brs, 1H), 4.85(d, 2H, J=4.2Hz), 3.96-3.94(m, 8H), 1.32(s, 9H)
139	24-4		A	<sup>1</sup> H NMR(300MHz, CDCl <sub>3</sub> ) : δ 8.19-8.16(m, 1H), 7.53-7.26(m, 5H), 6.68-6.56(m, 2H), 5.58(brs, 1H), 4.85(d, 2H, J=4.8Hz), 4.04-4.00(m, 4H), 3.74-3.70(m, 4H), 1.32(s, 9H)
140	24-5		A	<sup>1</sup> H-NMR(300MHz, CDCl <sub>3</sub> ) : δ 9.15 (s, 1H), 9.10 (m, 1H), 7.95 (s, 1H), 7.34 (d, 2H, J = 8.6 Hz), 7.25 (d, 2H, J = 8.6 Hz), 4.84 (d, 2H, J = 5.6 Hz), 1.25 (s, 9H)
141	24-6		A	<sup>1</sup> H NMR (CDCl <sub>3</sub> ) δ 7.35(m, 2H), 7.18(m, 4H), 5.62(bs, 1H), 4.92(s, 2H), 4.87(d, 2H, d=2.25Hz), 3.98(m, 2H), 2.94(m, 2H), 1.32(s, 9H)



**24-2****24-3****24-4****24-5****24-6**

5

Example 142: Synthesis of 1-benzyl-1-(4-hydroxy-3-methoxybenzyl)-3-phenethylthiourea (25-1)




Vaniline (200 mg) and benzylamine (129 mg) were dissolved in methanol (3 ml) and the solution was stirred for 30 minutes. To the solution was added a catalytic amount of 10 % platinum/carbon to be subjected to the hydrogenation reaction (1 atm) .

After the completion of the reaction, the resulting mixture was filtered and evaporated under reduced pressure to remove methanol. The obtained residue was dissolved in dichloromethane (3 ml) and to the solution was added phenethylisothiocyanate (196 mg, 1.2 mmol), followed by stirring at room temperature for 5 hours. Then, dichloromethane was evaporated under reduced pressure and the obtained residue was column-chromatographed (hexane/ethyl acetate = 1/1) to yield the compound **25-1** (400 mg, 82 %) as a white solid.

$^1\text{H}$  NMR (300MHz,  $\text{CDCl}_3$ ):  $\delta$  7.25 (m, 10H), 6.94 (m, 3H), 6.69(m, 2H), 5.69(s, 1H), 5.51(t, 1H,  $J=4.68$  Hz), 4.88(s, 2H), 4.75(s, 2H), 3.89(m, 2H), 3.75(s, 3H), 2.78(t, 2H,  $J=6.57$  Hz): MS (EI) m/e 406 [ $\text{M}^+$ ]




## Example 143 ~ Example 167

Compounds 25-2 ~ 25-26 of Example 143 ~ Example 167, which are shown in the Scheme 25, were synthesized according to the similar procedure as described in Example 142, and properties and spectral data thereof are shown in below table.




5

Examp les	Compou nds No.	$R^M, R^N, R^P, m$	Spectral data
143	25-2	$R^M = -OH$ $R^N = -OCH_3$ $R^P = -(CH_2)_2Ph$ $m = 1$	$^1H$ NMR (300MHz, $CDCl_3$ ): $\delta$ 7.20(m, 1H), 6.82(d, 1H, $J=8.04$ Hz), 6.66(s, 1H), 6.58(d, 1H, $J=8.04$ Hz) 5.59(s, 1H), 5.30(t, 1H), 4.59(s, 2H), 3.88(m, 4H), 3.81(s, 3H), 2.84(m, 6H); MS(EI) m/e 420 [ $M^+$ ]
144	25-3	$R^M = -OH$ $R^N = -OCH_3$ $R^P = -(CH_2)_3Ph$ $m = 1$	$^1H$ NMR (300MHz, $CDCl_3$ ): $\delta$ 7.20(m, 10H), 6.83(d, 1H, $J=8.04$ Hz), 6.72(s, 1H), 6.57(d, 1H, $J=8.04$ Hz) 5.58(s, 2H), 5.21(t, 1H, $J=4.62$ Hz), 4.72(s, 2H), 3.85(t, 2H, $J=6.57$ Hz), 3.81(s, 3H), 2.82(t, 2H, $J=7.68$ Hz) 2.51(t, 2H, $J=8.55$ Hz) MS (EI) m/e 434 [ $M^+$ ]
145	25-4	$R^M = -OH$ $R^N = -OCH_3$ $R^P = -(CH_2)_4Ph$ $m = 1$	$^1H$ NMR (300MHz, $CDCl_3$ ): $\delta$ 7.19(m, 10H), 6.70(m, 3H), 5.58(s, 1H) 4.69(s, 2H), 3.79(s, 3H), 3.87(m, 2H), 3.38(m, 2H), 2.84(t, 2H, $J=6.6$ Hz), 2.58(t, 2H, $J=7.7$ Hz), 1.55(m, 4H); MS (EI) m/e 448 [ $M^+$ ]
146	25-5	$R^M = -OH$ $R^N = -OCH_3$ $R^P = -C_8H_{17}$ $m = 1$	$^1H$ NMR (300MHz, $CDCl_3$ ): $\delta$ 7.20(m, 5H), 6.74(m, 3H), 5.63(s, 1H) 5.36(t, 1H), 4.77(s, 2H), 3.94(m, 2H), 3.85(s, 3H), 3.49(t, 2H, $J=7.8$ Hz), 2.89(t, 2H, $J=6.57$ Hz), 1.48(t, 2H), 1.28(m, 2H), 0.90(t, 3H) MS (EI) m/e 428 [ $M^+$ ]










5










Examp les	Compou nds No.	R <sup>M</sup> , R <sup>N</sup> , R <sup>P</sup> , m	Spectral data
147	25-6	R <sup>M</sup> = -OH R <sup>N</sup> = -OCH <sub>3</sub> R <sup>P</sup> = isopropyl m = 1	<sup>1</sup> H NMR (300MHz, CDCl <sub>3</sub> ): δ 6.86(m, 8H), 5.75(s, 1H), 5.59(s, 1H) 5.35(s, 1H), 4.32(s, 2H), 3.80(s, 3H), 3.85(m, 3H), 2.74(t, 2H, J=6.71 Hz), 1.18(d, 6H); MS (EI) m/e 358 [M <sup>+</sup> ]
148	25-7	R <sup>M</sup> = -OH R <sup>N</sup> = -OCH <sub>3</sub> R <sup>P</sup> = cyclohexyl m = 1	<sup>1</sup> H NMR (300MHz, CDCl <sub>3</sub> ): δ 7.07(m, 5H), 6.67(m, 3H), 5.56(s, 2H) 5.34(m, 4H), 4.37(s, 2H), 3.86(m, 2H), 3.79(s, 3H), 2.74(t, 2H, J=6.71 Hz), 1.43(m, 10H); MS (EI) m/e 398 [M <sup>+</sup> ]
149	25-8	R <sup>M</sup> = -OH R <sup>N</sup> = -OH R <sup>P</sup> = -(CH <sub>2</sub> ) <sub>3</sub> Ph m = 1	<sup>1</sup> H NMR (300MHz, CDCl <sub>3</sub> ): δ 7.08(m, 10H), 6.46(m, 3H), 6.38(s, 1H) 3.70(t, 2H, J=7.23 Hz), 3.42(t, 2H, J=7.61 Hz), 2.78(t, 2H, J=7.32 Hz), 1.70(m, 2H); MS (EI) m/e 420 [M <sup>+</sup> ]
150	25-9	R <sup>M</sup> = -OH R <sup>N</sup> = -OCH <sub>3</sub> R <sup>P</sup> = -(CH <sub>2</sub> ) <sub>2</sub> Ph m = 2	<sup>1</sup> H NMR (300MHz, CDCl <sub>3</sub> ): δ 7.21(m, 10H), 6.82(d, 1H, J=8.04 Hz), 6.64(s, 1H) 6.56(d, 1H, J=7.56 Hz), 5.53(s, 1H), 5.10(m, 1H), 3.87(s, 3H), 3.82(d, 2H, J=5.13 Hz), 3.63(d, 2H, J=5.13 Hz), 2.80(m, 6H); MS (EI) m/e 434 [M <sup>+</sup> ]
151	25-10	R <sup>M</sup> = -OH R <sup>N</sup> = -OCH <sub>3</sub> R <sup>P</sup> = -isopropyl m = 2	<sup>1</sup> H NMR (300MHz, CDCl <sub>3</sub> ): δ 7.28(m, 5H), 6.70(m, 3H), 5.56(m, 2H) 5.20(m, 1H), 3.95(m, 2H), 3.88(s, 3H), 3.45(m, 1H), 2.94(t, 2H), 2.69(t, 2H, J=7.53 Hz), 1.18(d, 2H, J=6.57 Hz) MS (EI) m/e 372 [M <sup>+</sup> ]
152	25-11	R <sup>M</sup> = -OH R <sup>N</sup> = -OCH <sub>3</sub> R <sup>P</sup> = -benzyl m = 3	<sup>1</sup> H NMR (300MHz, CDCl <sub>3</sub> ): δ 7.18(m, 10H), 6.66(m, 3H), 5.47(s, 1H) 5.20(m, 1H), 4.77(s, 2H), 3.83(s, 3H), 3.83(m, 2H), 3.54(t, 2H, J=7.68 Hz), 2.79(t, 2H, J=6.825 Hz), 2.46(t, 2H, J=7.44 Hz), 1.82(m, 2H); MS (EI) m/e 434 [M <sup>+</sup> ]
153	25-12	R <sup>M</sup> = -OH R <sup>N</sup> = -OCH <sub>3</sub> R <sup>P</sup> = -(CH <sub>2</sub> ) <sub>2</sub> Ph m = 3	<sup>1</sup> H NMR (300MHz, CDCl <sub>3</sub> ): δ 7.20(m, 10H), 6.69(m, 3H), 5.51(s, 1H) 5.07(t, 2H, J=7.30 Hz), 3.85(m, 5H), 3.71(t, 2H, J=7.68 Hz), 3.33(t, 2H, J=7.80 Hz), 2.84(m, 4H), 2.47(t, 2H, J=7.30 Hz), 1.79(m, 2H); MS (EI) m/e 448 [M <sup>+</sup> ]






**25-10****25-11****25-12**

Examp les	Compou nds No.	$R^M, R^N, R^P, m$	Spectral data
154	25-13	$R^M = -OH$ $R^N = -OCH_3$ $R^P = -(CH_2)_3Ph$ $m = 3$	$^1H$ NMR (300MHz, $CDCl_3$ ): $\delta$ 7.22(m, 5H), 6.73(m, 3H), 5.55(s, 1H) 5.04(t, 1H, $J=4.96$ Hz), 3.88(s, 3H), 3.83(m, 2H), 3.48(m, 4H), 3.88(t, 2H, $J=6.80$ Hz), 2.56(t, 2H, $J=7.58$ Hz), 2.51(t, 2H, $J=7.45$ Hz), 1.85(m, 4H); MS (EI) m/e 462 [ $M^+$ ]
155	25-14	$R^M = -OH$ $R^N = -OCH_3$ $R^P = -H$ $m = 3$	$^1H$ NMR (300MHz, $CDCl_3$ ): $\delta$ 7.23(m, 5H), 6.74(m, 3H), 3.84(m, 5H) 3.61(m, 2H), 3.27(m, 2H), 2.87(m, 2H), 2.59(t, 2H, $J=7.94$ Hz), 2.83(m, 2H); MS (EI) m/e 344 [ $M^+$ ]




156	25-15	$R^M = -OH$ $R^N = -OCH_3$ $R^P = -CH_3$ $m = 3$	$^1H$ NMR (300MHz, $CDCl_3$ ): $\delta$ 7.23(m, 5H), 6.70(m, 3H), 5.28(s, 2H) 3.86(m, 5H), 3.64(m, 2H), 3.02(s, 3H), 2.92(t, 2H, $J=6.69$ Hz), 2.52(t, 2H, $J=7.43$ Hz), 1.84(m, 2H); MS (EI) m/e 358 [ $M^+$ ]
157	25-16	$R^M = -OH$ $R^N = -OCH_3$ $R^P = -C_8H_{17}$ $m = 3$	$^1H$ NMR (300MHz, $CDCl_3$ ): $\delta$ 7.28(m, 5H), 6.73(m, 3H), 5.50(s, 1H) 5.12(m, 1H), 3.91(m, 5H), 3.55(t, 2H, $J=7.34$ Hz), 2.93(m, 2H), 2.53(t, 2H, $J=7.50$ Hz), 1.87(m, 2H), 1.44(m, 2H), 1.25(m, 10H), 0.91(m, 3H); MS (EI) m/e 456 [ $M^+$ ]
158	25-17	$R^M = -OH$ $R^N = -OCH_3$ $R^P = -isobutyl$ $m = 3$	$^1H$ NMR (300MHz, $CDCl_3$ ): $\delta$ 7.21(m, 5H), 6.70(m, 3H), 3.88(m, 5H) 5.59(m, 2H), 5.25(m, 2H), 3.11(m, 4H), 2.75(m, 1H), 2.56(m, 2H), 1.83(m, 2H), 0.86(m, 2H), 0.79(d, 6H) MS (EI) m/e 400 [ $M^+$ ]
159	25-18	$R^M = -OH$ $R^N = -OCH_3$ $R^P = -isopropyl$ $m = 3$	$^1H$ NMR (300MHz, $CDCl_3$ ): $\delta$ 7.26(m, 5H), 6.67(m, 3H), 5.53(s, m, 2H) 5.02(t, 1H), 3.85(m, 2H), 3.80(m, 2H) 3.09(t, 2H, $J=8.28$ Hz), 2.85(t, 2H, $J=6.81$ Hz), 2.45(t, 2H, $J=6.95$ Hz), 2.72(m, 2H), 1.09(d, 6H); MS (EI) m/e 386 [ $M^+$ ]
160	25-19	$R^M = -OH$ $R^N = -OCH_3$ $R^P = -cyclo-hexyl$ $m = 3$	$^1H$ NMR (300MHz, $CDCl_3$ ): $\delta$ 7.23(m, 5H), 6.65(m, 3H), 5.50(s, 1H) 4.93(m, 2H), 3.85(s, 3H), 3.83(m, 2H), 3.13(t, 2H, $J=7.8$ Hz), 2.83(t, 2H, $J=6.82$ Hz), 2.42(t, 2H, $J=7.07$ Hz), 1.65(m, 9H), 1.18(m, 5H); MS (EI) m/e 426 [ $M^+$ ]
161	25-20	$R^M = -OH$ $R^N = -OCH_3$ $R^P = -CH(Ph)_2$ $m = 3$	$^1H$ NMR (300MHz, $CDCl_3$ ): $\delta$ 7.64(s, 1H), 7.23(m, 15H), 6.52(m, 3H) 5.48(s, 1H), 5.25(t, 1H, $J=5.00$ Hz), 3.85(m, 5H), 3.33(t, 2H, $J=8.30$ Hz), 2.83(t, 2H, $J=6.823$ Hz), 2.07(t, 2H, $J=4.49$ Hz), 1.26(m, 2H); MS (EI) m/e 510 [ $M^+$ ]








Examp les	Compou nds No.	R <sup>M</sup> , R <sup>N</sup> , R <sup>P</sup> , m	Spectral data
162	25-21	R <sup>M</sup> = -OH R <sup>N</sup> = -OCH <sub>3</sub> R <sup>P</sup> = p-t-butylb enzyl m = 3	<sup>1</sup> H NMR (300MHz, CDCl <sub>3</sub> ): δ 7.17(m, 9H), 6.68(m, 3H), 5.49(s, 1H) 5.22(m, 1H), 4.71(s, 2H), 3.85(m, 5H), 3.61(m, 2H), 2.81(t, 2H, J=6.83 Hz), 2.50(t, 2H, J=7.44 Hz), 1.88(m, 2H), 1.31(s, 9H); MS (EI) m/e 490 [M <sup>+</sup> ]
163	25-22	R <sup>M</sup> = -OH R <sup>N</sup> = -OH R <sup>P</sup> = -isopropyl m = 3	<sup>1</sup> H NMR (300MHz, CDCl <sub>3</sub> ): δ 7.28(m, 5H), 6.73(m, 3H), 6.45(t, 2H, J=8.04 Hz) 3.80(m, 4H), 3.05(m, 4H), 2.88(m, 2H), 2.54(m, 1H), 2.39(t, 2H, J=6.83 Hz), 1.71(m, 4H), 1.11(d, 6H) MS (EI) m/e 372 [M <sup>+</sup> ]
164	25-23	R <sup>M</sup> = -OCH <sub>3</sub> R <sup>N</sup> = -OCH <sub>3</sub> R <sup>P</sup> = -isopropyl m = 3	<sup>1</sup> H NMR (300MHz, CDCl <sub>3</sub> ): δ 7.23(m, 5H), 6.69(m, 3H), 5.31(s, 1H) 3.85(m, 5H), 3.11(t, 2H, J=7.32), 2.85(t, 2H, J=6.71 Hz), 2.46(t, 2H, J=6.83 Hz), 1.75(m, 2H), 1.90(m, 1H), 1.09(d, 6H, J=3.32 Hz); MS (EI) m/e 400 [M <sup>+</sup> ]

165	25-24	$R^M = -OH$ $R^N = -H$ $R^P = -isopropyl$ $m = 3$	$^1H$ NMR (300MHz, $CDCl_3$ ): $\delta$ 7.14(m, 5H), 6.77(m, 4H), 3.77(m, 7H) 3.10(m, 2H), 2.88(m, 1H), 0.83(m, 10H); MS (EI) m/e 356 [ $M^+$ ]
166	25-25	$R^M = -H$ $R^N = -OCH_3$ $R^P = -isopropyl$ $m = 3$	$^1H$ NMR (300MHz, $CDCl_3$ ): $\delta$ 7.23(m, 5H), 6.69(m, 3H), 5.32(m, 1H) 3.77(m, 5H), 3.11(t, 2H, $J=7.07$ Hz), 2.87(t, 2H, $J=6.60$ Hz), 2.49(t, 2H, $J=7.20$ Hz), 2.73(m, 2H), 1.91(m, 1H), 1.08(d, 6H, $J=6.84$ Hz); MS (EI) m/e 370 [ $M^+$ ]
167	25-26	$R^M = -H$ $R^N = -H$ $R^P = -isopropyl$ $m = 3$	$^1H$ NMR (300MHz, $CDCl_3$ ): $\delta$ 7.21(m, 10H), 5.48(m, 1H), 5.038(m, 1H) 3.83(m, 2H), 3.11(t, 2H, $J=8.30$ Hz), 2.89(t, 2H, $J=6.83$ Hz), 2.54(t, 2H, $J=7.19$ Hz), 1.78(m, 2H), 1.11(d, 2H, $J=6.81$ Hz); MS (EI) m/e 340 [ $M^+$ ]






5      **Example**                                      **168:**                                      **Synthesis**                                      **of**

**N-(4-t-butylbenzyl)-3-(3-fluoro-4-methanesulfonylamino)propionamide**

**(26-3)**



Step 1: Synthesis of (3-fluoro-4-methanesulfonylamino)cinnamic acid methyl

10      ester **(26-1)**

2-fluoro-4-iodomethanesulfonylamino benzene **3-2** (200 mg) was dissolved in dimethylformamide (16 ml) and to the solution were added palladium acetate (7.2 mg),



1,1'-bis(diphenylphosphino)ferrocene (20 mg), triethylamine (200  $\mu$ l) and methylacrylate (550 mg), followed by stirring at 60 °C for a day. The reaction mixture was cooled to room temperature, diluted with dichloromethane (40 ml) and then washed with water and aqueous hydrochloric acid solution. The obtained mixture was dried  
5 over anhydrous magnesium sulfate, concentrated under reduced pressure, and then column-chromatographed (ethyl acetate/hexane = 1/1) to yield the compound 26-1 (214 mg, 70 %).

$^1\text{H}$  NMR(300MHz,  $\text{CDCl}_3 + \text{CD}_3\text{OD}$ ) :  $\delta$  7.62(d, 1H,  $J=16.3\text{Hz}$ ), 7.55(t, 1H,  $J=8.3\text{Hz}$ ), 7.46(dd, 1H,  $J=2.0, 11.7\text{Hz}$ ), 7.41(dd, 1H,  $J=2.0, 8.3\text{Hz}$ ), 6.50(d, 1H,  $J=15.8\text{Hz}$ ), 3.77(s, 3H), 3.03(s, 3H)  
10

Step 2: Synthesis of methyl  
3-(3-fluoro-4-methanesulfonylaminophenyl)propionate (26-2)

The compound 26-1 (78 mg) prepared according to the same procedure as  
15 described in Step 1 was dissolved in methanol (10 ml) and to the solution was added a catalytic amount of 10 % palladium/carbon, followed by stirring at room temperature under hydrogen atmosphere for 2 hours. The resulting mixture was diluted with ether, filtered through celite, and then concentrated under reduced pressure to yield the compound 26-2 (68 mg, 86 %).

$^1\text{H}$  NMR(300MHz,  $\text{CDCl}_3$ ) :  $\delta$  7.45(t, 1H,  $J=8.2\text{Hz}$ ), 6.98(d, 2H), 6.46(s, 1H),  
3.66(s, 3H), 3.00(s, 3H), 2.91(t, 2H,  $J=7.6\text{Hz}$ ), 2.60(t, 2H,  $J=7.6\text{Hz}$ )


Step 3: Synthesis of N-(4-t-butylbenzyl)

5 3-(3-fluoro-4-methanesulfonylaminophenyl)propionamide (**26-3**)

The compound **26-2** (30 mg) prepared in Step 2 was dissolved in toluene (4 ml) and to the solution was added 4-t-butylbenzylamine (150  $\mu\text{l}$ ), followed by refluxing for 3 hours. The resulting mixture was concentrated under reduced pressure and the obtained residue was chromatographed on silica gel column (ethyl acetate/hexane = 1/1) to yield the compound **26-3** (28 mg, 58 %).

$^1\text{H}$  NMR(300MHz,  $\text{CDCl}_3$ ) :  $\delta$  7.39(t, 1H,  $J=8.3\text{Hz}$ ) 7.29(d, 2H), 7.07(d, 2H), 6.95(m, 2H), 6.33(s, 1H), 5.54(s, 1H), 4.31(d, 2H,  $J=5.6\text{Hz}$ ), 2.93(s, 3H), 2.92(t, 2H,  $J=7.4\text{Hz}$ ), 2.41(t, 2H,  $J=7.6\text{Hz}$ ), 1.24(s, 9H)

15 **Example 169: Synthesis of N-(3-fluoro-4-methanesulfonylaminobenzyl) 4-t-butylbenzamide (27)**




Hydrochloride salt 3-4 (100 mg) prepared according to the same procedure as described in Example 13 was dissolved in dichloromethane (6 ml) and to the solution were added 4-t-butylbenzoylchloride (85 mg) and triethylamine (60  $\mu$ l), followed by stirring at room temperature for 2 hours. The resulting mixture was concentrated under reduced pressure and the obtained residue was column-chromatographed (ethyl acetate/hexane = 1/1) to yield the compound 27 (110 mg, 72 %).

$^1\text{H}$  NMR(300MHz,  $\text{CDCl}_3$ ) :  $\delta$  7.72(d, 2H), 7.49(t, 1H,  $J=8.0\text{Hz}$ ) 7.43(d, 2H), 7.13(m, 2H), 6.54(s, 1H), 4.59(d, 2H,  $J=5.9\text{Hz}$ ), 2.93(s, 3H), 2.99(s, 3H), 1.31(s, 9H)

10


**Example 170: Synthesis of (3-fluoro-4-methanesulfonylaminobenzyl)dithiocarbamic acid 4-t-butylbenzyl ester (28)**



The compound 3-4 (15.4 mg) prepared by Example 13 was dissolved in dimethylformamide (1 ml) and to the solution were added tetrabutylammonium iodide (67 mg), cesium (I) carbonate (59 mg) and carbon bisulfide (7  $\mu$ l), followed by stirring at 0 °C for 1 hour. To the mixture was added 4-t-butylbenzylbromide (34  $\mu$ l) and  
5 stirred at room temperature for 1 hour. After the completion of the reaction, the resulting mixture was concentrated under reduced pressure and the obtained residue was chromatographed on silica gel column eluting with ethyl acetate/hexane (1/3) to yield the compound 28 (12 mg, 52 %).

$^1\text{H}$  NMR(300MHz,  $\text{CD}_3\text{OD}$ ) :  $\delta$  7.43 (t, 1H,  $J=8.3\text{Hz}$ ), 7.25-7.34 (m, 4H),  
10 7.10-7.16 (t, 2H,  $J=8.3\text{Hz}$ ), 4.88 (s, 2H), 4.55 (s, 2H), 2.97 (s, 3H), 1.30 (s, 9H)

**Example 171: Synthesis of 1-(4-t-butylbenzyl)-3-(3-fluorophenethyl)urea (29)**




4-t-butylbenzylamine (3.2 g) was dissolved in dichloromethane (10 ml) and to  
15 the solution was added triethylamine (2.79 ml), followed by cooling to 0°C and slowly adding dropwise a solution of triphosgene (1.98 g) in dichloromethane (5 ml). The mixture was stirred at room temperature for 5 hours and water (10 ml) was added

thereto. The resulting mixture was extracted with dichloromethane, dried over anhydrous sodium sulfate, and then concentrated under reduced pressure. The obtained residue was purified by column-chromatography (hexane/ethyl acetate = 20/1) to yield 4-t-butylbenzylisocyanate (880 mg) as a solid. The obtained compound (400 mg) and 3-fluorophenethylamine (290 mg) were dissolved in dichloromethane (20 ml) and the solution was stirred at room temperature for 22 hours. The solvent was removed therefrom and the residue was purified by column-chromatography (hexane/ethyl acetate = 4/1) to yield the compound 29 (400 mg, 58 %) as a solid.

$^1\text{H}$  NMR(300MHz,  $\text{CDCl}_3$ ) :  $\delta$  7.35-6.82(m, 8H), 4.91(s, 1H), 4.39(d, 2H,  $J=5.4\text{Hz}$ ), 3.60-3.48(m, 2H), 2.79(t, 2H,  $J = 6.9\text{Hz}$ ), 1.31(s,9H)

**Example 172: Synthesis of 1-(4-t-butylbenzyl)-3-(2-fluorobenzoyl)thiourea (30)**




Potassium thiocyanate (KSCN) (240 mg) was dissolved in acetone (5 ml) and the solution was allowed to warm up to 50°C. To the solution was added 2-fluorobenzoylchloride (330 mg) and the mixture was stirred at 50°C for 4 hours. The produced potassium chloride was filtered off and to the obtained solution was

4-t-butylbenzylamine (330 mg), followed by stirring at room temperature for 24 hours.

The resulting mixture was concentrated and the residue was purified by column-chromatography (hexane/ethyl acetate = 5/1) to yield the compound **30** (156 mg, 23 %) as a liquid.

5  $^1\text{H}$  NMR(300MHz,  $\text{CDCl}_3$ ) :  $\delta$  8.18-8.11(m, 1H), 7.50-7.07(m, 8H), 7.02(brs, 1H), 4.70-4.65(m, 2H), 1.31(s,9H)

**Example 173: Synthesis of**  
**N''-cyano-N-(4-t-butylbenzyl)-N'-(2-pyridinylethyl)guanidine (31-1)**



10

N-(4-t-butylbenzyl) N'-cyano-S-methylisothiurea (180 mg) was dissolved in xylene (10 ml) and to the solution was added 2-(2-aminoethyl)pyridine (86 mg), followed by refluxing for 7 hours. The resulting mixture was concentrated under reduced pressure and the obtained residue was purified by column-chromatography (acetone/ethyl acetate = 1/1) to yield the compound **31-1** (70 mg, 30 %) as a liquid.

15


$^1\text{H}$  NMR(300MHz,  $\text{CDCl}_3$ ) :  $\delta$  8.01(brs, 1H), 7.62-7.56(m, 1H), 7.39-7.35(m, 2H), 7.26-7.20(m, 3H), 7.14-7.03(m, 2H), 6.42(brs, 1H), 4.34(d,2H, J=5.1Hz),

3.71-3.65(m, 2H), 3.03-2.98(m, 2H), 1.32(s, 9H)






### Example 174 ~ Example 178

Compounds of Example 174 ~ Example 178, which are shown in the Scheme


- 5 31, were synthesized according to the similar procedure as described in Example 173, and properties and spectral data thereof are shown in below table



Examples	Compounds	R=	Spectral data
174	31-2		<sup>1</sup> H NMR(300MHz, CDCl <sub>3</sub> ) : δ 7.38-7.35(m, 2H), 7.27-7.20(m, 1H), 7.13-7.10(m, 2H), 6.95-6.78(m, 3H), 5.53(brs, 1H), 4.77(brs, 1H), 4.23(d,2H, J=5.4Hz), 3.49-3.42(m, 2H), 2.79(t,2H, J=6.9Hz), 1.32(s, 9H)
175	31-3		<sup>1</sup> H NMR(300MHz, CDCl <sub>3</sub> ) : δ 7.40-7.35(m, 2H), 7.14-7.10(m, 2H), 7.08-6.99(m, 1H), 6.93-6.86(m, 1H), 6.82-6.77(m, 1H), 5.75(brs, 1H), 4.84(brs, 1H), 4.25(d,2H, J=5.4Hz), 3.46-3.39(m, 2H), 2.76(t,2H, J=6.9Hz), 1.32(s, 9H)
176	31-4		<sup>1</sup> H NMR(300MHz, CDCl <sub>3</sub> ) : δ 7.39-7.35(m, 2H), 7.32-7.23(m, 2H), 7.19-7.16(m, 2H), 7.12-6.98(m, 2H), 5.65(brs, 1H), 5.35(brs, 1H), 4.42(d,2H, J=6.0Hz), 4.34(d,2H, J=5.4Hz), 1.32(s, 9H)
177	31-5		<sup>1</sup> H NMR(300MHz, CDCl <sub>3</sub> ) : δ 7.39-7.35(m, 2H), 7.23-7.20(m, 2H), 7.12-7.05(m, 1H), 6.95-6.88(m, 1H), 6.16(brs, 1H), 5.88(brs, 1H), 4.79(d,2H, J=5.4Hz), 4.52(d,2H, J=4.8Hz), 1.31(s, 9H)
178	31-6		<sup>1</sup> H NMR(300MHz, CDCl <sub>3</sub> ) : δ 7.41-7.37(m, 2H), 7.27-7.15(m, 6H), 6.81(brs, 1H), 5.55(brs, 1H), 5.32(brs, 1H), 4.38-4.34(m, 4H), 3.01(s, 3H), 1.31(s, 9H)



5	Example	179:	Synthesis	of
	<p><b>N''-cyano-N-(4-t-butylbenzyl)-N'-(2,6-difluoro-3-methanesulfonylaminobenzyl)guanidine (31-7)</b></p>			



1-(4-t-butylbenzyl)-3-(2,6-difluoro-3-methanesulfonylaminobenzyl)thiourea


10 (44 mg) and lead cyanamide (30 mg) were added to ethyl acetate (10 ml) and the



mixture was refluxed for 18 hours. The resulting mixture was purified by column-chromatography (hexane/ethyl acetate = 1/1) to yield the compound 31-7 (35 mg, 78 %).

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.47(dt, *J*=5.7, 8.7Hz, 1H), 7.37(d, *J*=8.4Hz, 2H), 7.21(d, *J*=8.4Hz, 2H), 6.90(t, *J*=8.7Hz, 1H), 6.67(bs, 1H), 6.28(bs, 1H), 6.16(bs, 1H), 4.78(d, *J*=5.4Hz, 2H), 4.55(d, *J*=4.2Hz, 2H), 3.00(s, 3H), 1.31(s, 9H)


Example 180: Synthesis of N''-cyano-N-(4-*t*-butylbenzyl)-N'-(2-fluoro-5-methanesulfonylaminobenzyl)guanidine (31-8)



Compound 31-8 was synthesized according to the similar procedure as described in Example 179.

<sup>1</sup>H NMR(CDCl<sub>3</sub>): δ 7.34(d, *J*=8.1Hz, 2H), 7.28(dd, *J*=2.4, 6.0Hz, 1H), 7.20(d, *J*=8.1Hz, 2H), 7.18(m, 1H), 6.98(t, *J*=9.0Hz, 1H), 6.48(bs, 1H), 6.34(bs, 1H), 4.74(d, *J*=5.7Hz, 2H), 4.56(d, *J*=4.2Hz, 2H), 2.95(s, 3H), 1.29(s, 9H)


**Example 181: Synthesis of**  
**N''-cyano-N-[2-(1-methyl-1H-pyrrol-2-yl)ethyl]-N'-[1-(4-t-butylbenzyl)]guanidine**  
**(31-9)**



5           1-(4-t-butylbenzyl)-3-[2-(1-methyl-1H-pyrrol-2-yl)ethyl]thiourea (0.2 g) and  
 lead cyanamide (170 mg) were dissolved in ethyl acetate (20 ml) and the solution was  
 refluxed for 12 hours. After confirming the completion of the reaction, the resulting  
 mixture was filtered to remove the yellow solid, and the obtained residue was  
 concentrated under reduced pressure and purified by column-chromatography (ethyl  
 10 acetate/hexane = 2/3) to yield the compound **31-9** (174 mg, 85 %) as a yellow solid.

<sup>1</sup>H NMR (300MHz, CDCl<sub>3</sub>): δ 7.38(d, 2H), 7.21(d, 2H), 7.15(m, 2H), 6.05(d,  
 1H, J=2.1Hz), 4.48(m, 2H), 3.86(m, 2H), 2.99(t, 2H, J=6.9Hz), 1.31(s, 9H)

**Example 182: Synthesis of**  
 15   **1-(4-chlorobenzyl)-3-(6-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)thiourea (32-2)**



Step 1: Synthesis of 6-methoxy-1,2,3,4-tetrahydro-naphthalen-1-ylamine (32-1)

6-methoxy-1-tetralone (881 mg) and hydroxylamine hydrochloride (1.19 g) were dissolved in methanol (50 ml) and to the solution was slowly added pyridine (645 mg) at room temperature, followed by stirring for 18 hours. The resulting mixture was concentrated under reduced pressure. The concentrate was dissolved in ethyl acetate (30 ml), washed with water (10 ml  $\times$  2) and aqueous saturated copper sulfate solution (10 ml), dried over magnesium sulfate, and then concentrated under reduced pressure. The residue was purified by column-chromatography (hexane/ethyl acetate = 3/1) to yield an intermediate material, oxime (886 mg, 93 %).


The obtained oxime (586 mg) was dissolved in methanol (50 ml) and the solution was cooled to  $-30^{\circ}\text{C}$ , followed by adding nickel(II) chloride hexahydrate (1.46 g) thereto. After the solid was completely dissolved, to the solution was slowly added sodium borohydride (1.16 g) and the mixture was stirred at  $-30^{\circ}\text{C}$  for 30 minutes. Then, the mixture was stirred at room temperature for 90 minutes and concentrated under reduced pressure. The obtained residue was dissolved in 10 % hydrochloric acid (30 ml) and the solution was slowly basified with 1 N aqueous sodium hydroxide

solution. The obtained solution was extracted with ethyl acetate (50 ml  $\times$  3) and the organic layers were collected. The total organic layer was washed with brine, dried over magnesium sulfate, concentrated under reduced pressure, and then purified by column-chromatography (dichloromethane/methanol = 10/1) to yield the compound

5 **32-1** (385 mg, 71 %).

$^1\text{H}$  NMR( $\text{CDCl}_3$ ):  $\delta$  7.31(d,  $J=8.7\text{Hz}$ , 1H), 6.75(dd,  $J=8.5$ ,  $2.4\text{Hz}$ , 1H), 6.61(d,  $J=2.4\text{Hz}$ , 1H), 3.94(t,  $J=5.4\text{Hz}$ , 1H), 3.78(s, 3H), 2.75(m, 2H), 1.96(m, 2H), 1.73(bs, 2H), 1.70(m, 2H)

10 The similar compounds **32-3** and **32-5** were synthesized according to the same procedure as described above.



Examples -step	Compounds No.	$\text{R}^{\text{R}}=$	Spectral data
183-1	<b>32-3</b>	5-OMe	$^1\text{H}$ NMR( $\text{CDCl}_3$ ): $\delta$ 7.17(t, $J=7.8\text{Hz}$ , 1H), 7.02(d, $J=7.8\text{Hz}$ , 1H), 6.71(d, $J=7.8\text{Hz}$ , 1H), 3.97(t, $J=5.7\text{Hz}$ , 1H), 3.81(s, 3H), 2.65(m, 2H), 1.94(m, 2H), 1.76(bs, 2H), 1.73(m, 2H).

184-1	32-5	7-OMe	<sup>1</sup> H NMR(CDCl <sub>3</sub> ): δ 7.00(d, J=8.7Hz, 1H), 6.97(d, J = 3.0 Hz, 1H), 6.73(dd, J=8.7, 3.0Hz, 1H), 3.94(t, J=5.6Hz, 1H), 3.80(s, 3H), 2.70(m, 2H), 2.00(m, 1H), 1.90(m, 1H), 1.80(bs, 2H), 1.77(m, 2H).
-------	------	-------	---


Step 2: Synthesis of  
 5 1-(4-chlorobenzyl)-3-(6-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)thiourea (32-2)

The compound 32-1 (100 mg) prepared according to the same procedure as described in Step 1 was dissolved in ethyl acetate (4 ml) and to the solution were added a solution of 4-chlorobenzylisothiocyanate (123 mg) in ethyl acetate (2 ml), followed by stirring at room temperature for 18 hours. The obtained reaction mixture was  
 10 concentrated under reduced pressure and purified by column-chromatography (hexane/ethyl acetate = 2/1) to yield the compound 32-2 (201 mg, 99 %).

<sup>1</sup>H NMR(DMSO-d<sub>6</sub>): δ 7.62(d, J=7.5Hz, 1H), 7.52(bs, 1H), 7.23(d, J=8.4 Hz, 2H), 7.14(d, J=8.4Hz, 2H), 6.92(bs, 1H), 6.55(d, J=8.7Hz, 1H), 6.47(s, 1H), 5.30(bs, 1H), 4.50(bs, 2H), 3.53(s, 3H), 2.52(m, 2H), 1.71(m, 1H), 1.55(m, 3H)







15

The similar compounds 32-4 and 32-6 ~ 32-10 were synthesized according to the same procedure as described above.



Examp les	Compoun ds No.	$R^R=$ $R^S=$ $R^T=$	Spectral data
183	32-4	$R^R=5\text{-OMe}$ $R^T=\text{Cl}$	$^1\text{H NMR(DMSO-}d_6\text{): } \delta$ 7.85(d, $J=8.0\text{Hz}$ , 1H), 7.69(bs, 1H), 7.40(d, $J=8.4\text{Hz}$ , 2H), 7.32(d, $J=8.4\text{Hz}$ , 2H), 7.12(t, $J=8.0\text{Hz}$ , 1H), 6.81(d, $J=8.0\text{Hz}$ , 1H), 5.54(bs, 1H), 4.68(bs, 2H), 3.76(s, 3H), 2.56(m, 2H), 1.88(m, 2H), 1.73(m, 2H).
184	32-6	$R^R=7\text{-OMe}$ $R^T=\text{Cl}$	$^1\text{H NMR(CDCl}_3\text{): } \delta$ 7.29(d, $J=8.7\text{Hz}$ , 2H), 7.22(d, $J=8.7\text{Hz}$ , 2H), 6.99(d, $J=9.0\text{Hz}$ , 1H), 6.74(m, 3H), 6.23(bs, 1H), 5.92(bs, 1H), 5.40(bs, 1H), 4.56(bs, 2H), 3.72(s, 3H), 2.67(m, 2H), 2.05(m, 1H), 1.77(m, 3H).
185	32-7	$R^R=5\text{-OMe}$ $R^T=\text{t-butyl}$	$^1\text{H NMR(acetone-}d_6\text{): } \delta$ 7.38(d, $J=8.4\text{Hz}$ , 2H), 7.29(d, $J=8.4\text{Hz}$ , 2H), 7.17(bs, 1H), 7.10(t, $J=8.0\text{Hz}$ , 1H), 7.04(bs, 1H), 6.91(d, $J=8.0\text{Hz}$ , 1H), 6.78(d, $J=8.0\text{Hz}$ , 1H), 5.71(bs, 1H), 4.77(d, $J=5.1\text{Hz}$ , 2H), 3.80(s, 3H), 2.83(t, $J=6.0\text{Hz}$ , 2H), 1.89(m, 1H), 1.80(m, 3H), 1.30(s, 9H).
186	32-8	$R^R=6\text{-OMe}$ $R^T=\text{t-butyl}$	$^1\text{H NMR(acetone-}d_6\text{): } \delta$ 7.38(d, $J=8.4\text{Hz}$ , 2H), 7.29(d, $J=8.4\text{Hz}$ , 2H), 7.21(d, $J=8.4\text{Hz}$ , 1H), 7.14(bs, 1H), 7.05(bs, 1H), 6.51(dd, $J=8.4$ , 2.4Hz, 1H), 6.62(d, $J=2.4\text{Hz}$ , 1H), 5.65(bs, 1H), 4.76(d, $J=5.4\text{Hz}$ , 2H), 3.76(s, 3H), 2.73(m, 2H), 2.02(m, 1H), 1.81(m, 3H), 1.31(s, 9H).
187	32-9	$R^R=7\text{-OMe}$ $R^T=\text{t-butyl}$	$^1\text{H NMR(acetone-}d_6\text{): } \delta$ 7.37(d, $J=8.4\text{Hz}$ , 2H), 7.30(d, $J=8.4\text{Hz}$ , 2H), 7.20(bs, 1H), 7.11(bs, 1H), 6.98(d, $J=8.4\text{Hz}$ , 1H), 6.92(d, $J=2.7\text{Hz}$ , 1H), 6.73(dd, $J=8.4$ , 2.7Hz, 1H), 5.71(bs, 1H), 4.77(d, $J=4.8\text{Hz}$ , 2H), 3.71(s, 3H), 2.67(m, 2H), 2.06(m, 1H), 1.81(m, 3H), 1.30(s, 9H).

188	32-10	$R^R=6\text{-OMe}$ $R^S=7\text{-OMe}$ $R^T=t\text{-butyl}$	$^1\text{H NMR}(\text{CDCl}_3)$ : $\delta$ 7.34(d, $J=8.1\text{Hz}$ , 2H), 7.21(d, $J=8.1\text{Hz}$ , 2H), 6.76(s, 1H), 6.50(d, 1H), 6.32(bs, 1H), 5.96(bs, 1H), 5.40(bs, 1H), 4.52(bs, 2H), 3.80(s, 3H), 3.75(s, 3H), 2.63(m, 2H), 1.92(m, 2H), 1.70(m, 2H), 1.29(s, 9H).
-----	-------	--	--



5


Example

189:

Synthesis

of

1-(4-t-butylbenzyl)-3-(5-hydroxy-1,2,3,4-tetrahydronaphthalen-1-yl)thiourea (32-11)




The compound 32-3 (570 mg) prepared by Step 1 of Example 183 was dissolved in 48 % hydrobromic acid (10 ml) and the mixture was refluxed for 24 hours. The mixture was cooled to room temperature, and then concentrated under reduced pressure to remove the hydrobromic acid (residue : 766 mg, 97 %). Part (500 mg) of the residue was dissolved in dimethylformamide (5 ml) and the solution was cooled to 0°C. To the obtained mixture was added 5 M sodium hydroxide (800  $\mu$ l), followed by stirring for 15 minutes to obtain a solution. To the solution was slowly added a solution of 4-t-butylbenzylisothiocyanate (421 mg) in dimethylformamide (5 ml) and the mixture was stirred at room temperature for 48 hours. Then, to the obtained solution was added water and the resulting mixture was extracted with ether (50 ml  $\times$ 3). The extracted organic layer was collected, washed with 1 N hydrochloric acid, water and saturated aqueous sodium chloride solution, dried over magnesium sulfate, and then concentrated under reduced pressure. The residue was purified by column-chromatography (hexane/ethyl acetate = 2/1) to yield the compound 32-11 (550 mg, 73 %).



$^1\text{H}$  NMR(acetone- $\text{d}_6$ ):  $\delta$  7.38(d,  $J=8.4\text{Hz}$ , 2H), 7.29(d,  $J=8.4\text{Hz}$ , 2H), 7.15(bs, 1H), 7.03(bs, 1H), 6.95(t,  $J=7.8\text{Hz}$ , 1H), 6.81(d,  $J=7.8\text{ Hz}$ , 1H), 6.69(d,  $J=7.8\text{Hz}$ , 1H), 5.70(bs, 1H), 4.77(d,  $J=5.1\text{Hz}$ , 2H), 2.63(t,  $J=6.0\text{Hz}$ , 2H), 2.00(m, 1H), 1.81(m, 3H), 1.30(s, 9H)


5

The similar compound 32-12 was synthesized according to the same procedure as described above.




Example	Compound No.	$\text{R}^{\text{R}}=$ $\text{R}^{\text{T}}=$	Spectral data
190	32-12	$\text{R}^{\text{R}}=7\text{-OH}$ $\text{R}^{\text{T}}=\text{Cl}$	$^1\text{H}$ NMR( $\text{CD}_3\text{OD}$ ): $\delta$ 7.32(s, 4H), 6.89(d, $J=8.4\text{Hz}$ , 1H), 6.71(d, $J=2.4\text{Hz}$ , 1H), 6.59(dd, $J=8.4$ , 2.4Hz, 1H), 5.54(bs, 1H), 4.75(bs, 2H), 2.65(m, 2H), 2.03(m, 1H), 1.79(m, 3H).

10



**Example 191: Synthesis of 1-(4-t-butylbenzyl)-3-(3-formylchromone)thiourea (33-2)**




5            2-amino-3-formylchromone 33-1 (100 mg) was dissolved in anhydrous tetrahydrofuran (15 ml) and the solution was stirred. To the solution was added sodium hydride (15 mg) at 0°C and the mixture was stirred for 30 minutes. To the mixture was added 4-t-butylbenzylisothiocyanate (130 mg), followed by stirring for 6 hours. The resulting mixture was neutralized with an iced water and concentrated under reduced

10    pressure. The residue was extracted with ethyl acetate (30 ml ×3), dried over magnesium sulfate, and then filtered. The filtrate was purified by column-chromatography (ethyl acetate/hexane = 3/2) to yield the compound 33-2 (25 mg, 10 %).

$^1\text{H}$  NMR(300MHz,  $\text{CDCl}_3$ ) :  $\delta$ 8.75(s, 1H), 8.14(m, 1H), 7.77(m, 1H), 7.42(m,

15    6H), 5.73(s, 2H), 1.33(s, 9H)


**Example 192: Synthesis of (4-t-butylbenzyl)thiocarbamic acid -O-(3,5-dimethylpyrazol-1-ylmethyl)ester (33-4)**



3,5-dimethylpyrazol-1-methanol 33-3 (200 mg) and sodium hydride (42 mg) were dissolved in anhydrous tetrahydrofuran (20 ml) and the solution was stirred for 1 hour. To the solution was added 4-t-butylbenzylisothiocyanate (330 mg) and the mixture was stirred at room temperature for 12 hours. The resulting mixture was filtered under reduced pressure and the solvent was removed therefrom. The residue was purified by column-chromatography (ethyl acetate/hexane = 1/2) to yield the compound 33-4 (253 mg, 48 %) as a solid.

$^1\text{H}$  NMR (300MHz, acetone- $\text{d}_6$ )  $\delta$  7.29(m, 4H), 7.09(m, 1H), 6.30(s, 2H), 4.68(d, 2H,  $J=2.85\text{Hz}$ ), 2.33(s, 3H), 2.22(s, 3H), 1.30(s, 9H)

**Example 193: Synthesis of N-(3-fluoro-4-methanesulfonylaminobenzyl) 3-(4-t-butylphenyl)propionamide (34-5)**



Step 1: Synthesis of 4-t-butylcinnamic acid ethyl ester (**34-2**)

4-t-butylbenzaldehyde (**34-1**) (69 mg) was dissolved in acetonitrile (16 ml) and to the solution were added diisopropylethylamine (84 mg) and triethyl  
 5 phosphonoacetate (117 mg), followed by stirring at room temperature for 1 hours. The resulting mixture was diluted with dichloromethane (20 ml), washed with water and aqueous hydrochloric acid solution, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. The residue was column-chromatographed (ethyl acetate/hexane = 1/5) to yield the compound **34-2** (64 mg, 65 %)

10  $^1\text{H}$  NMR(300MHz,  $\text{CDCl}_3$ ) :  $\delta$  7.65(d, 1H,  $J=16.1\text{Hz}$ ), 7.46~7.34 (m, 4H), 6.38(d, 1H,  $J=16.1\text{Hz}$ ), 4.24(q, 2H,  $J=7.2\text{Hz}$ ), 1.31(m, 12H)

Step 2: Synthesis of ethyl 3-(4-t-butylphenyl)propionate (**34-3**)

The compound **34-2** (64 mg) according to the same procedure as described in  
 15 Step 1 was dissolved in methanol (10 ml) and to the solution was added a catalytic amount of 10 % palladium/carbon, followed by stirring at room temperature under hydrogen gas atmosphere for 2 hours. The resulting mixture was diluted with ether,

filtered through celite, and then concentrated under reduced pressure to yield the compound **34-3** (60 mg, 93 %)

$^1\text{H}$  NMR(300MHz,  $\text{CDCl}_3$ ) :  $\delta$  7.28(d, 2H,  $J=8.0\text{Hz}$ ), 7.11(d, 2H,  $J=8.0\text{Hz}$ ), 4.11(q, 2H,  $J=7.1\text{Hz}$ ), 2.90(t, 2H,  $J=7.6\text{Hz}$ ), 2.59(t, 2H,  $J=7.6\text{Hz}$ ), 1.29(s, 9H), 1.21(t, 5 3H,  $J=6.8\text{Hz}$ )


Step 3: Synthesis of N-(3-fluoro-4-methanesulfonylaminobenzyl) 3-(4-t-butylphenyl)propionamide (**34-5**)

The compound **34-3** (60 mg) prepared according to the same procedure as  
10 described in Step 2 was dissolved in 50 % aqueous tetrahydrofuran solution (10 ml) and to the solution was added lithium hydroxide (24 mg). The mixture was stirred at room temperature for 5 hours to hydrolyze the compound **34-3** and the solvent was removed therefrom. The residue was dissolved in ethyl acetate and extracted to the obtain the compound **34-4** (43 mg, 81 %). The compound **34-4** was dissolved in benzene (2 ml)  
15 and to the solution was added dropwise oxalyl chloride (100  $\mu\text{l}$ ), followed by refluxing for 2 hours. The reaction mixture obtained by concentrating the resultant under reduced pressure and hydrochloride compound **3-4** (67 mg) prepared in Example 13 were added to dichloromethane (6 ml), and to the mixture was added triethylamine (60  $\mu\text{l}$ ), followed by stirring at room temperature for 2 hours. The resulting mixture was

concentrated under reduced pressure and the obtained residue was purified by column-chromatography (ethyl acetate/hexane = 1/1) to yield the compound 34-5 (34 mg, 38 %).

$^1\text{H}$  NMR(300MHz,  $\text{CDCl}_3$ ) :  $\delta$  7.40(t, 1H,  $J=8.2\text{Hz}$ ) 7.23(d, 2H,  $J=8.3\text{Hz}$ ),  
 5 7.06(d, 2H,  $J=8.3\text{Hz}$ ), 6.90(m, 2H), 6.49(s, 1H), 5.68(s, 1H), 4.30(d, 2H,  $J=5.6\text{Hz}$ ),  
 2.93(s, 3H), 2.89(t, 2H,  $J=7.6\text{Hz}$ ), 2.47(t, 2H,  $J=7.4\text{Hz}$ ), 1.19(s, 9H)

**Example 194: Synthesis of**  
**1-(4-t-butylbenzyl)-3-(4-methylaminosulfonylaminobenzyl)thiourea (35-2a)**



10

**Step 1: Synthesis of**  
**N-t-butyloxycarbonyl-4-methylaminosulfonylaminobenzylamine (35-1a)**

Sodium hydride (18 mg) was suspended in dimethylformamide, and to the suspension was added a solution of N-t-butyloxycarbonyl-p-aminobenzylamine (150 mg) and methylaminosulfamoylchloride (97 mg) in dimethylformamide while the  
 15 temperature was controlled to  $0^\circ\text{C}$ , followed by stirring at room temperature for 3 hours.  
 The reaction solution was evaporated under reduced pressure, and the residue was

diluted with ethyl acetate (70 ml), washed with saturated aqueous sodium bicarbonate solution, water and saturated saline, and then evaporated under reduced pressure. The obtained residue was purified by column-chromatography (hexane/ethyl acetate = 5/1) to yield the compound **35-1a** (170 mg, 79 %).

5  $^1\text{H}$  NMR(300MHz, DMSO) :  $\delta$ 7.27(d, 2H,  $J=8.5$  Hz), 7.10(m, 2H), 4.18(s, 2H),  
3.29(s, 3H), 1.43(s, 9H)

Step 2: Synthesis of 1-(4-t-butylbenzyl)-3-(4-methylaminosulfonylaminobenzyl)thiourea (**35-2a**)


The compound **35-1a** (170 mg) prepared in Step 1 was dissolved in anhydrous dichloromethane (4 ml), and to the solution was added excess trifluoroacetic acid while the temperature was controlled to 0°C, followed by stirring for 30 minutes. The resulting mixture was evaporated under reduced pressure to remove excess trifluoroacetic acid and the residue was dissolved in anhydrous dichloromethane (4 ml). To the solution were added triethylamine (98  $\mu$ l) and 4-*t*-butylbenzylisothiocyanate (144 mg) and the mixture was stirred at room temperature for 3 hours. The reaction solution was evaporated under reduced pressure, and the remained was diluted with ethyl acetate (70 ml), washed with water and saturated saline, and then concentrated under reduced pressure. The obtained residue was purified by

column-chromatography (hexane/ethyl acetate = 10/1) to yield the compound **35-2a** (157 mg, 69 %).

$^1\text{H}$  NMR(300MHz, MeOH- $d_5$ ) :  $\delta$ 7.33(d, 2H,  $J=8.5$  Hz), 7.17(m, 2H), 4.65(s, 4H), 2.55(s, 3H), 1.25(s, 9H)

5 MS (FAB)  $m/e$  421[ $M^+ + 1$ ]

**Example 195: Synthesis of 1-(4-*t*-butylbenzyl)-3-(4-N,N-dimethylaminosulfonylaminobenzyl)thiourea (35-2b)**



10 Step 1: Synthesis of N-*t*-butoxycarbonyl-4-N,N-dimethylaminosulfonylaminobenzylamine (**35-1b**)

Compound **35-1b** (393 mg, 53 %) was synthesized by adding dimethylsulfonylchloride (266  $\mu\text{l}$ ) and then by being allowed to warm up to 60 °C according the procedure as described in Example 194.

15  $^1\text{H}$  NMR(300MHz,  $\text{CDCl}_3$ ) :  $\delta$ 7.18(m, 8H), 4.16(s, 4H), 2.77(s, 3H), 1.45(s, 9H)



Step 2: Synthesis of

1-(4-t-butylbenzyl)-3-(4-N,N-dimethylaminosulfonylaminobenzyl)thiourea (**35-2b**)


Compound **35-2b** (337 mg, 65 %) was synthesized according to the similar procedure as described in Example 194.

<sup>1</sup>H NMR(300MHz, CDCl<sub>3</sub>) : δ 7.18(m, 8H), 4.56(s, 4H), 3.92(s, 3H), 1.27(s, 9H)

MS (FAB) m/e 435[M<sup>+</sup>+1]

Example 196: Synthesis of

10 1-(4-t-butylbenzyl)-3-(4-aminosulfonylaminobenzyl)thiourea (**35-2c**)



Step 1: Synthesis of

N-t-butyloxycarbonyl-4-N-(t-butyloxycarbonylaminosulfonyl)aminobenzylamine  
(**35-1c**)

15 Compound **35-1c** (333 mg, 54 %) was synthesized by adding N-(t-butyloxycarbonyl)-N-[4-(dimethylazaniumylidene)-1,4-dihydropyridin-1-ylsulfonyl]azanide (464 mg) and then by being allowed to warm up to 60 °C according the

procedure as described in Example 194.


$^1\text{H}$  NMR(300MHz, DMSO) :  $\delta$  7.12(m, 4H), 4.06(d, 2H,  $J=5.9$  Hz), 1.37(s, 9H),  
1.33(s, 9H)

5                      Step                      2:                      Synthesis                      of  
1-(4-t-butylbenzyl)-3-(4-aminosulfonylaminobenzyl)thiourea (35-2c)

Compound 35-2c (257 mg, 69 %) was synthesized according to the similar  
procedure as described in Example 194.

$^1\text{H}$  NMR(300MHz, DMSO) :  $\delta$  7.18(m, 8H), 4.58(s, 4H), 1.25(s, 9H)  
10                      MS (FAB) m/e 407[ $\text{M}^+ + 1$ ]

Example                      197:                      Synthesis                      of  
1-(4-t-butylbenzyl)-3-(4-methanesulfonylamino-3-nitrobenzyl)thiourea (35-5)



15                      Step 1: Synthesis of 4-methanesulfonylamino-3-nitrobenzonitrile (35-4)

3-nitro-4-aminobenzonitrile (150 mg) and sodium bistrimethylsilylamide (2 ml)  
were dissolved in anhydrous tetrahydrofuran (6 ml), and to the solution was added

methanesulfonic anhydride (191 mg) at 0°C, followed by stirring for 3 hours. The reaction solution was evaporated under reduced pressure and the residue was diluted with ethyl acetate (70 ml), washed with diluted aqueous hydrochloric acid solution, saturated aqueous sodium bicarbonate solution, water and brine, and then evaporated under reduced pressure. The obtained residue was purified by column-chromatography (hexane/ethyl acetate = 5/1) to yield the compound 35-4 (120 mg, 54 %)

$^1\text{H}$  NMR(300MHz, Pyridine- $\text{d}_5$ ) :  $\delta$ 8.60(s, 1H), 8.17(d, 1H,  $J=8.76$  Hz), 7.88(dd, 1H,  $J=1.95, 8.79$  Hz), 3.48(s, 3H)

Step 2: Synthesis of  
1-(4-t-butylbenzyl)-3-(4-methanesulfonylamino-3-nitrobenzyl)thiourea (35-5)

The compound 35-4 (90 mg) prepared according to the same procedure as described in Step 1 was dissolved in anhydrous tetrahydrofuran and to the solution was added borane (1 M, 1.1 ml), followed by stirring for 6 hours. The resulting mixture was evaporated under reduced pressure, and the residue was diluted with ethyl acetate (50 ml), washed with water and brine, and then evaporated under reduced pressure to obtain amine. The obtained amine, which was not purified, was dissolved in dichloromethane (2 ml) and to the solution were added triethylamine (57  $\mu\text{l}$ ) and 4-t-butylbenzylisothiocyanate (8.4 mg) at 0°C, followed by stirring at room temperature


for 3 hours. The reaction solution was evaporated under reduced pressure. The residue was diluted with ethyl acetate (70 ml), and washed with water and brine. The solvent was evaporated under reduced pressure, and then the obtained residue was purified by column-chromatography (hexane/ethyl acetate = 30/1) to yield the compound 35-5 (56 mg, 33 %).

$^1\text{H}$  NMR(300MHz,  $\text{CDCl}_3$ ) :  $\delta$ 8.60(s, 1H), 8.17(d, 1H,  $J=8.76$  Hz), 7.88(dd, 1H,  $J=1.95, 8.79$  Hz), 7.40(m, 4H), 4.80(d, 2H,  $J=5.13$  Hz), 4.55(s, 2H), 3.10(s, 3H), 1.27(s, 9H)

MS (FAB)  $m/e$  451 $[\text{M}^++1]$

10

**Example 198: Synthesis of 1-(4-*t*-butylbenzyl)-3-(1-(4-methanesulfonylphenyl)ethyl)thiourea (36-4)**



**36-4**

Step 1: Synthesis of 4-methanesulfonylaminoacetophenone (36-1)

4-aminoacetophenone (300 mg) was dissolved in dichloromethane, and to the solution were added methanesulfonyl anhydride (2.44 mmol) and pyridine (53.85  $\mu\text{l}$ ) at  $0^\circ\text{C}$ , followed by stirring at room temperature for 3 hours. After confirming the

completion of the reaction using TLC, the reaction was quenched with saturated sodium bicarbonate solution. The reaction mixture was diluted with dichloromethane, washed with water and saturated aqueous sodium chloride solution, dried over anhydrous sodium sulfate, and then concentrated under reduced pressure to obtain a solid. The  
5 solid was recrystallized with ethyl acetate and hexane, to yield a pale yellow crystal (293.2 mg, 61.95 %).

mp: 155.1-161.2°C;

$^1\text{H}$  NMR(400MHz,  $\text{CDCl}_3$ ) :  $\delta$  7.98(d, 2H, J=8.8Hz), 7.27(d, 2H, J=8.8 Hz),  
3.11(d, 3H, J=1.6 Hz), 2.59(d, 3H, J=1.6 Hz)

10 IR(KBr pellet,  $\text{cm}^{-1}$ ) : 3290.93, 3003.59, 2928.38, 1667.16, 1600.63, 1469.49,  
1330.64, 1279.54, 1146.47

#### Step 2: Synthesis of 4-methanesulfonylaminoacetophenonoxime (36-2)

4-methanesulfonylaminoacetophenone (36-1) (360.2 mg) was dissolved in  
15 ethanol and to the solution was added a solution of hydroxylamine hydrochloride (129.11 mg) and sodium acetate (249.40 mg) in minimal amount of water. To the mixture was added ethanol until the solution became clear and then the solution was refluxed for 20 hours, thereby to be changed from transparent yellow to transparent colorlessness. After confirming the completion of the reaction using TLC, the ethanol

was removed therefrom, and the residue was extracted with ethyl acetate, washed with water and saturated aqueous sodium chloride solution, dried over anhydrous sodium sulfate, and then concentrated under reduced pressure to obtain a solid. The solid was recrystallized with ethyl acetate and hexane to yield a pale yellow crystal (289.6 mg, 5 75.11 %).

mp: 181.5 - 182.1 °C;

<sup>1</sup>H NMR(400MHz, CDCl<sub>3</sub>): δ 7.60(d, 2H, J=7.2 Hz), 7.26(d, 2H, J=7.4 Hz), 2.96(s, 3H), 2.21(s, 3H).

IR(KBr pellet, cm<sup>-1</sup>) : 3495.35, 3255.25, 3023.84, 2926.38, 1605.45, 1323.89, 10 1155.15;

### Step 3: Synthesis of 1-(4-methanesulfonylaminophenyl)ethylamine (36-3)

4-methanesulfonylaminoacetophenonoxime (36-2) (279 mg) was dissolved in methanol and to the solution was added palladium/carbon (55.8 mg), followed by 15 stirring under hydrogen atmosphere. After confirming the completion of the reaction using TLC, palladium/carbon was filtered off and the filtrate was concentrated under reduced pressure to remove the methanol, thereby to yield a transparent yellow liquid (251.1 mg, 95.89 %).

<sup>1</sup>H NMR(400MHz, CDCl<sub>3</sub>) : δ 7.28(d, 2H, J=8.8 Hz), 7.15(d, 2H, J=8.8 Hz),

4.09(q, 1H, J=6.6 Hz), 2.95 (s, 3H), 1.35(d, 3H, J=6.4 Hz)

IR(NaCl neat,  $\text{cm}^{-1}$ ) : 3350.71, 3270.69, 3136.65, 3023.84, 2965.98, 1610.27,  
1512.88, 1325.82, 1153.22;

5                      Step                      4:                      Synthesis                      of  
  
1-(4-t-butylbenzyl)-3-(1-(4-methanesulfonylphenyl)ethyl)thiourea (36-4)

The compound 36-3 (56.3 mg) prepared in Step 3 was dissolved in dichloromethane and to the solution was added 4-t-butylbenzylisothiocyanate (64.7 mg), followed by stirring at room temperature for 12 hours. After confirming the completion  
10 of the reaction using TLC, dichloromethane was evaporated under reduced pressure and the residue was purified by column-chromatography (hexane/ethyl acetate = 4/1) to yield a white solid (41.9 mg, 38.01 %).

mp: 177.8-178.5 °C

$^1\text{H}$  NMR(400MHz,  $\text{CDCl}_3$ ) :  $\delta$  9.33(s, 1H), 7.28(m, 8H), 5.51(s, 1H), 4.68(s,  
15 2H), 4.08(q, 1H, J=4.8Hz), 2.93(s, 3H), 1.48(d, 3H, J=4.8Hz), 1.31(s, 9H).


IR(KBr pellet,  $\text{cm}^{-1}$ ) : 3356.50, 3262.97, 3057.58, 3025.76, 2964.05, 2868.59,  
1544.70, 1512.88, 1325.82

Example

199:

Synthesis

of

**1-(1-(4-methanesulfonylphenyl)ethyl)-3-phenethylthiourea (36-5)****36-5**


Solution of compound 36-3 (50 mg) in dichloromethane was mixed with phenethylisothiocyanate (65.7 mg) and the mixture was stirred at room temperature for 12 hours, followed by confirming the completion of the reaction using TLC. Dichloromethane was evaporated and the residue was column-chromatographed (hexane/ethyl acetate = 2/1) to yield a white solid (12.8 mg, 14.53 %).

mp : 190.8-192.1 °C

<sup>1</sup>H NMR(400MHz, DMSO-d<sub>6</sub>) : δ 9.63(s, 1H), 7.78(s, 1H), 7.19(m, 9H), 5.34(s, 1H), 3.56(s, 1H), 2.92(s, 2H), 2.74(t, 2H, J=6.6Hz), 2.47(s, 3H), 1.33(d, 3H, J=6.6Hz). IR(NaCl neat, cm<sup>-1</sup>) : 3365.17, 3229.22, 3020.94, 1731.76, 1523.49, 1374.03;

Example	200:	Synthesis	of
15	<b>1-(4-t-butylbenzyl)-3-(1-(4-methanesulfonylphenyl)ethyl)-3-methylthiourea (36-6)</b>		



**36-6**

Compound 36-1 (200 mg) was dissolved in methanol and to the solution was added palladium/carbon (30.0 mg), followed by bringing the atmosphere of the reactor into an atmosphere of hydrogen gas. To the solution was added methylamine solution (2 M) and the mixture was allowed to be reacted for 5 days. After confirming the completion of the reaction using TLC, palladium/carbon was filtered off and the filtrate was purified by column-chromatography eluting with hexane/ethyl acetate (3/1) to remove neural material and subsequently eluting with dichloromethane/methanol (10/1) to obtain a yellow liquid (70 mg, 32.70 %). The obtained compound (70 mg) was dissolved in dichloromethane and to the solution was added phenethylisothiocyanate (75.5 mg), followed by stirring at room temperature for 4 hours. After confirming the completion of the reaction using TLC, the resulting mixture was diluted with dichloromethane, washed with water and saturated aqueous sodium chloride solution, dried over anhydrous sodium sulfate, and then concentrated under reduced pressure to obtain a solid. The solid was purified by column-chromatography (hexane/ethyl acetate = 3/1) to yield a colorless liquid (42.6 mg, 32 %).

$^1\text{H}$  NMR(400MHz,  $\text{CDCl}_3$ ) :  $\delta$  7.27(m, 8H), 6.90(q, 1H,  $J=7.2\text{Hz}$ ), 5.53(s, 1H), 4.84(d, 2H,  $J=4.4\text{Hz}$ ), 2.98(s, 3H), 2.66(s, 3H), 1.58(s, 1H), 1.52(d, 3H,  $J=7.2\text{Hz}$ ), 1.29(s, 3H).

IR(NaCl neat,  $\text{cm}^{-1}$ ) : 3386.39, 3267.79, 2963.09, 1512.88, 1326.79;

5

### Experimental Example. Biological potency test

#### (1) $^{45}\text{Ca}$ influx test

1) Separation of spinal dorsal root ganglia (DRG) in newborn rats and primary culture thereof

10 Neonatal(2-day old or younger than 2-day old) SD rats were put in ice for 5 minutes to anesthetize and disinfected with 70% ethanol. DRG of all part of spinal cord were dissected (Wood et al., 1988, J. Neurosci. 8, pp3208-3220) and collected in DME/F12 medium to which 1.2 g/l sodium bicarbonate, 50 mg/l gentamycin were added. The DRG were incubated sequentially at 37°C for 30 min in 200 U/ml  
15 collagenase and 2.5 mg/ml trypsin, separately. The ganglia were washed twice with DME/F12 medium supplemented with 10% horse serum, triturated through a fire-polished Pasteur pipette, filtered through Nitex 40 membrane to obtain single cell suspension. This was subjected to centrifugation, then re-suspended in cell culture medium at certain level of cell density. As the cell culture medium, DME/F12

medium supplemented with 10% horse serum, diluted 1:1 with identical medium conditioned by C6 glioma cells (2 days on a confluent monolayer) was used, and NGF(Nerve Growth Factor) was added to final concentration of 200 ng/ml. After the cells were grown 2 days in medium where cytosine arabinoside (Ara-C, 100  $\mu$ M) was added to kill dividing nonneuronal cells, medium was changed to one without Ara-C. The resuspended cells were plated at a density of 1500-1700 neurons/well onto Terasaki plates previously coated with 10  $\mu$ g/ml poly-D-ornithine.

## 2) $^{45}$ Ca influx experiments

DRG nerve cells from the primary culture of 2-3 days were equilibrated by washing 4 times with HEPES (10mM, pH 7.4)-buffered  $\text{Ca}^{2+}$ ,  $\text{Mg}^{2+}$ -free HBSS (H-HBSS). The solution in each well was removed from the individual well. Medium containing the test compound plus capsaicin (final concentration 0.5  $\mu$ M) and  $^{45}\text{Ca}$  (final concentration 10  $\mu\text{Ci/ml}$ ) in H-HBSS was added to each well and incubated at room temperature for 10 min. Terasaki plates were washed six times with H-HBSS and dried in an oven. To each well, 0.3% SDS (10  $\mu\text{l}$ ) was added to elute  $^{45}\text{Ca}$ . After the addition of 2ml of scintillation cocktail into each well, the amount of  $^{45}\text{Ca}$  influx into neuron was measured by counting radioactivity. Antagonistic activities of test compounds against vanilloid receptor were calculated as percent of the inhibition of maximal response of capsaicin at a concentration of 0.5  $\mu$ M and results are given as

IC<sub>50</sub> (Table 1a, 1b and 1c).

Agonistic activities of the test compounds for vanilloid receptor were determined as a concentration of the test compound showing 50% of the <sup>45</sup>Ca influx, compared to the maximal amount of <sup>45</sup>Ca influx in case of using 3  $\mu$ M capsaicin and results are given as EC<sub>50</sub> (Table 1d).

## (2) Channel activity assay

Antagonistic activities of test compounds were assayed based on electrical change of cation channel connected to vanilloid receptor and experiments were conducted according to reference method (Oh et al., 1996, J. Neuroscience 16, pp1659-1667) (Table 1a, 1b and 1c).

Table 1a. Results of Calcium Influx and Patchclamp Tests

Examples	Calcium Uptake Test(IC <sub>50</sub> )	Patchclamp Test (antagonistic activities)
5	1.1	
9	0.23	
13	0.037	++
15	1.2	
17	0.0084	++
18	0.72	
19	0.0058	++
30	1.5	
32	0.031	+
33	0.11	
36	1.1	
44	0.11	+
51	0.7	

NR: no response

+: antagonistic potency equal to capsazepine

++: antagonistic potency 10 times higher than capsazepine

5

Table 1b. Results of Calcium Influx and Patchclamp Tests

Examples	Calcium Uptake Test (IC <sub>50</sub> )	Patchclamp Test (antagonistic activities)
60	1.14	+
61	0.25	+
62	0.06	+
64	0.35	+
65	0.019	+
66	0.25	+
67	0.5	+
68	0.063	+
69	0.77	+
70	0.58	+
73	1.2	
83	1.1	
90	0.42	
96	0.59	

+: antagonistic potency equal to capsazepine

10 Table 1c. Results of Calcium Influx and Patchclamp Tests

Examples	Calcium Uptake Test (IC <sub>50</sub> )	Patchclamp Test (antagonistic activities)
----------	---	---

134	0.81	
152	0.95	+
153	0.38	
161	0.46	
178	0.11	
193	0.21	
194	0.31	
196	0.15	
Capsazepine	0.59	+

+: antagonistic potency equal to capsazepine

5 Table 1d. Results of Calcium Influx Tests

Examples	Calcium Uptake Test (EC <sub>50</sub> )
6	14.6
24	8.2
41	7.0
46	2.6
82	2.8

(3) Analgesic activity test: Mouse writhing test by inducing with phenyl-p-quinone

Male ICR mice (mean body weight 25g) were maintained in a controlled  
 10 lighting environment (12 h on/ 12 h off) for experiment. Animals received an  
 intraperitoneal injection of 0.3ml of the chemical irritant phenyl-p-quinone (dissolved in

saline containing 5% ethanol to be a dose of 4.5mg/kg) and 6 min later, the number of abdominal constrictions was counted in the subsequent 6 min period. Animals (10 animals/group) received 0.2ml of test compounds solution in vehicle of ethanol/Tween 80/saline (10/10/80) intraperitoneally 30 min before the injection of phenyl-p-quinone.

- 5 A reduction in the number of writhes responding to the test drug compound relative to the number responding in saline control group was considered to be indicative of an analgesic effect. Analgesic effect was calculated by % inhibition equation ( $\% \text{ inhibition} = (C - T) / C \times 100$ ), wherein C and T represent the number of writhes in control and compound-treated group, respectively (Table 2).

- 10 The test results demonstrated that analgesic effect of the compounds used in this experiment is as potent as indomethacin which is a very potent antiinflammatory and analgesic agent. In particular, it is significant to clarify that vanilloid receptor antagonist can exhibit such potent analgesic effect, and the results suggests that vanilloid receptor antagonist has potential as an analgesic agent.

15

Table 2. Test result of analgesic activity for writhing by phenyl-p-quinone

Examples	Dose(mg/kg)	Analgesic effect (% Inhibition)
5	10	53
13	10	82

17	10	98
44	3	92
52	10	94
73	10	88
83	10	85
96	10	58
104	10	95
107	10	44
153	1	57
161	1	73
Indomethacin	3	94

(4) Antiinflammatory activity test: TPA(12-O-tetradecanoylphorbol 13-acetate)-induced mouse ear edema test

Male ICR mice(body weight 25-30g), 10 animals/group, were treated topically on the right ear with 30  $\mu$ l of TPA (2.5  $\mu$ g) solution in acetone and after 15 min, 30  $\mu$ l of acetone or test compound solution in acetone was applied topically. After six hours, an identical treatment was applied again. After twenty four hours following the treatment of TPA, the animals were sacrificed and ear tissue was dissected using 6 mm-diameter punch. Ear tissue dissected were weighed to the nearest 0.1 mg on an electrobalance. The increased weight of the tissue compared to control group was considered as an index of inflammation. The percent inhibition is defined by the following equation:



% inhibition  $= (C-T)/C \times 100$ , wherein C and T represent an increase of ear weight in TPA-treated and TPA+drug-treated group, respectively (Table 3).

The above experiment shows that vanilloid receptor antagonist exhibits anti-inflammatory effects of the same level with indomethacin which is very potent anti-inflammatory and analgesic agent. This phenomenon can be understood by connecting with the action of vanilloid receptor in neurogenic inflammation, and suggests potential applicability of vanilloid receptor antagonist in various inflammatory diseases, in particular, neurogenic inflammatory diseases.

Table 3. TPA-induced mice ear edema test

Examples	Dose (mg/ear)	Anti-inflammatory effect (% Inhibition)
13	1	74
17	1	80
33	1	66
44	1	83
73	1	77
107	1	75
Indomethacin	1	74

(5) Ulcer test: ethanol-induced anti-ulcer test

Male SD rats (body weight 180-200 g), 5 animals/group, were fasted for 24

hours, and their stomachs were damaged. The rats were administered with 10 ml/kg of test drug suspended in 1 % methylcellulose orally and, after 1 hour, 1 ml of 99% ethanol orally. After 1 hour without food and water, the rats were sacrificed by cervical dislocation and stomachs thereof were removed. The removed stomachs  
 5 were incised along the greater curvature and opened. Then, the degree of gastric damage was scored based on the following ulcer index which is a criterion for evaluation and the percent inhibition of test drug against ulcer was calculated compared to control group (1% methylcellulose) (table 4). % inhibition =[(ulcer index of control group - ulcer index of drug-treated group)/(ulcer index of control group)] x 100

10 According to the present study using ethanol-induced ulcer model, the vanilloid receptor antagonist was found out to exhibit significant anti-ulcerous activities, contrary to ranitidine, which is a representative antiulcerant but did not show anti-ulcer activity in the present study. This study is the first to demonstrate the anti-ulcerous potential of vanilloid receptor antagonist. Based on the result, possibility that vanilloid receptor  
 15 antagonist will be developed as an anti-ulcerant is suggested.

Scoring(grade)	Ulcer Index (UI)
0	No lesion
1	One hemorrhagic ulcer of length less than 5mm & thin
2	One hemorrhagic ulcer of length not less than 5mm & thin

3	More than one ulcer of grade 2
4	One ulcer of length not less than 5mm & width not less than 2mm
5	Two or three ulcers of grade 4
6	Four or five ulcers of grade 4
7	More than six ulcers of grade 4
8	Complete lesion of the mucosa

Table 4. Ethanol-induced anti-ulcer test

Examples	Dose(mg/kg)	Anti-ulcerous effect (% inhibition)
13	30	30
17	30	58
33	30	31
44	30	36
73	30	22
107	30	18
Ranitidine	30	4

5


### Industrial Applicability

The compounds according to the present invention are useful in the prevention or treatment of pain, acute pain, chronic pain, neuropathic pain, post-operative pain, migraine, arthralgia, neuropathies, nerve injury, diabetic neuropathy, neurodegeneration, neurotic skin disorder, stroke, urinary bladder hypersensitiveness, irritable bowel

syndrome, a respiratory disorder such as asthma and chronic obstructive pulmonary diseases, irritation in skin, eye or mucous membrane, stomach-duodenal ulcer, inflammatory bowel disease, inflammatory disease, etc.

## CLAIMS

1. A compound of the following formula (I):



(I)


5 or a pharmaceutically acceptable salt thereof,

wherein:

X represents S, O or -NCN;

Y represents single bond, NR<sup>3</sup>, O or S;

R<sup>1</sup> represents




10

pyridinylmethyl, pyrrolylmethyl, oxazolylmethyl, pyrazolylmethyl, imidazolylmethyl, anthracenylmethyl, naphthylmethyl, quinolinylmethyl, alkoxycarbonyl or alkylcarbonyloxy (wherein, m is 0, 1, 2, 3 or 4; R<sup>4</sup> and R<sup>5</sup> are independently hydrogen, lower alkyl having 1 to 5 carbon atoms, hydroxy, methanesulfonylamino, lower alkoxy

having 1 to 5 carbon atoms, methoxyalkoxy, methoxyalkoxyalkyl, alkoxyalkoxy, benzyloxy, acetoxymethyl, propionyloxymethyl, butoxyalkyl, trimethylacetoxy, trimethylacetoxymethyl or halogen; and  $R^6$  and  $R^7$  are independently hydrogen, lower alkyl having 1 to 5 carbon atoms);


5  $R^2$  represents  $R^8-(CH_2)_n-$

{wherein,  $n$  is 0, 1, 2, 3 or 4;  $R^8$  is benzoyl, imidazolyl, indolyl, indazolyl, thiazolyl, pyrazolyl, oxazolyl, isoxazolyl, benzimidazolyl, chromonyl or benzothiazolyl substituted or unsubstituted with lower alkyl having 1 to 5 carbon atoms, nitro, amino, cyano, methanesulfonylamino, formyl or halogen, or



10





(wherein,  $R^9$  is hydrogen, halogen, lower alkyl having 1 to 5 carbon atoms, lower alkoxy having 1 to 5 carbon atoms, hydroxy, nitro, cyano,  $-NHSO_2R^{12}$ ,  $-S(O)_pR^{12}$ ,  $-NR^{13}R^{14}$ , carboxyl;  $R^{10}$  is hydrogen, nitro,  $NHSO_2R^{12}$ ,  $S(O)_pR^{12}$  or  $NR^{13}R^{14}$ ;  $R^{11}$  is hydrogen or cyano;  $R^{12}$  is lower alkyl having 1 to 5 carbon atoms, methylphenyl,   
 15  $NR^{13}R^{14}$ , trifluoromethyl or alkenyl;  $R^{13}$  and  $R^{14}$  are independently hydrogen or lower alkyl having 1 to 5 carbon atoms; and  $p$  is 0 or 2.); or



or

(wherein, Z is O, S, NH or -NCH<sub>3</sub>; R<sup>15</sup> is hydrogen, halogen, lower alkyl having 1 to 5 carbon atoms, nitro, cyano, -NHSO<sub>2</sub>R<sup>12</sup>, -S(O)<sub>p</sub>R<sup>12</sup>, N,N-dimethylaminomethyl or alkoxycarbonylamino; and p and R<sup>12</sup> have the same  
 5 meanings as defined in R<sup>9</sup>);


or



or

(wherein, W is O, S, NH, NR<sup>16</sup>, -N(SO<sub>2</sub>CH<sub>3</sub>)- or -CH<sub>2</sub>-; and R<sup>16</sup> is pyridinyl or pyrimidinyl substituted or unsubstituted with lower alkyl having 1 to 5 carbon atoms,  
 10 nitro, methanesulfonylamino or halogen; or benzyl or phenethyl substituted or unsubstituted with lower alkyl having 1 to 5 carbon atoms, alkoxy, hydroxy, nitro, methanesulfonylamino or halogen);

or



or

(wherein,  $R^{17}$ ,  $R^{18}$ ,  $R^{19}$ ,  $R^{20}$  and  $R^{21}$  are independently hydrogen, halogen, lower alkyl having 1 to 5 carbon atoms, alkoxy, methylenedioxy, methanesulfonylaminomethyl, alkoxy carbonyl, hydroxy, sulfamoyl, aminoalkoxy, alkoxy carbonylamino,  $-NHCH_2CO_2H$ , alkoxyalkylcarbonylamino, alkoxy carbonylalkylamino, nitro, formyl, acetyl, formylamino, acetoxylamino, cyano,  $-OSO_2CH_3$ ,  $-NHSO_2R^{12}$ ,  $-N(SO_2R^{12})CH_3$ ,  $-N(SO_2R^{12})_2$ ,  $-S(O)_pR^{12}$ ,  $-NR^{13}R^{14}$ , thiocarbamoyl,  $-C(=O)NHNH_2$ ,  $-C(=O)NHOH$ ,  $-C(=O)NHOCH_3$ ,  $-PO(=O)(OCH_3)_2$ , carboxyl, NHBoc,  $-NHC(=O)SCH_3$  or guanidine;  $R^{22}$  and  $R^{23}$  are independently hydrogen, halogen, alkoxy or hydroxy; and p,  $R^{12}$ ,  $R^{13}$  and  $R^{14}$  have the same meanings as defined in  $R^9$ );

or hydroxyphenylalkyl or (methanesulfonylaminophenyl)alkyl}; and

$R^3$  represents hydrogen, alkyl or cycloalkyl having 1 to 8 carbon atoms, lower alkylphenyl having 1 to 5 carbon atoms, pyridinylethyl, bisphenylmethyl; or phenylalkyl substituted with lower alkyl having 1 to 5 carbon atoms, halogen or methanesulfonylamino.

2. A compound or a pharmaceutically acceptable salt thereof according to claim




1, wherein,

X represents S, O or -NCN;

Y represents  $\text{NR}^3$  or O;

$\text{R}^1$  represents




5

(wherein, m is 0, 1 or 2; and  $\text{R}^4$  and  $\text{R}^5$  are independently hydrogen, lower alkyl having 1 to 4 carbon atoms, hydroxy, methanesulfonylamino, lower alkoxy having 1 to 5 carbon atoms, methoxyalkoxy, methoxyalkoxyalkyl, benzyloxy, acetoxymethyl, trimethylacetoxymethyl or halogen);

10  $\text{R}^2$  represents  $\text{R}^8-(\text{CH}_2)_n-$


{wherein, n is 0, 1, 2 or 3;  $\text{R}^8$  is benzoyl, imidazolyl, indolyl, indazolyl, thiazolyl, pyrazolyl, oxazolyl, benzimidazolyl or chromonyl substituted or unsubstituted with lower alkyl having 1 to 5 carbon atoms, nitro, amino, cyano, methanesulfonylamino, formyl or halogen, or



15


(wherein,  $R^9$  is hydrogen, halogen, lower alkyl having 1 to 4 carbon atoms, lower alkoxy having 1 to 4 carbon atoms, nitro, cyano,  $-NHSO_2R^{12}$ ,  $-NR^{13}R^{14}$  or carboxyl;  $R^{10}$  is hydrogen, nitro,  $NHSO_2R^{12}$  or  $-NR^{13}R^{14}$ ;  $R^{11}$  is hydrogen or cyano;  $R^{12}$  is lower alkyl having 1 to 4 carbon atoms, methylphenyl,  $-NR^{13}R^{14}$  or trifluoromethyl;   
 5  $R^{13}$  and  $R^{14}$  are independently hydrogen or lower alkyl having 1 to 4 carbon atoms; and p is 0 or 2);

or



or

(wherein, Z is O, S, NH or  $-NCH_3$ ;  $R^{15}$  is hydrogen, lower alkyl having 1 to 4 carbon atoms, nitro, cyano or  $NHSO_2R^{12}$ ; and  $R^{12}$  has the same meanings as defined in  $R^9$ ); or




or

(wherein, W is O, S, NH,  $NR^{16}$  or  $-CH_2-$ ; and  $R^{16}$  is pyridinyl or pyrimidinyl substituted or unsubstituted with lower alkyl having 1 to 4 carbon atoms, nitro or

methanesulfonylamino; or benzyl or phenethyl substituted or unsubstituted with lower alkyl having 1 to 4 carbon atoms, alkoxy, hydroxy or methanesulfonylamino);

or



or

5 (wherein,  $R^{17}$ ,  $R^{18}$ ,  $R^{19}$ ,  $R^{20}$  and  $R^{21}$  are independently hydrogen, halogen, lower alkyl having 1 to 5 carbon atoms, alkoxy, methylenedioxy, methanesulfonylaminomethyl, alkoxycarbonyl, hydroxy, sulfamoyl, alkoxycarbonylamino,  $-NHCH_2CO_2H$ , alkoxyalkylcarbonylamino, alkoxycarbonylalkylamino, nitro, formyl, acetyl, formylamino, acetoxymino, cyano,  $-OSO_2CH_3$ ,  $-NHSO_2R^{12}$ ,  $-N(SO_2R^{12})CH_3$ ,  $-N(SO_2R^{12})_2$ ,  $-S(O)_pR^{12}$ ,  $NR^{13}R^{14}$ , thiocarbamoyl,  $-C(=O)NHNH_2$ ,  $-C(=O)NHOH$ ,  $-C(=O)NHOCH_3$ , carboxyl,  $NHBoc$ ,  $-NHC(=O)SCH_3$ , guanidine;  $R^{22}$  and  $R^{23}$  are independently hydrogen, alkoxy or hydroxy; and p,  $R^{12}$ ,  $R^{13}$  and  $R^{14}$  have the same meanings as defined in  $R^9$ );

or hydroxyphenylalkyl or (methanesulfonylaminophenyl)alkyl}; and

15  $R^3$  represents hydrogen, alkyl having 1 to 4 carbon atoms, lower alkylphenyl having 1 to 3 carbon atoms, pyridinylethyl or bisphenylmethyl; or phenylalkyl substituted with lower alkyl having 1 to 4 carbon atoms, halogen or


methanesulfonylamino.

3. A compound or a pharmaceutically acceptable salt thereof according to claim 2, wherein,

X represents S, O or -NCN;

5 Y represents  $\text{NR}^3$  or O;

$\text{R}^1$  represents




(wherein, m is 1 or 2; and  $\text{R}^4$  and  $\text{R}^5$  are independently hydrogen, t-butyl, hydroxy, methanesulfonylamino, lower alkoxy having 1 to 5 carbon atoms, methoxymethoxy, methoxyethoxy, benzyloxy, acetoxymethyl, trimethylacetoxymethyl or halogen);

10

$\text{R}^2$  represents  $\text{R}^8-(\text{CH}_2)_n-$


{wherein, n is 1, 2 or 3;  $\text{R}^8$  is benzoyl, imidazolyl, indolyl, indazolyl, thiazolyl, pyrazolyl or benzimidazolyl substituted or unsubstituted with methyl, nitro or halogen;

15 or



(wherein,  $R^9$  is hydrogen, halogen, methyl, nitro or methanesulfonylamino;  $R^{10}$  is hydrogen or nitro; and  $R^{11}$  is hydrogen or cyano);

or




5

or

(wherein, Z is O, S, NH or  $-NCH_3$ ; and  $R^{15}$  is hydrogen, methyl, nitro, cyano or methanesulfonylamino);


or



or

10 (wherein, W is O, S, NH,  $NR^{16}$  or  $-CH_2-$ ; and  $R^{16}$  is pyridinyl, pyrimidinyl; or benzyl or phenethyl substituted or unsubstituted with methyl, methoxy or hydroxy);

or



or

- (wherein, R<sup>17</sup>, R<sup>18</sup>, R<sup>19</sup>, R<sup>20</sup> and R<sup>21</sup> are independently hydrogen, halogen, lower alkyl having 1 to 4 carbon atoms, methoxy, methylenedioxy, methanesulfonylaminomethyl, methoxycarbonyl, hydroxy, sulfamoyl, alkoxycarbonylamino, -NHCH<sub>2</sub>CO<sub>2</sub>H, methoxymethylcarbonylamino, alkoxycarbonylalkylamino, nitro, acetyl, formylamino, acetoxymino, cyano, -OSO<sub>2</sub>CH<sub>3</sub>, -NHSO<sub>2</sub>R<sup>12</sup>, -N(SO<sub>2</sub>R<sup>12</sup>)CH<sub>3</sub>, -N(SO<sub>2</sub>R<sup>12</sup>)<sub>2</sub>, -S(O)<sub>p</sub>R<sup>12</sup>, NR<sup>13</sup>R<sup>14</sup>, thiocarbamoyl, -C(=O)NHNH<sub>2</sub>, -C(=O)NHOH, -C(=O)NHOCH<sub>3</sub>, carboxyl, NHBoc, -NHC(=O)SCH<sub>3</sub>, guanidine; R<sup>22</sup> and R<sup>23</sup> are independently hydrogen, methoxy or hydroxy; and p, R<sup>12</sup>, R<sup>13</sup> and R<sup>14</sup> are the same meanings as defined in R<sup>9</sup>);

or hydroxyphenylalkyl or (methanesulfonylaminophenyl)alkyl}; and

R<sup>3</sup> represents hydrogen, methyl, isopropyl, isobutyl, cyclohexyl, benzyl, phenethyl or bisphenylmethyl; or phenylalkyl substituted with t-butyl, halogen or methanesulfonylamino.

4. A compound or a pharmaceutically acceptable salt thereof according to claim 1, wherein the formula (I) represents

1-(4-t-butylbenzyl)-3-[2-(1-methyl-1H-pyrrol-2-yl)ethyl]thiourea;

- 1-(4-t-butylbenzyl)-3-(4-amino-2,5-difluorobenzyl)thiourea;
- 1-(4-t-butylbenzyl)-3-(4-sulfamoylbenzyl)thiourea;
- 1-(4-t-butylbenzyl)-3-(3-fluoro-4-methanesulfonylaminobenzyl)thiourea;
- 1-phenethyl-3-(3-fluoro-4-methanesulfonylaminobenzyl)thiourea;
- 5 1-(4-t-butylbenzyl)-3-(3-chloro-4-methanesulfonylaminobenzyl)thiourea;
- 1-(4-t-butylbenzyl)-3-(3-methoxycarboxyl-4-methanesulfonylaminobenzyl)thio  
urea;
- 1-(4-t-butylbenzyl)-3-(3-carboxyl-4-methanesulfonylaminobenzyl)thiourea;
- 1-(4-t-butylbenzyl)-3-((3-N-hydroxyaminocarbonyl-4-methanesulfonylamino)b  
10 enzyl)thiourea;
- 1-(4-t-butylbenzyl)-3-(3-methoxycarboxylbenzyl)thiourea;
- 1-(4-t-butylbenzyl)-3-(3-carboxylbenzyl)thiourea;
- 1-(4-t-butylbenzyl)-3-(2,3,5,6-tetrafluoro-4-methanesulfonylaminobenzyl)thiou  
rea;
- 15 1-(4-t-butylbenzyl)-3-(2,5-difluoro-4-methanesulfonylaminobenzyl)thiourea;
- 1-(4-t-butylbenzyl)-3-[(3-methanesulfonylamino-6-pyridinyl)methyl]thiourea;
- 1-(4-t-butylbenzyl)-3-(2,6-dichloro-5-methanesulfonylaminobenzyl)thiourea;
- 1-(4-t-butylbenzyl)-3-(4-methanesulfonylaminophenethyl)thiourea;
- 1-(4-t-butylbenzyl)-3-(4-methanesulfonylaminobenzyl)thiourea;

1-(4-t-butylbenzyl)-3-[2,6-difluoro-3-(N-methanesulfonylamino)benzyl]thiourea

a;

1-(4-t-butylbenzyl)-3-[3-(N-methanesulfonylamino)benzyl]thiourea;

1-(4-t-butyl-2-methoxybenzyl)-3-(4-methanesulfonylamino)benzyl]thiourea;

5 1-(4-t-butyl-2-ethoxybenzyl)-3-(4-methanesulfonylamino)benzyl]thiourea;

1-(4-t-butyl-2-propoxybenzyl)-3-(4-methanesulfonylamino)benzyl]thiourea;

1-(4-t-butyl-2-butoxybenzyl)-3-(4-methanesulfonylamino)benzyl]thiourea;

1-(4-t-butyl-2-isopropoxybenzyl)-3-(4-methanesulfonylamino)benzyl]thiourea;

1-(4-t-butyl-2-isobutoxybenzyl)-3-(4-methanesulfonylamino)benzyl]thiourea;

10 1-(4-t-butyl-2-neopentoxymethyl)-3-(4-methanesulfonylamino)benzyl]thiourea;

1-(4-t-butyl-2-methoxymethoxybenzyl)-3-(4-methanesulfonylamino)benzyl]thio

urea;

1-(4-t-butyl-2-methoxyethoxybenzyl)-3-(4-methanesulfonylamino)benzyl]thio

urea;

15 1-(4-t-butyl-2-benzyloxybenzyl)-3-(4-methanesulfonylamino)benzyl]thiourea;

1-(2-acetoxymethyl-4-t-butylbenzyl)-3-(4-methanesulfonylamino)benzyl]thiourea;

a;

1-(4-t-butylbenzyl)-3-[2-(4-methylthiazol-5-yl)ethyl]thiourea;

1-(4-t-butylbenzyl)-3-((2-chloro-5-pyridinyl)methyl)thiourea;



- 1-(4-t-butylbenzyl)-3-(2-pyridin-2-ylethyl)thiourea;
- 1-(4-t-butylbenzyl)-3-(2,5-difluorobenzyl)thiourea;
- 1-(4-t-butylbenzyl)-3-(3-fluorophenethyl)thiourea;
- 1-(4-t-butylbenzyl)-3-(4-sulfamoylphenethyl)thiourea;
- 5 1-(4-t-butylbenzyl)-3-(4-morpholinylethyl)thiourea;
- 1-(4-t-butylbenzyl)-3-[2-(1H-imidazol-4-yl)ethyl]thiourea;
- 1-(4-t-butylbenzyl)-3-[2-thiophen-2-ethyl]thiourea;
- 1-(4-t-butylbenzyl)-3-(4-methanesulfonylamino-1-methyl-1H-pyrrol-2-yl)thiourea;
- 10 1-benzyl-1-(3-(4-hydroxy-3-methoxyphenyl)propyl)-3-phenethylthiourea;
- 1-(3-(4-hydroxy-3-methoxyphenyl)propyl)-1-phenethyl-3-phenethylthiourea;
- 1-bisphenylmethyl-1-(3-(4-hydroxy-3-methoxyphenyl)propyl)-3-phenethylthiourea; or
- N"-cyano-N-(4-t-butylbenzyl)-N'-(4-methanesulfonylaminobenzyl)guanidine.
- 15 5. A compound or a pharmaceutically acceptable salt thereof according to claim 1, wherein the formula (I) represents
- 1-(4-t-butylbenzyl)-3-(3-fluoro-4-methanesulfonylaminobenzyl)thiourea;
- 1-(4-t-butylbenzyl)-3-(3-chloro-4-methanesulfonylaminobenzyl)thiourea;
- 1-(4-t-butylbenzyl)-3-(3-methoxycarboxyl-4-methanesulfonylaminobenzyl)thio

urea;

1-(4-t-butylbenzyl)-3-(4-methanesulfonylaminobenzyl)thiourea; or

1-(4-t-butyl-2-isobutoxybenzyl)-3-(4-methanesulfonylamino)thiourea.

6. A pharmaceutical composition comprising the compound according to claim  
5 1 or a pharmaceutically acceptable salt thereof as an active ingredient together with a  
pharmaceutically acceptable carrier.

7. A pharmaceutical composition according to claim 6, wherein the compound  
according to claim 1 or a pharmaceutically acceptable salts thereof as an active  
ingredient together with an pharmaceutically acceptable carrier is present in an  
10 effective amount for preventing or treating pain, acute pain, chronic pain, neuropathic  
pain, post-operative pain, migraine, arthralgia, neuropathies, nerve injury, diabetic  
neuropathy, neurodegeneration, neurotic skin disorder, stroke, urinary bladder  
hypersensitiveness, irritable bowel syndrome, a respiratory disorder such as asthma  
or chronic obstructive pulmonary disease, irritation of skin, eye or mucous membrane,  
15 stomach-duodenal ulcer, inflammatory bowel disease or inflammatory diseases.

8. A method for preventing or treating pain, acute pain, chronic pain,  
neuropathic pain, post-operative pain, migraine, arthralgia, neuropathies, nerve injury,  
diabetic neuropathy, neurodegeneration, neurotic skin disorder, stroke, urinary  
bladder hypersensitiveness, irritable bowel syndrome, a respiratory disorder such as

asthma or chronic obstructive pulmonary disease, irritation of skin, eye or mucous membrane, stomach-duodenal ulcer, inflammatory bowel disease or inflammatory diseases, wherein the method comprises administering a therapeutically effective amount of the compound selected from the group consisting of compounds of  
5 formula I or a pharmaceutically acceptable salt thereof.

9. Use of a compound selected from the group consisting of compound of formula I or a pharmaceutically acceptable salt thereof as an antagonist of vanilloid receptor.

10. Use of a compound selected from the group consisting of compound of  
10 formula I or a pharmaceutically acceptable salt thereof as an agonist of vanilloid receptor.

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/KR01/01407

**A. CLASSIFICATION OF SUBJECT MATTER****IPC7 C07C 335/16, C07C 311/00, A61K 31/00, C07D 221/00**

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

C07C, A61K, C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Journal, KR document

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

STN(REG, CAPlus) ; chemical structural search and capsa? and vanilloid? and (thiourea or (thio (w) urea))

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	Jaewoo Lee et al, Thiourea analogues of resiniferatoxin as ligands for the vanilloid receptor, Bioorganic & Medicinal Chemistry Letters, Vol 5. No 13, pp 1331-1334, 1995, See the whole document	1-7, 9-10
A	US-A-6057451(2000.5.2) & US-A-6288091(2001.9.11) See the group 2(all schema), tables	1-7, 9-10
A	JP-A-58-55417(1983.4.1) & None See the whole document	1-7, 9-10
A	WO-A-99-37675(1999.7.29) & EP-A1-1047711(2000.11.2) & AU-A1-1998-72151(1998.1.22) See the whole document	1-7, 9-10
	-----End of Documents-----	

☐ Further documents are listed in the continuation of Box C.

☐ See patent family annex.

\* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&amp;" document member of the same patent family

Date of the actual completion of the international search

22 NOVEMBER 2001 (22.11.2001)

Date of mailing of the international search report

23 NOVEMBER 2001 (23.11.2001)

Name and mailing address of the ISA/KR

Korean Intellectual Property Office  
Government Complex-Daejeon, Dunsan-dong, Seo-gu, Daejeon  
Metropolitan City 302-701, Republic of Korea

Facsimile No. 82-42-472-7140

Authorized officer

PARK, Kil Chae

Telephone No. 82-42-481-5536



# INTERNATIONAL SEARCH REPORT

International application No.

PCT/KR01/01407

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 8  
because they relate to subject matter not required to be searched by this Authority, namely:  
Method for treatment of the human body by therapy
2. ☐ Claims Nos.:  
because they relate to part of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Search Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be established without effort justifying an additional fee, this Authority did not invite payment of any addition fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

**THIS PAGE BLANK (USPTO)**